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Abstract 
Through the recognition of potentially harmful stimuli, Toll-like receptors 
(TLRs) initiate the innate immune response and induce the expression of 
hundreds of immune and pro-inflammatory genes. TLRs are critical in mounting 
a defence against invading pathogens however, strict control of TLR signalling 
is vital to prevent host damage from excessive or prolonged immune activation. 
In this thesis the role of the IκB protein Bcl (B-cell lymphoma)-3 in the regulation 
of TLR signalling is investigated. Bcl3-/- mice and cells are hyper responsive to 
TLR stimulation and are defective in LPS tolerance.  Bcl-3 interacts with and 
blocks the ubiquitination of homodimers of the NF-κB subunit, p50. Through 
stabilisation of inhibitory p50 homodimers, Bcl-3 negatively regulates NF-κB 
dependent inflammatory gene transcription following TLR activation. Firstly, we 
investigated the nature of the interaction between Bcl-3 and p50 and using 
peptide array technology. Key amino acids required for the formation of the 
p50:Bcl-3 immunosuppressor complex were identified. Furthermore, we 
demonstrate for the first time that interaction between Bcl-3 and p50 is 
necessary and sufficient for the anti-inflammatory properties of Bcl-3. Using the 
data generated from peptide array analysis we then generated cell permeable 
peptides designed to mimic Bcl-3 function and stabilise p50 homodimers. These 
Bcl-3 derived peptides are potent inhibitors of NF-κB dependent transcription 
activity in vitro and provide a solid basis for the development of novel gene-
specific approaches in the treatment of inflammatory diseases. Secondly, we 
demonstrate that Bcl-3 mediated regulation of TLR signalling is not limited to 
NF-κB and identify the MAK3K Tumour Progression Locus (Tpl)-2 as a new binding 
partner of Bcl-3.  Our data establishes role for Bcl-3 as a negative regulator of 
the MAPK-ERK pathway. 
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SEM  Standard error of the mean 
SOB  Super Optimal Broth 
SOC  Super Optimal Broth with catabolite repression 
SRD  Signal receiving domain 
ssRNA  Single-stranded RNA   
TAB  TAK1-binding proteins 
TAD  Trans activating domain 
TAK1  Transforming growth factor-β-activated kinase-1  
TAT  Trans-Activator of Transcription 
TBS  Tris buffer saline 
TBS-T  Tris buffer saline-Tween  
TCR  T-cell receptor 
tGP1-mucins Trypanosoma cruzi glycosylphosphatidylinositol-anchored mucin-
like glycoprotein 
TIR  Toll/interleukin-1 receptor  
TIRAP  TIR -domain-containing adapter protein  
TNF  Tumour necrosis factor  
TNFR  Tumour necrosis factor receptor 
Tpl-2  Tumour Progression Locus 2 
 
 
TRAF  Tumour necrosis factor receptor–associated factor 
TRAM  TRIF-related adaptor molecule  
TRIF  TIR-domain-containing adaptor protein inducing IFN beta  
TLR  Toll like receptor 
TWEAK  Tumour necrosis factor -related weak inducer of apoptosis  
Ub  Ubiquitin 
uM  Micro molar 
Usp  ubiquitin-specific-processing protease  
UV  Ultra violet 
VCAM  Vascular cell adhesion protein  
VSV  Vesicular stomatitis virus 
W/V  Weight per volume 
WB  Western blot 
WT  Wild-type  
  
 
 
List of Amino Acid Abbreviations    
Alanine   Ala  A 
Arginine   Arg  R 
Asparagine   Asn  N 
Aspartate   Asp  D 
Aspartate or Asparagine Asx  B 
Cysteine   Cys  C 
Glutamate   Glu  E 
Glutamine   Gln  Q 
Glutamate or Glutamine Glx  Z 
Glycine   Gly  G 
Histidine   His  H 
Isoleucine   Ile  I 
Leucine   Leu  L 
Lysine    Lys  K 
Methionine   Met  M 
Phenylalanine   Phe  F 
Proline    Pro  P 
Serine    Ser  S 
Threonine   Thr  T 
Tryptophan   Trp  W 
Tyrosine   Tyr  Y 
Valine    Val  V  
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1 General Introduction 
Nuclear factor (NF)-κB has evolved as a latent, inducible family of transcription 
factors, fundamental in the control of a number of important biological 
processes including cell survival, differentiation and proliferation, in addition 
to having an essential role in the development and homeostasis of the immune 
system (Hayden and Ghosh, 2012). Although originally identified as a B-
lymphocyte-specific immunoglobulin κ-chain enhancer binding protein,  NF-κB 
is not limited to B-cells and is activated by a plethora of stimuli, in almost all 
mammalian cell types (Figure 1.1) (Sen and Baltimore, 1986b, Sen, 2011). 
 
 
Figure 1.1 Multifaceted gene regulation by NF-κB.  
NF-κB is activated in response to a wide variety of signals (red circles) which induces 
the expression of over 500 genes (blue circles) involved in the innate and adaptive 
immune responses, the regulation of normal developmental processes, cellular growth 
and apoptosis. (For a full list, see http://www.bu.edu/nf-kb)  
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NF-κB regulates the inducible transcription of hundreds of genes and as such, 
aberrant NF-κB activation is associated with a number of pathological states 
including but not limited to autoimmunity, cancer and neurodegenerative and 
cardiovascular diseases (DiDonato et al., 2012, Hayden and Ghosh, 2012). Due 
to the number and significance of NF-κB target genes, tight regulation is 
essential and many mechanisms have evolved to induce specific gene expression 
patterns in a stimulus- and cell type-specific manner. 
 
1.1 Molecular Components of the NF-κB pathway 
1.1.1 NF-κB 
The mammalian NF-κB family consists of five members, p65 (RelA), RelB, c-Rel, 
p50 and p52 (Figure 1.2), which associate to form homo- or heterodimeric 
complexes. p50 and p52 are synthesised as large precursor proteins, p105 and 
p100, respectively, that are partially proteolysed by the 26S proteasome. This 
processing removes the C-terminal halves of p105 and p100 to generate the 
active p50 and p52 subunits, respectively (discussed in detail in 1.3.3). All NF-
κB subunits are characterised by a conserved N-terminal amino acid sequence 
termed the Rel homology domain (RHD) or Rel homology region (RHR).  The RHD 
is a 300 amino acid motif identified following the cloning of NF-κB p50. 
Sequence analysis revealed homology to the viral  oncogene v-rel and the 
Drosophila protein dorsal, establishing NF-κB proteins as members of the larger 
rel family of transcription factors  (Ghosh et al., 1990, Rushlow and Warrior, 
1992).  
The RHD is responsible for DNA-binding, dimerization, nuclear localisation and 
interaction with IκB proteins. The first three-dimensional structure of the RHD 
was determined by x-ray crystallography of the NF-κB p50 homodimer bound to 
DNA (Muller et al., 1995, Ghosh et al., 1995). This structure revealed a 
symmetrical protein DNA complex  described as resembling a butterfly with two 
protein domain “wings” connected to a cylindrical double-stranded DNA “body” 
(Figure 1.2) (Ghosh et al., 1995). The RHD consists of two folded domains 
connected by a short linker, approximately 10 amino acids in length (Figure 
1.2). The amino (N)-terminal domain and the shorter carboxyl (C)-terminal 
domain adopt an immunoglobulin-like fold, which wraps around the major 
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groove, enclosing the DNA. Unlike DNA binding, dimer contacts are made solely 
in the C-terminal dimerization domain which consists of a hydrophobic core 
surrounded by polar residues (Müller and Harrison, 1995). The five NF-κB 
proteins assemble to form homo- and hetero-dimers and although in theory 15 
combinations are possible, only  12 of these have been identified in vivo (Figure 
1.3) (Huxford and Ghosh, 2009). The physiological relevance for all dimers has 
not been fully explored and in addition, some dimers may be limited subsets of 
cells (Oeckinghaus and Ghosh, 2009). Although the abundance of a particular 
NF-κB dimer is dependent on cell type and in some cases is stimulus-specific, in 
general the p65:p50 heterodimer is the most predominant form of NF-κB and is 
expressed in most cell types (Hoffmann et al., 2006, Moorthy et al., 2010). 
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Figure 1.2 NF-κB family of transcription factors. 
(A) Schematic representation of the NF-κB family members with structural domains 
indicated. All subunits share a Rel homology domain (RHD) and p65, c-Rel and RelB 
contain a transactivating domain (TAD). p105 and p100 proteins contain a large C-
terminus ankyrin  repeat domain and a  glycine rich region (GRR)  which signal their 
limited proteasomal processing, generating the p50 and p52 subunits respectively. (B) 
Crystal structure of the murine p65/p50 heterodimer bound to DNA (PDB: 1VKX). p65 
subunit is shaded in green, p50 subunit is shaded in yellow and the dimerization and 
amino-terminal domains are indicated. 
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Of the 15 possible NF-κB dimers, 12 of these can bind DNA to potentially 
regulate transcription (Hoffmann et al., 2006). As p50 and p52 lack a 
transactivation domain (TAD) but can still bind DNA, homodimers of these 
subunits are considered repressors of transcription. It has been proposed that 
p50 and p52 homodimers compete with TAD-containing NF-κB dimers for binding 
to κB sites thereby negatively regulating NF-κB dependent transcription. 
However, studies have also demonstrated that homodimers can enhance the 
expression of specifics gene such as Skp2 and Bcl-2 (Barré and Perkins, 2010, 
Viatour et al., 2000). Although p50 and p52 lack transactivation capabilities, 
through dimerization with TAD-containing subunits they can also positively 
regulate transcription. 
 
 
 
Figure 1.3  Possible NF-κB homo- and heterodimers. 
NF-κB subunits form 15 possible homo-and hetero-dimers with each other via their RHDs. 
There are two structural classes of NF-κB based on the presence of a transactivation 
domain. p50 and p52 represent one class and do not contain a transactivation domain 
and therefore homodimers of these subunits cannot activate transcription (orange 
shading). The second class consists of RelB, p65 and c-Rel which all contain 
transactivation domains. Dimers containing at least one subunit from this second class 
have transactivation capabilities (blue shading) with the exception of the RelB:p65 
heterodimer which cannot bind DNA (pink shading). Not all possible dimer combinations 
may exist in vivo however, and grey shading represents dimers that have not currently 
been identified.  
  
 7 
 
NF-κB dimers bind to 9–11 base pair DNA binding sites (κB sites), with a loose 
consensus sequence of G-5G-4G-3R-2N-1N0Y+1Y+2C+3C+4 (where R represents purine, 
N represents any nucleotide and Y represents pyrimidine) (Natoli et al., 2005). 
The list of NF-κB target genes known to contain a κB site in the promoter region 
is currently over five hundred (for up to date list see http://www.bu.edu/nf-
kb) and contain many immune modulators such as cytokines, chemokines and 
immunoreceptors. In general most κB site show little selectivity for a given NF-
B dimer, however differences in dimer affinities are possible, ranging from 10- 
300nM (Udalova et al., 2002, Phelps et al., 2000, Saccani et al., 2003, Hoffmann 
et al., 2006). Furthermore, p50 and p52 homodimers preferentially bind 11 bp 
κB sites whereas 10 bp sites are preferentially  bound by heterodimers of p50 
and either p65 or c-Rel (Huang et al., 2001). Some dimers can also selectively 
regulate target promoters, however there is considerable redundancy in gene 
activation with most genes induced by more than one NF-κB dimer (Saccani et 
al., 2003). Although different NF-κB dimers can bind the same κB site, the 
transcriptional output following dimer binding is not equivalent (Natoli et al., 
2005, Lin et al., 1995). In addition, dimer-specific synergy with other 
transcription factors and interactions with co-factors can also regulate distinct 
gene sets following NF-κB DNA binding (Hoffmann et al., 2003). Moreover, 
promoter occupancy is a highly dynamic process and it has been suggested that 
dimer exchange at the same promoter may allow fine tuning of the NF-κB 
response over time (Bosisio et al., 2006, Saccani et al., 2003). 
Knockout mouse models for the various NF-κB family members have provided 
considerable information in elucidating the distinct and overlapping functions 
of each NF-κB subunit, these however, may also be cell type and tissue 
dependent.  For example RelA-/- mice are embryonically lethal due to extensive 
tumour necrosis factor (TNF) α-mediated fetal hepatocyte apoptosis (Beg et al., 
1995). Conversely, c-Rel is dispensable for mouse embryonic development and 
differentiation of hemopoietic precursors, nevertheless, mature lymphocytes 
and macrophages exhibit a number of activation-associated defects associated 
with B- and T-cell proliferation (Gerondakis et al., 2000). Knockout mice for 
more than one NF-κB subunit such as the Nfkb1-/-RelB-/-, Nfkb1-/- Nfkb2-/- c-Rel-
/- Nfkb1-/- and Rela-/- Nfkb1-/- animals have more severe phenotypes than of 
those seen in the individual knockouts, suggesting some functional 
compensation between the NF-κB subunits (Gerondakis et al., 2000). This was 
further highlighted in a genetic study using a panel of cell lines deficient in 
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individual or multiple NF-κB proteins (Hoffmann et al., 2003).  Although a 
number of NF-κB dependent genes with distinct subunit requirements were 
identified, considerable compensation was evident within the family. p50 or p52 
deficiency did not have an effect on the TNF-induced expression of a number of 
genes, however the activation of several genes such as RANTES, IP-10 and M-
CSF were defective in cells lacking both subunits. The p50:p65 heterodimer is 
major NF-κB dimer present in fibroblasts, however, neither p65-/- or p50-/- cells 
are deficient in κB binding activity as p52 and c-Rel compensate in the absence 
of p50 and p65 respectively (Hoffmann et al., 2003). 
 
1.1.2 IκB  
Shortly after discovering NF-κB, Baltimore and colleagues described it’s 
cytoplasmic localisation in resting cells (Baeuerle and Baltimore, 1988a).This 
cytoplasmic pool of NF-κB was found to be inactive, however in the presence of 
a dissociating agent, cytoplasmic NF-κB could in fact exhibit DNA binding 
activity (Baeuerle and Baltimore, 1988b). This suggested that in unstimulated 
cells, NF-κB was maintained in an inactive form by reversible association with 
an inhibitor which they termed IκB (Baeuerle and Baltimore, 1988a, Baeuerle 
and Baltimore, 1988b). Upon purification of this inhibitor, two forms of IκB, 
IκBα and IκBβ were identified and subsequently cloned (Zabel and Baeuerle, 
1990, Haskill et al., 1991, Thompson et al., 1995). Both IκB variants bound to a 
p65 containing NF-κB heterodimer and exhibited similar inhibitory activity 
raising the question as to why two biochemically distinct inhibitors were 
apparently functionally similar. This was the first suggestion that interaction 
with IκB proteins may be responsible for the differential  regulation of NF-κB 
(Zabel and Baeuerle, 1990). A theory that indeed proved correct, with nine 
mammalian IκB proteins now described, each differing in NF-κB dimer affinity, 
activation kinetics, regulation and function. 
Following the initial characterisation of the major IκB proteins found in 
mammalian cells, multiple IκB proteins were identified based on sequence and 
structural homology to IκBα and IκBβ. The IκB family has grown extensively in 
recent times to include eleven members, (IκBα, IκBβ, IκBε, Catcus, p100, p105 
Relish, IκBζ, IκBη, IκBNS and B-cell lymphoma (Bcl)-3). Drosophila proteins, 
Catcus and Relish however only exist in invertebrates (Basith et al., 2013). In 
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addition to their inhibitory ability, the defining feature of these IκB proteins is 
the presence of multiple copies of ankyrin (ANK) repeats, forming a central 
ankyrin repeat domain (ARD). The ankyrin repeat is a 33 residue motif first 
identified in the sequences of yeast Swi6 and Cdc10 and Drosophila 
melanogaster (Breeden and Nasmyth, 1987). It was later named due the 
presence of twenty four of these repeats in the cytoskeletal protein, Ankyrin 
(Lux et al., 1990).  Ankyrin repeats are present in all three super kingdoms as 
well as some viral genomes and as of 2013 there were 46,742 ANK domains 
identified in 25,863 proteins in the non-redundant SMART database (Letunic et 
al., 2012, Schultz et al., 1998). This huge number of proteins include those 
involved in cell-cell signalling, cytoskeleton integrity, transcription and cell 
development and differentiation (Mosavi et al., 2004, Li et al., 2006). The 
number of repeats per protein can vary from 1 to 33 and function to mediate 
protein-protein interactions. The high degree of conservation between ankyrin 
repeats has led to the identification of a consensus sequence and structure. The 
ARD exhibits a canonical helix-turn-helix conformation in which the two α-
helices are arranged in an antiparallel fashion with an almost perpendicular 
outward projecting β-hairpin loop (Li et al., 2006, Mosavi et al., 2004). The 
outer helix (helix-2) comprises nine residues, spanning positions 15-24 and is 
packed against the shorter inner helix (helix-1) positions 5-12. This difference 
in helix length and packing between helices results in a slight L-shaped 
curvature (Mosavi et al., 2004). The structures of IκB proteins IκBα, IκBβ and 
Bcl-3 have been resolved and although the ARDs differ in size they retain this 
characteristic stacked repeat structure with a slight left handed twist (Michel 
et al., 2001, Jacobs and Harrison, 1998, Huxford et al., 1998, Malek et al., 2003) 
(Figure 1.4) Insertions in the ARD are not uncommon and are often found in the 
loop regions, IκBβ for example contains a large 41 residue insertion between 
ANK 3 and ANK 4 which is responsible for masking the NLS of one of the p65 
subunits (Malek et al., 2003). Homology modelling also identified a 20 and 27 
residue insertions within ANK4 of IκBNS and IκBζ, respectively (Manavalan et al., 
2010). 
Although all IκB proteins contain a ARD, they are distinguished by the number 
of ANK repeats and also important regulatory sequences contained at their C- 
and N- termini. Based on phylogenetic and structural analysis, IκB proteins can 
be classified into three subfamilies, classical or cytoplasmic IκB proteins, NF-κB 
precursor proteins and atypical or nuclear IκB proteins (Huxford and Ghosh, 
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2009, Basith et al., 2013) (Figure 1.5). The classical IκB proteins, contain six 
ANK repeats and are flanked at the N -terminus by a signal receiving domain 
(SRD) which contains sites of IKK phosphorylation, poly ubiquitination and for 
IκBα, nuclear export (Huxford and Ghosh, 2009, Huang et al., 2000). At the C-
terminus IκBα, IκBβ but not IκBε also contain an acidic PEST domain, a region 
rich in proline, glutamic acid, serine and threonine residues. PEST domains are 
also common to many other rapidly degraded proteins and are implicated in 
regulating IκB protein half-life (Rogers et al., 1986, Rodriguez et al., 1995). The 
PEST domain is also critical for interaction with NF-κB (Ernst et al., 1995) and 
possibly provides a structural mechanism for the divergent functions  of IκBα 
and IκBβ (Malek et al., 2003). 
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Figure 1.4 Ankyrin repeat consensus sequence and structure. 
(A) 33 residue ankyrin repeat consensus sequence with residues 1-33 indicated and 
positions colour coded according to conservation as described previously (Mosavi et al., 
2002). Blue shading represents well-conserved positions where one amino acid was 
present >50% of the time. Semi conserved (two to four amino acid residues occurred 
with a higher frequency than any others) positions were subdivided into two categories. 
Pink denotes high frequency residues had the same biochemical property and green 
denotes residues belonging to different groups of amino acids. Non-conserved positions 
were shaded in yellow. (B) Ribbon structures of IκBα from the NF-κB heterodimer: IκBα 
complex crystal structure (PDB ID: 1K1A), IκBβ from the NF-κB p65 homodimer: IκBβ 
complex crystal structure (PDB ID: 1K3Z) and Bcl-3 crystal structure (PDB ID: 1K1A) with 
ankyrin repeats indicated. 
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Figure 1.5 The family of mammalian IκB proteins. 
Schematic representation of the three groups of IκB proteins: classical, precursor 
proteins and atypical. Although p105 and p100 are precursors for the NF-κB proteins p50 
and p52 respectively, they also function as IκB like molecules via their C-terminal ANK 
domains. Important structural domains are indicated and residue numbering 
corresponds to murine IκB sequences.  
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1.1.2.1 Classical IκB proteins 
In most resting cells NF-κB is associated with one of the typical cytoplasmic IκB 
proteins, IκBα, IκBβ or the lesser described IκBε. They are ubiquitously 
expressed with higher levels of expression in spleen (IκBα, IκBε), testis (IκBβ, 
IκBε), thymus (IκBα), and lung (IκBε) (Hinz et al., 2012). IκB proteins exhibit 
different affinities for NF-κB dimers, with classical IκB proteins preferentially 
binding dimers containing at least one p65 or c-Rel subunit (Jacobs and Harrison, 
1998, Malek et al., 2003, Huxford et al., 1998, Whiteside et al., 1997, Li and 
Nabel, 1997, Thompson et al., 1995). The first NF-κB:IκB complex to be resolved 
was that of a p50:p65 heterodimer bound to IκBα and remains the best studied 
interaction to date (Müller and Harrison, 1995, Ghosh et al., 1995). 
When it was observed that nuclear localisation signal (NLS) deficient p65 
mutants could no longer interact with IκBα, the first mechanism for NF-κB 
cytoplasmic retention by IκB proteins was proposed (Beg et al., 1992). IκB 
proteins were thought to mask the NLS of NF-κB subunits thereby preventing 
nuclear translocation of NF-κB. Therefore, IκB degradation following a cellular 
stimulus (discussed in detail in 1.3.2) would allow free NF-κB dimers to 
translocate from the cytoplasm to the nucleus, supporting the original model of 
inducible NF-κB regulation (Baeuerle and Baltimore, 1988a, Baeuerle and 
Baltimore, 1988b). Though still extensively used, the simplicity of this general 
model of NF-κB regulation by all IκB proteins is inaccurate. Although X-ray 
crystallography confirmed that indeed IκBα contacts the NLS of p65 in a p65:p50 
NF-κB heterodimer, the NLS of p50 remains exposed (Jacobs and Harrison, 1998, 
Huxford et al., 1998). The nuclear localisation capability of IκBα:p50/p65 
complexes was finally shown following the identification of a nuclear export 
signal (NES) in IκBα. Studies using Leptomycin B (LMB), an inhibitor of 
chromosome region maintenance 1 protein (CRM1), demonstrated redistribution 
of NF-κB:IκBα complexes from the cytoplasm to the nucleus (Johnson et al., 
1999, Rodriguez et al., 1999, Huang et al., 2000, Tam et al., 2000).These 
remarkable results suggested that NF-κB:IκBα complexes, previously assumed 
to be cytoplasmic were in fact constantly shuttling  between the cytoplasm and 
nucleus in resting cells (Huang et al., 2000). The incomplete masking of the p50 
NLS is thought to be responsible for the nuclear translocation ability of NF-
κB:IκBα complexes (Malek et al., 2001). However, due to dominant IκBα and 
p65 NESs, the rate of nuclear export exceeds that of nuclear import, the steady 
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state location for this complex is the cytoplasm (Ghosh and Karin, 2002, Huang 
et al., 2000). 
In contrast, IκBβ lacks an NES and free IκBβ remains cytoplasmic in the presence 
of LMB (Malek et al., 2001, Chen et al., 2003). Therefore unlike IκBα, NF-κB:IκBβ 
complexes do not undergo nucleo-cytoplasmic shuttling and are retained in the 
cytoplasm in resting cells. Furthermore, IκBβ masks the NLS on both subunits of 
a NF-κB heterodimer explaining the strict cytoplasmic localisation of NF-κB:IκBβ 
complexes in resting cells (Malek et al., 2001). Thus it is apparent that even 
within a subset of IκB proteins, not all NF-κB:IκB interactions are identical. 
Although Iκβα, Iκββ and Iκβε share many biochemical properties and NF-κB 
dimer specificity, the stimulus dependent expression and degradation dynamics 
of these proteins vary significantly, which are fundamental to their distinct 
functions (Hinz et al., 2012). Moreover, novel roles of IκB proteins are only 
recently emerging although discovered over 25 years ago. A number of studies 
have identified alternative nuclear functions for members of the classical IκB 
proteins (Espinosa et al., 2011, Mulero et al., 2013, Aguilera et al., 2004). 
Nuclear IκBα can associate with histone deacetylases  (HDAC) -1 and-5 and  is 
recruited to the Notch-target gene, hes1, promoter and is associated with 
transcriptional repression (Rao et al., 2010). IκBβ can also be recruited to the 
promoters of specific genes such as IL-1β, forming a complex with p65:c-Rel  
heterodimers, prolonging the expression of a subset of LPS-induced genes 
(Scheibel et al., 2010).   
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Figure 1.6 Inhibition of NF-κB by IκB proteins. 
NF-κB is maintained in an inactive state by association with one of the typical IκB 
proteins. Multiple stimuli induce the IκB kinase (IKK) mediated phosphorylation (P) and 
subsequent Lys48-linked polyubiquitination (Ub) of IκBs. IκBs are then targeted to the 
26S proteasome for degradation, thereby releasing associated NF-κB dimers. Free NF-
KB can translocate to the nucleus and bind to the promoter regions of NF-κB-responsive 
genes to activate transcription. Newly synthesised IκB enters the nucleus and dissociates 
DNA bound NF-κB exporting it back to the cytoplasm, terminating the NF-κB response. 
Iκβε shares many biochemical properties and NF-κB dimer specificity, the stimulus 
dependent expression and degradation dynamics of these proteins vary significantly, 
which are fundamental to their distinct functions (Hinz et al., 2012). 
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1.1.2.2 NF-κB precursors  
As previously mentioned the p105 and p100 proteins have dual roles as NF-κB 
precursors of p50 and p52 and as inhibitors of NF-κB (Basak et al., 2007). These 
precursors are responsible for inhibiting nearly half of NF-κB in resting cells and 
as such represent an important second class of IκB proteins (Huxford and Ghosh, 
2009). Cytoplasmic retention of NF-κB by p105 and p100 can also compensate 
for the absence of classical IκBs (Tergaonkar et al., 2005). However, unlike 
classical IκB proteins that form 1:1 complexes with their respective NF-κB 
binding partner, NF-κB precursors form large multiprotein assemblies. p105 and 
p100 can form high-molecular weight complexes that incorporate multiple NF-
κB subunits which are released in response to specific cellular stimulation 
(Savinova et al., 2009). The current model of these large multiprotein 
complexes stems from the unique structure of the precursor proteins having 
both a RHD and an ANK repeat domain. p105 is thought to be involved in at least 
three types of interactions: dimerisation of RHDs, binding of preformed RHD 
dimers to ANK repeat domains of p105 and dimerisation of the α-helical domain 
in the C-terminal half of p105 (Savinova et al., 2009). 
 
1.1.2.3 Atypical IκB proteins 
Containing seven ANK repeats and the ability to bind NF-κB dimers, atypical IκBs 
display homology to the cytoplasmic IκB proteins, however they do not exhibit 
the properties of these prototypic IκBs. In contrast, the atypical IκBs, Bcl-3, 
IκBζ, IκBNS and Iκβη reside predominantly in the nucleus and apart from IκBη 
are expressed  at low levels in resting cells which increases significantly upon 
stimulation with NF-κB inducing agents (Yamamoto et al., 2004, Fiorini et al., 
2002, Yamazaki et al., 2001, Ohno et al., 1990, Yamauchi et al., 2010, Hinz et 
al., 2012). Unlike the typical Iκβs, they are not degraded upon IKK activation 
and bind nuclear NF-κB dimers to modulate gene transcription in response to 
distinct stimuli. Acting in the nucleus to directly inhibit and in some cases 
activate NF-κB, atypical IκBs increase the specificity of NF-κB gene regulation 
and as revealed by multiple knockout studies (Table 1), are critical in mounting 
an effective immune response.  
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Table 1. Knockouts of atypical IκB proteins 
Adapted from (Hinz et al., 2012, Beinke and Ley, 2004, Franzoso et al., 1997, Schwarz 
et al., 1997, Paxian* et al., 2002, Pène et al., 2011, Carmody et al., 2007b). 
 
Bcl-3 was the first atypical IκB protein to be described however it was originally 
identified as a putative proto-oncogene (McKeithan et al., 1987, Kerr et al., 
1992, Ohno et al., 1990). BCL3 was initially cloned from neoplastic cells from 
patients suffering from B-cell chronic lymphocytic leukaemia (CLL) displaying 
the t(14;19)(q32;q13.1) translocation (McKeithan et al., 1987). Cloning of the 
gene located at the break-point junction in this translocation revealed that it 
encoded a protein of 446 amino acids (Kerr et al., 1992). The amino acid 
sequence predicted a basic protein with a proline-rich amino terminus, a series 
of seven tandem ankyrin repeats, and a proline- and serine-rich carboxyl 
terminus (Kerr et al., 1992). It was subsequently classified as an IκB family 
member by virtue of these seven ankyrin repeat domains which mediate 
selective interaction with homodimers of p50 and p52 (Nolan et al., 1993, 
Wulczyn et al., 1992). Although Bcl-3 is probably the best studied atypical IκB 
protein, the precise function of Bcl-3 in NF-κB regulation remained unclear for 
many years. Conflicting early reports suggested that Bcl-3 could both enhance 
and inhibit p50 homodimer DNA binding and act as both a transcriptional co-
activator and repressor of NF-κB gene expression (Franzoso et al., 1992, Fujita 
et al., 1993, Franzoso, 1993, Caamaño et al., 1996, Bours et al., 1993, Richard 
et al., 1999). The subsequent development of Bcl3 knockout mice revealed a 
Knockout Phenotype 
Bcl-3
−/−
 Defects in splenic and lymph node microarchitecture, reduced 
Peyer’s patches size and number, absent germinal centres.  
Defects in T-cell differentiation and severe defects in protective 
humoral immune response 
Hypersensitivity to endotoxin shock. 
IκBζ
−/−
 Severe atopic dermatitis-like disease with inflammatory cell 
infiltration. 
Impaired expression of specific genes activated by TLR/IL-1R signal 
transduction, e.g. IL-6 
IκBNS
−/−
 High sensitivity to LPS-induced endotoxin shock and intestinal 
inflammation.  
Reduced T-cell proliferation and deregulated production of subset 
of cytokines e.g IL-12p40, IL-6 and IL-18 
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critical role for Bcl-3 in the regulation of the immune response and in central 
tolerance. 
Bcl3-/- mice develop normally however they exhibit severe defects in response 
to immunogenic challenge from pathogens and display altered 
microarchitecture of their secondary lymphoid organs including reduced Peyer’s 
patches size and number and lack of germinal centres (Schwarz et al., 1997, 
Franzoso et al., 1997, Paxian* et al., 2002). Mice deficient in Bcl-3  fail to 
develop immunologic resistance to  Toxoplasma gondii and succumb to infection 
within  3–5 weeks whereas control littermates survived longer than 6 months 
(Franzoso et al., 1997). Bcl3-/- mice are also unable to clear Listeria 
monocytogenes and are more susceptible to infection with Streptococcus 
pneumonia relative to wild-type mice (Schwarz et al., 1997). Furthermore, Bcl3 
deficiency renders cells and mice hypersensitive to Toll-like receptor (TLR) 
activation and Lipopolysaccharide (LPS)-induced septic shock (Carmody et al., 
2007b). Many defects observed in Bcl3-/- mice are very similar to those seen in 
p52 deficient animals, including loss of B cell follicles within their spleens and 
lymph nodes and absence of germinal centres. Mice lacking both Bcl-3 and p52 
exhibit a more severe phenotype and fail to survive past 4 weeks of birth.  
Bcl-3 negatively regulates the expression of a number of cytokines and 
chemokines following TLR stimulation and plays an essential role in LPS 
tolerance a process also dependent on p50 homodimers (Riemann et al., 2005, 
Carmody et al., 2007b) 85]. LPS tolerance is a phenomenon in which cells or 
organisms exposed to continuous or repeated stimulation with LPS enter into a 
state altered responsiveness (Biswas and Lopez-Collazo, 2009, Beeson and 
Roberts, 1947) (Bohuslav et al., 1998). Tolerance is an essential host adaption, 
limiting the deleterious consequences of excessive inflammation such as septic 
shock caused by the overproduction of inflammatory cytokines by monocytes 
and macrophages. Tolerance was initially viewed as a transient state of hypo 
responsiveness of macrophages to repeated or prolonged stimulation with LPS 
(Medvedev et al., 2000). Recent transcriptomic analysis however revealed that, 
TLR-induced genes can be categorised into two classes, ‘toleriseable’ (class T), 
genes that are supressed during LPS tolerance and ‘non-toleriseable’ (class NT), 
genes that are inducible to equal or greater levels in tolerant macrophages. Pro-
inflammatory effectors such as TNF and IL-6 belonging to class T genes are 
rapidly tolerised following prolonged exposure to LPS whereas the expression of 
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a number anti-microbial peptides, anti-inflammatory and pro-resolution factors 
are induced. This gene specific regulation is thought to depend on chromatin 
modifications mediated by primary gene products transcribed during the first 
stimulation, resulting in the differential regulation of TLR-induced genes with 
diverse biological functions  (Foster et al., 2007). Bcl3-/- mice and macrophages 
are hyper-responsive to TLR stimulation and are defective in LPS tolerance. Bcl-
3 stabilises inhibitory p50 homodimers on toleriseable gene promoters thereby 
preventing further transactivation by c-Rel or p65 containing NF-κB dimers 
(Carmody et al., 2007b) (Discussed in detail in 1.3.4). 
 
1.1.3 IKK complex 
NF-κB signal transduction converges on a core enzymatic complex, the IκB 
kinase (IKK). The IKK complex is composed of two kinases, IKKα (or IKK-1) and 
IKKβ (or IKK-2) together with the regulatory subunit, IKKγ also known as NF-κB 
essential modulator (NEMO). The IKK complex was discovered in 1996 following 
attempts to identify the serine-kinase responsible for IκB stimulus induced 
phosphorylation (Mercurio et al., 1997, DiDonato et al., 1997, Rothwarf et al., 
1998). The kinase subunits, IKKα and IKKβ are 50% identical and share a similar 
structure, including an amino-terminal kinase domain, a helix-loop-helix and a 
leucine zipper domain (Figure 1.7). The leucine zipper domain is responsible for 
homo-or heterodimerisation of the kinases, which is essential for the formation 
of active IKK (Israël, 2010). The exact mechanism of IKK activation is not fully 
understood, however upstream kinases, transforming growth factor- β-activated 
kinase-1 (TAK1) and NF-κB-inducing kinase (NIK) act as IKK kinases in  response 
to certain stimuli (Israël, 2010). Phosphorylation of IKKα and IKKβ is critical for 
their kinase activity and essential phosphorylation sites in the kinase domain 
activation loops have been identified (Delhase et al., 1999). Once activated, 
the IKK complex is responsible for the phosphorylation of a number of 
substrates, many of which are involved in the NF-κB pathway. In the case of the 
IκB proteins, phosphorylation by IKK creates a degron or destruction motif 
recognised by the ubiquitin ligase complex, Skp1–Cullin1–F-box protein, beta- 
transducin repeat-containing proteins (SCF β-TrCP). β-TrCP interacts with a 
substrate via the binding of aspartic acid and phosphorylated serines within the 
destruction motif (Fuchs et al., 0000, Wu et al., 2003). Polyubiquitinated IκBs 
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are then rapidly degraded or as in the case for the NF-κB precursors p105 and 
p100, partially proteolysed or processed by the 26S proteasome (Discussed in 
detail 1.3.3). 
 
 
 
 
 
Figure 1.7 IKK complex and β-TrCP destruction motif. 
(A) Schematic representation of the catalytic subunits of the IKK complex with structural 
domains indicated. IKKα and IKKβ are 85-kDa and 87 kDa serine/threonine kinases 
respectively , each containing an amino-terminal kinase domain helix-loop-helix (HLH)  
and a leucine zipper (LZ). The activation loop is contained within the kinase domain, 
amino acids 176–180 of IKKα and 177–181 of IKKβ. IKKβ also contains a ubiquitin-like 
domain (UBL), the function of which is unknown.  (B) NF-κB-related IKK substrates with 
β-TrCP destruction/degron motif underlined. X represents any amino acid and n is >2. 
Phosphorylated serines are in bold. Numbering corresponding to murine IκB proteins. 
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1.2 Signaling to NF-κB 
Several pathways lead to NF-κB activation, almost all converging on IKK 
activation and IκB degradation. Engagement of various receptors, TNF receptor 
(TNFR),Toll- like receptor (TLR), Interleukin-1 receptor , T-cell receptor (TCR), 
B-cell receptor (BCR) and receptor activator of nuclear factor kappa-B (RANK) 
and B-cell activating factor (BAFF) receptor for example, all culminate in the 
activation of NF-κB transcriptional activity.  Despite significant overlap within 
these pathways, there are fundamental differences preceding IKK activation, 
highlighting the specificity of the NF-κB response.  NF-κB signalling is also 
considered to occur through either the canonical or non-canonical pathways 
(Figure 1.8). Non-canonical   or alternative NF-κB activation is triggered by a 
subset of stimuli including CD40L, lmphotoxin-β and BAFF. Unlike canonical NF-
κB activation which relies on the inducible degradation of classical IκBs, non-
canonical NF-κB signalling is dependent on the inducible processing of p100. 
This pathway activates the RelB/p52 heterodimer and regulates specific 
biological functions such as lymphoid organogenesis-cell survival and maturation 
(Sun, 2012).   
 
1.2.1 TLRs 
TLRs are an important subset of the pattern-recognition receptor (PRR) family 
of transmembrane proteins expressed by innate immune cells. TLRs receive 
their name from similarity to the protein encoded by the Toll gene in identified 
in Drosophila melanogaster (Chin and Beachy, 1994, Anderson et al., 1985) . 
PRRs are germline encoded and function to recognise conserved molecular 
motifs associated with microbial pathogens and also cellular stress (Janeway, 
1989). These motifs known as pathogen-associated molecular patterns (PAMPs) 
and danger-associated molecular patterns (DAMPs) are recognised by PRRs, 
activating the innate immune response to protect the host during infectious and 
non-infectious inflammatory responses. 13 mammalian TLRs (TLR1 to TLR13)  
have been identified to date which are activated by a number unrelated ligands 
of bacterial, viral, parasitic and fungal origin eliciting a specific transcriptional 
response to the pathogen encountered (Lee et al., 2012).  Of these 13, only 10 
functional TLRs (TLR1 to TLR10) have been identified in humans, in contrast,  
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Figure 1.8 Canonical and Non-canonical NF-κB signalling. 
In response to diverse stimuli, numerous cellular immune receptors (such as Toll-like 
receptors (TLRs), interleukin-1 receptors (IL-1Rs), TNF receptors (TNFRs), B-cell 
receptors and T-cell receptors) activate the canonical NF-κB pathway. Classical or 
canonical NF-κB signalling is mediated by IKKβ activation by upstream kinases.  IKKβ 
activation results in the induced proteasomal degradation of IκB proteins and 
subsequent released of NF-κB dimers such as the prototypic p65/p50 heterodimer.  
Liberated NF-κB translocates to the nuclease modulating the expression of target genes. 
A subset of TNF family members including CD40, lymphotoxin-β, B cell-activating factor 
(BAFF), receptor activator of NF-κB ligand (RANKL) and TNF-related weak inducer of 
apoptosis (TWEAK) activate the alternative or non-canonical NF-κB signalling. Non-
canonical NF-κB signalling is dependent on IKKα phosphorylation by NIK. IKKα induces 
the phosphorylation and proteasomal processing of p100 to p52. Newly formed p52 
forms a heterodimer with RelB and translocates to the nucleus. 
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TLR1 to TLR9 and TLR11 to TLR13 are expressed in mice.  TLRs not only differ 
in ligand specificity but also in subcellular distribution, residing both at the 
plasma membrane (TLR1, TLR2, TLR4, TLR5, TLR6, TLR11) and intracellularly 
on the endosome (TLR3, TLR7, TLR8, TLR9) (Lee et al., 2012).  Ligands for 
almost all TLRs have been identified with the exceptions of TLR10, TLR12 and 
TLR13 (Table 2). TLRs are type I integral membrane receptors, characterised by 
an N-terminal ligand recognition domain, a single transmembrane helix, and a 
C-terminal cytoplasmic signalling domain (Botos et al., 2011). This signalling 
domain was found to share homology with the signalling domain of IL-1R family 
members and so was named the Toll-IL-1 receptor (TIR) domain (Gay and Keith, 
1991).  The conserved TIR domain is responsible for the recruitment of signalling 
adaptor molecules to TLR and IL-1 receptors (O'Neill and Bowie, 2007). TIR 
domains are not restricted to TLRs and IL-1Rs however and have also been found 
in the plant kingdom in addition to number of TLR related adaptor molecules 
(Whitham et al., 1994). Myeloid differentiation primary-response protein 
(MYD88), MYD88-adaptor-like (TIRAP), TIR-domain-containing adaptor protein 
inducing IFNbeta (TRIF), TRIF-related adaptor molecule (TRAM) and sterile 
alpha- and armadillo-motif-containing protein (SARM) all contain TIR domains 
(O'Neill and Bowie, 2007). The N-terminal domain contains tandem copies of a 
leucine-rich-repeat (LRR), typically a 22-29 residue motif found in many other 
proteins involved in immune recognition (Botos et al., 2011). TLRs typically 
contain 1-25 of these repeats which assemble to form the ectodomain 
responsible for pathogen recognition (Botos et al., 2011). 
  
 24 
 
Table 2. List of TLR Ligands 
  
Trypanosoma cruzi glycosylphosphatidylinositol-anchored mucin-like glycoprotein (tGPI-
mucins) , high-mobility group box 1 protein (HMGB1), lipoteichoic acid (LTA), double-
stranded RNA (dsRNA),  vesicular stomatitis virus (VSV ), respiratory syncytial virus 
(RSV),  heat-shock protein (HSP), single-stranded RNA  (ssRNA). Adapted from (Lee et 
al., 2012). 
  
Receptor Subcellular localisation 
 
Physiological ligands 
TLR1–TLR2 Plasma membrane Triacylated lipopeptides 
TLR2 Plasma membrane 
Peptidoglycan  
Phospholipomannan  
tGPI-mucins 
Haemagglutinin 
Porins  
Lipoarabinomannan  
Glucuronoxylomannan  
HMGB1 
TLR2–TLR6 Plasma membrane 
Diacylated lipopeptides 
LTA 
Zymosan 
TLR3 Endosome dsRNA 
TLR4 Plasma membrane 
LPS 
VSV glycoprotein G  
RSV fusion protein  
MMTV envelope protein 
Mannan  
Glucuronoxylomannan 
Glycosylinositolphospholipids 
HSP60 
HSP70  
Fibrinogen  
Nickel 
HMGB1 
TLR4–TLR6 Plasma membrane 
OxLDL 
Amyloid-β fibrils 
TLR5 Plasma membrane FLAGellin 
TLR7 Endosome ssRNA 
TLR8 Endosome ssRNA 
TLR9 Endosome 
DNA 
Haemozoin 
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1.2.1.1 TLR4 
Originally named hToll, TLR4  was one of the first Toll homologues to be 
identified and cloned (Medzhitov et al., 1997). A year later, four further TLRs 
were reported however considerable focus remained on the characterisation 
TLR4 (Rock et al., 1998). Much like its Drosophila equivalent, dToll, TLR4 is a 
type 1 transmembrane protein and was found to induce transcription of immune 
response genes (Medzhitov et al., 1997, Hashimoto et al., 1991, Hashimoto et 
al., 1988). Drosophila Toll mediates the nuclear gradient and activity of the Rel 
homologue, Dorsal, which suggested a potential role for its human counterpart 
in NF-κB signal transduction (Steward, 1989, Schneider et al., 1991, Wasserman, 
1993). Early studies using a constitutive active mutant of TLR4 induced the 
transcription of  NF-κB dependent genes IL-1 and IL-8 and also NF-κB reporter 
activity (Medzhitov et al., 1997). Subsequent studies using C3H/HeJ mice which 
contain a missense mutation in Tlr4 and Tlr4 deficient mice identified an 
essential role for TLR4 in LPS signal transduction (Poltorak et al., 1998, Hoshino 
et al., 1999). LPS is the major component of the outer membrane of Gram-
negative bacteria responsible for endotoxin induced sepsis and had previously 
been shown to induce NF-κB (Sen and Baltimore, 1986a). Although LPS is the 
best studied TLR4 ligand, other PAMPs (Table 2) can also stimulate signal 
transduction through TLR4 to induce the expression of proinflammatory 
cytokines and Type 1 interferons (IFN) (Uematsu and Akira, 2007). TLR signalling 
has been divided into two pathways based on the requirement of the adaptor 
protein MYD88 (Figure 1.9) (Medzhitov et al., 1998).  TLR4 signals through both 
the MYD88-dependent and independent pathways to activate canonical NF-κB 
signalling. In addition to NF-κB, members of the mitogen activated protein 
kinase (MAPK) and interferon regulatory transcription factor (IRF) families are 
also activated following TLR4 stimulation. 
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1.2.2 MyD88-dependent and independent NF-κB activation 
All TLRs with the exception of TLR 3 signal through MyD88, however the specific 
combination of additional adaptors utilised by each TLR may differ (Kawai and 
Akira, 2007). In addition to MyD88, TLR4 interacts with 3 other adaptor proteins 
TIRAP, TRIF and TRAM (Yamamoto et al., 2003a, Horng et al., 2001, Fitzgerald 
et al., 2001, Fitzgerald et al., 2003, Yamamoto et al., 2003b, Oshiumi et al., 
2003b). Following ligand binding and receptor dimerisation, MyD88 is recruited 
to TLRs directly via its TIR domain (TLRs 5, 7, 8, 9) or through the bridging 
adaptor TIRAP (TLRs 4, 2, 2/1, 2/6). MyD88 then interacts with members of the  
serine/threonine IL-1 receptor–associated kinase (IRAK) families, including 
IRAK-1, -2 and -4 via their respective death domains (Meylan and Tschopp, 2008, 
Kawai and Akira, 2007). Activated IRAK-4 recruits and subsequently 
phosphorylates IRAK-1. IRAK-1 then auto-phosphorylates, recruiting the ring 
domain ubiquitin ligase ,tumour necrosis factor receptor–associated factor-6 
(TRAF6) (Deng et al., 2000). Together with Ubc13/Uev1A,  TRAF6  promotes Lys-
63 linked polyubiquitination of target proteins including TRAF6 itself and NEMO 
(Adhikari et al., 0000, Chen et al., 2006). Ubiquitinated TRAF6 recruits a kinase 
complex involving TAK1 and TAK1 binding proteins (TABs) 2 and 3. This TAK 
complex activates two major pathways involving NF-κB and MAPKs, c-Jun amino 
(N)-terminal kinases (JNKs) and p38 (Wang et al., 2001, Sato et al., 2005, Shim 
et al., 2005) . Recent studies, however, have shown that the role of TAK1 in TLR 
activation of MAPKs and NF-κB is cell type- specific.  TAK1 is an essential positive 
regulator of LPS induced IKK, extracellular signal-regulated kinases (ERK)-1/2, 
p38 and JNK activation in fibroblasts and B cells (Sato et al., 2005). In contrast, 
TAK1 negatively regulates LPS-induced activation of IKK, p38 and JNK activation 
in neutrophils and is not required for ERK1/2 activation in macrophage or 
monocytes (Alagbala Ajibade et al., 2012, Courties et al., 2010, Lee et al., 
2000).  
Multiple TLRs can also signal independently of MYD88 and although the kinetics 
of activation are delayed, stimulation of MyD88-/- cells with Lipid A, a 
component of LPS, results in NF-κB activation (Kawai et al., 1999, Kawai et al., 
2001). In the absence of MyD88, the TIR domain-containing adaptor, TRIF 
mediates NF-κB signalling.  TLR3 exclusively signals through TRIF, which is 
required for NF-κB activation and interferon (IFN)-β production following IRF3 
induction (Yamamoto et al., 2003a, Oshiumi et al., 2003a). Through association 
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with the bridging adaptor TRAM, TLR4 also utilises TRIF to signal independently 
of MyD88 (Yamamoto et al., 2003b). This pathway is activated downstream of 
endosomal TLR4 mediating the delayed phase of NF-κB activation and type 1 
IFN expression. 
  
 28 
 
 
Figure 1.9 TLR signalling 
Ligand binding to the TLR4 receptor induces receptor dimerization, activating TLR 
signalling. TLR4 is localised at the plasma membrane and also in endosomal 
compartments following endocytosis. The cytoplasmic TIR domain of TLR4 engages the 
bridging adaptors TIRAP and TRAM.  TIRAP and TRAM interact with the TIR domains of 
MYD88 or TRIF initiating the MYD88-dependent and- independent pathways respectively. 
MyD88 recruits members of the IRAK family (IRAK1, IRAK2 and IRAK4) and TRAF6. TRAF6 
with ubiquitin conjugating enzymes Ubc13 and Uev1A, activates the TAK1 complex 
(TAK1, TAB2 and TAB3) via K63-linked ubiquitination (Ub) triggering the p38 and JNK 
MAPK pathways. The regulatory subunit of the IKK complex, NEMO is also recruitment 
to the TAK complex facilitated by binding Lys63-linked ubiquitin chains.  Activated TAK1 
phosphorylates IKKβ thus activating the IKK complex and the canonical NF-κB pathway. 
IKK also phosphorylates p105 at S927 and S932 resulting in induced proteolysis of p105 
by the 26S proteasome. The ubiquitin ligase complex SCF β-TrCP facilitates Lys48-linked 
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ubiquitination of p105 triggering its degradation and subsequent release of Tpl-2. 
Liberated Tpl-2 phosphorylates MEK1/2 activating downstream ERK signalling. The 
MyD88 independent (or TRIF dependent) pathway is activated downstream of endosomal 
TLR4. Through the bridging adaptor TRAM, TRIF recruits TRAF3 and protein kinases TBK1 
and IKKε to phosphorylate IRF3. Phosphorylation induces dimerization and nuclear 
localisation of IRF3 where it activates type 1 interferons. TRIF also recruits the kinase 
RIP1 which activates the late phase of MAPK and NF-κB activation, however the exact 
mechanism is unclear.  Adapted from (Botos et al., 2011, Gantke et al., 2011, O'Neill et 
al., 2013, Carmody and Chen, 2007, Newton and Dixit, 2012).  
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1.2.3 TLR Induced MAPK Signalling 
MAPKs are a family of protein serine/threonine kinases that that regulate 
diverse cellular programs by relaying extracellular signals to intracellular 
responses (Cargnello and Roux, 2011). Growth factors, hormones, cytokines and 
environmental stress are among the variety of stimuli that activate MAPK 
signalling controlling a range biological responses including; gene transcription, 
cell proliferation, growth survival and cytokine production  (Chen et al., 2001). 
Conventional MAPKs are activated through a three  tiered cascade of 
sequentially acting kinases composed of a MAPK, MAPK kinase (MAP2K) and a 
MAPK kinase kinase (MAP3K)(Figure 1.10). Although considerable overlap occurs 
between MAPK cascades, MAPK substrate specificity is determined by a number 
of factors including, scaffolding interactions, distinct MAPK subcellular 
localisation,  signal intensity and duration (Keshet and Seger, 2010). Signal 
transduction through several receptor families, (receptor tyrosine kinases 
(RTK), G- protein-coupled receptors and PRRs), coordinate distinct cellular 
outcomes via downstream MAPKs, in a cell type- and stimulus- specific manner 
(Chiariello et al., 2010, Tarcic and Yarden, 2010).  
In the innate immune response, ligand binding by most TLRs activates the MAPK 
pathway, initiated by MAP3K activation. There are over 20 characterised MAP3Ks 
which provide the specificity for stimulus-dependent activation of MAP2Ks 
(Craig et al., 2008). Through unique protein–protein interactions and 
phosphorylation of signalling effectors, MAP3Ks can activate specific MAP2K-
MAPK pathways to regulate transcription factors such as such as cyclic-AMP-
responsive-element-binding protein 1 (CREB1), activator protein 1 (AP-1) and 
ETS domain-containing protein (ELK1). For example, in response to growth 
factors and mitogens, MAPK3Ks Rapidly Accelerated Fibrosarcoma (Raf) and Tat-
associated kinase (TAK)-1 play an essential role in cell growth and development 
through activation of ERK and p38/JNK MAPKs respectively. Conversely, TLR 
induced activation of these MAPKs is mediated by Tumour Progression Locus 2 
(Tpl-2), TAK1, and apoptosis signal-regulating kinase (ASK)-1, promoting the 
production of pro-inflammatory effectors. 
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Figure 1.10 MAPK signalling cascade. 
To date, 14 mammalian MAPKs have been characterised which can be subdivided based 
on sequence homology into conventional (extracellular signal-regulated kinases 1/2 
(ERK1/2), c-Jun amino (N)-terminal kinases 1/2/3 (JNK1/2/3), p38 isoforms (α, β, γ, 
and δ), and ERK5) and atypical (ERK3/4, ERK7, and Nemo-like kinase (NLK)) MAPKs . 
MAPKs are activated through a sequential phosphorylation cascade. An active MAP3K 
phosphorylates and activates a MAP2K, which in turn activates a MAPK by dual 
phosphorylation of the  Thr–X–Tyr activation motif (where X represents any amino acid). 
MAPKs can then activate several downstream kinases called MAPK activated kinases 
(MAPKAPK). MAPK/ERK kinase kinase (MEKK), tumour progression locus 2 (Tpl-2), rapidly 
accelerated fibrosarcoma (RAF), TGFβ-activated kinase 1 (TAK1), apoptosis signal-
regulating kinase  (ASK), dual leucine zipper kinase (DLK), mixed-lineage kinase  (MLK), 
MAP kinase kinase (MKK), p21-activated kinase 1 (PAK1), homeodomain-interacting 
protein kinase 2 (HIPK2), Nemo-Like Kinase (NLK), ribosomal protein S6 kinase (RSK), 
mitogen- and stress-activated kinase (MSK), MAPK signal-integrating kinase  (MNK) , 
Map Kinase-Activated Protein Kinase  (MK). (Adapted from (Arthur and Ley, 2013) 
and(Craig et al., 2008)). 
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1.2.3.1 Tpl-2 
Tpl-2 (also known as MAP3K8) is a serine/threonine protein kinase first described 
as a target for provirus integration in Moloney murine leukemia virus-induced T-
cell lymphomas (Patriotis et al., 1993). Cot (cancer Osaka thyroid), a shortened 
form of the human Tpl2 homolog was  independently identified as a transforming 
gene for a human thyroid carcinoma cell line (Miyoshi et al., 1991). Cot encodes 
a protein lacking a complete C-terminus. Full length Tpl-2 has week 
transforming potential and thus the oncogenic transformation of Tpl-2 is 
contributed to C-terminal truncation (Ceci et al., 1997). The physiological role 
of Tpl-2 as a regulator of MAPK signalling was elucidated from sequence 
homology comparisons and overexpression studies in COS-7 and MEF cells. 
Overexpression activates ERK1/2, JNK, p38γ and ERK5 MAPKs and also 
phosphorylates MEK1, MKK4, MEK5 and MKK6 in vitro (Patriotis et al., 1994, 
Salmeron et al., 1996, Chiariello et al., 2000). These early results suggested 
Tpl-2 acted directly as a MAP3K for a number of substrates however, subsequent 
in vivo studies using Tpl2-/-  mice  revealed the major function of Tpl-2 is in 
regulating ERK activation in immune responses. Tpl2-/- mice produce low levels 
of TNF when exposed to LPS and are resistant to LPS/D-Galactosamine-induced 
endotoxin shock (Dumitru et al., 2000).  Furthermore loss of Tpl-2 also protects 
from TNF-induced inflammatory bowel disease (IBD) (Kontoyiannis et al., 2002).  
Tpl-2 mediates ERK1/2 activation by all TLRs and some members of the TNFR 
superfamily in primary macrophages (Banerjee et al., 2006, Eliopoulos et al., 
2003) and is essential for  induction of a number of inflammatory mediators 
including TNF, IL-1β, IL-23p19 and cyclo-oxygenase (COX-2) (Dumitru et al., 
2000, Mielke et al., 2009, Kakimoto et al., 2010, Eliopoulos et al., 2002) 
following LPS stimulation. Following LPS induction, Tpl-2 specifically mediates 
activation of ERK1/2 in macrophage but not MAPKs, p38 and JNK (Dumitru et 
al., 2000). Tpl-2 is also required for optimal TNF production following LPS 
stimulation in other cell types however, unlike macrophages Tpl-2 may not be 
essential for TNF production in these cells. For example, Tpl-2 also plays a role 
in TNF induction in dendritic cells  however, this is only partially dependent on 
Tpl-2 (Mielke et al., 2009). Furthermore, Tpl-2 is not universally involved in TNF 
induction, curdlan stimulation of dectin-1, a Tpl-2 independent ERK activator, 
also induces TNF (Mielke et al., 2009). Tpl-2 can also regulate other MAPKS but 
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in a stimulus- and cell type- dependent manner and it has been suggested that 
Tpl-2 may not be the sole MAP3K utilised in these cascades (Das et al., 2005).   
In resting cells, Tpl-2 exists as part of a cytoplasmic complex with p105 and A20-
binding inhibitor of NF-κB 2 (Abin-2) (Belich et al., 1999, Lang et al., 2004) 
(Figure 1.11). All detectable Tpl-2 is associated with p105, however the majority 
of p105 in macrophages is not complexed with Tpl-2 (Beinke et al., 2004). By 
physically preventing access to MEK1/2, p105 negatively regulates Tpl-2 induced 
ERK activation (Waterfield et al., 2003, Beinke et al., 2003). p105 and Abin-2 
also maintain Tpl-2 stability as free Tpl-2 is very unstable. Nfkb1-/- macrophages 
are therefore defective in LPS induced ERK activation due to the reduced steady 
state levels of Tpl-2 in these cells (Waterfield et al., 2003, Beinke et al., 2003). 
Following LPS stimulation, IKKβ phosphorylates p105 on S927 and S932, targeting 
it for proteasomal degradation. IKK induced proteolysis of p105 releases Tpl-2 
from inhibition. Abin-2 is also released following p105 degradation and is not 
associated with the pool of Tpl-2 that can activate MEK. It is yet un clear if Abin-
2 has other functions other than stabilising Tpl-2 (Gantke et al., 2012). 
Liberated Tpl-2 once activated directly phosphorylates MEK1/2 thereby 
activating downstream ERK signalling (Waterfield et al., 2004, Beinke et al., 
2004). Activated ERKs phosphorylate and activate a number of important 
downstream effectors including the 90kDa ribosomal S6 kinase (RSK) family and 
mitogen- and stress-activated kinases (MSK) 1 and 2 (Murphy and Blenis, 2006). 
ERKs and RSKs can translocate to the nucleus immediately following activation 
where in addition to MSKs they can phosphorylate multiple transcription factors 
such as Elk-1  and cAMP response element-binding protein (CREB) to induce the 
transcription of a number of immediate-early (IE) genes including Fos, junB ,c-
Jun and Egr1 (Roux and Blenis, 2004).   
  
 34 
 
 
Figure 1.11 Regulation of Tpl-2-MEK kinase activity. 
In resting cells, Tpl-2 exists as part of a cytoplasmic complex with p105 and Abin-2. 
Association with these two proteins is required to maintain the steady state levels of 
Tpl-2, as free Tpl-2 is unstable. Association with p105 also inhibits the MEK-kinase ability 
of Tpl-2 by preventing Tpl-2 association with MEK1/2. Agonist stimulation of TLR4 
induces IKKβ-mediated phosphorylation of p105 at Serines 927 and 932 and triggers 
complete proteolysis of p105 by the proteasome. Liberated Tpl-2 is then free to bind to 
its substrate MEK1/2 and facilitate the phosphorylation of serines 217 and 221. Inducible 
phosphorylation of Tpl-2 at serine 400 by IKKβ and by an unknown kinase at threonine 
290 is also required for activation of MEK1/2. Activated MEK1/2 then phosphorylates 
and activates ERK1/2. Abin-2 is also released following p105 degradation but it is 
unclear if Abin-2 has other downstream targets or functions other than stabilising Tpl-
2. Tpl-2 is the sole MAP3K responsible for ERK activation in macrophages following TLR4 
engagement and although it is also important in other immune cells, for example 
dendritic cells,  it may not be the sole MAP3K utilised by these cells. Tumour Progression 
Locus 2 (Tpl-2), A20-binding inhibitor of NF-κB 2 (Abin-2), mitogen/extracellular signal-
regulated kinase (MEK), extracellular signal-regulated kinases (ERK).   
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1.3 Ubiquitination in NF-κB Regulation 
Independent of the stimulus and pathway engaged, activation and regulation of 
NF-κB relies heavily on post-translational modification. The IKKs, the IκBs and 
the NF-κB subunits themselves are all subjected to a number of regulatory 
modifications including acetylation, sumolation, nitrosylation, phosphorylation 
and ubiquitination (Figure 1.12). There are many critical cytoplasmic post- 
translational modifications required to activate NF-κB, either directly or 
through IκB degradation, however nuclear modifications play an equally 
important role (Perkins, 2000). Nuclear modifications of NF-κB are not only 
necessary for maximal transcriptional activity but are also emerging as a key to 
signal-specific responses. Stimulus-dependent induction of these modifications 
can affect the stability and  ability of NF-κB dimers to bind DNA, interact with 
IκB proteins and recruit essential co-activators (Guan et al., 2005, Hou et al., 
2003, Chen et al., 2002, Kiernan et al., 2003, Hayden and Ghosh, 2004, Ghosh 
and Hayden, 2008). The “NF-κB barcode hypothesis” suggests these covalent 
modifications alone or in combination, generate distinct patterns that function 
to direct transcription in a target gene-specific fashion (Moreno et al., 2010).  
Differential phosphorylation of serines 205, 276 and 281 for example, was shown 
to target p65 to particular gene subsets (Anrather et al., 2005), whereas 
acetylation of p65 at lysines 122 and 123 inhibited p65 transactivation while the 
same modification at lysines 218 and 221 enhanced p65 DNA binding (Chen et 
al., 2002, Kiernan et al., 2003). Although all NF-κB subunits are subjected to 
these regulatory modifications, post-translation modification of p65 is the best 
characterised with other NF-κB subunits receiving little attention in comparison 
(Perkins, 2000). 
The role of ubiquitination in NF-κB activation through IκB degradation and NF-
κB precursor processing pathway has been extensively studied, however 
ubiquitination is now also emerging as a critical step in the regulation of the NF-
κB transcriptional response (Colleran et al., 2013, Carmody et al., 2007b, Bosisio 
et al., 2006, Saccani et al., 2004). The poly-ubiquitination and subsequent 
proteasomal degradation of nuclear p65 not only regulates its stability, it 
promotes transcriptional termination by removing promoter bound p65:c-Rel 
dimers (Saccani et al., 2004, Geng et al., 2009). A number of key regulators of 
p65 poly-ubiquitination have been identified, including the deubiquitinase, 
ubiquitin-specific-processing protease 7 (Usp7), the ubiquitin ligases Pdlim2 
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(PDZ and LIM domain 2) and copper metabolism mouse U2af1-rs1 region 1-
domain-containing protein 1 (Commd1) and peptidyl-prolyl isomerase 1 (Pin1) 
(Tanaka et al., 2007, Geng et al., 2009, Colleran et al., 2013).  p50 homodimers 
are also subjected to DNA binding-dependent poly-ubiquitination, in contrast to 
p65 however, relatively little is known about the mechanisms regulating the 
post-translational modification of p50. 
 
 
 
Figure 1.12 Post translation modification of the NF-κB subunits. 
(A) Schematic representation of the structure of the NF-κB subunits, p50, p65, C-Rel, 
Relb and p52 with post translational modifications indicated. Experimentally 
characterised modifications of either human or mouse residues are illustrated with the 
amino acid numbering corresponding to the murine sequence. (B) Schematic 
representation of the structure of the NF-κB subunits p50 with post translational 
modifications identified only by proteomic discovery mode mass spectrometry 
illustrated  (Hornbeck et al., 2012, Perkins, 2000). 
 37 
 
1.3.1 The Ubiquitin Proteasome System 
Ubiquitin is a 76-amino-acid protein, that when covalently linked to target 
proteins may alter their half-life, localization, or function (Wertz and Dixit, 
2010). Attachment of a ubiquitin molecule to a substrate protein is achieved by 
a three component enzymatic system composed of a ubiquitin-activating 
enzymes (E1s), ubiquitin-conjugating enzyme (E2) and ubiquitin ligase (E3) 
(Figure 1.13) (Hershko et al., 1983). This sequential process begins with the ATP 
dependent activation of ubiquitin, in which the C-terminal carboxyl group of 
ubiquitin becomes linked to the sulfhydryl group of an E1 by a thioester bond. 
The activated ubiquitin is then transferred to the active site cysteine of one of 
over 30 E2 enzymes. In the final step, an E3 ligase acts as the substrate 
recognition molecule, binds to the target protein and catalyses the transfer of 
ubiquitin from the E2 to a lysine of the substrate protein. There are hundreds 
of E3 ubiquitin ligases, which along with the E2 confer a great specificity to the 
ubiquitin system. The process can end after the attachment of a single ubiquitin 
moiety (mono–ubiquitination) or additional ubiquitin molecules can be added, 
yielding multi-monoubiquitin or polyubiquitin chains. The outcome of a 
ubiquitinated protein is largely determined by the type of ubiquitin modification 
however, a ubiquitinated protein is not always committed to a particular fate. 
Aptly named, deubiquitinating enzymes (or deubiquitinases) remove ubiquitin 
from substrate proteins, opposing the ubiquitination process. These are highly 
specific cysteine proteases that hydrolyse the amide bond between ubiquitin 
and the substrate protein. Deubiquitination thereby alters the stability of 
substrate proteins by removing or modifying a potentially degradative signal  
and also serves to maintain steady state levels of ubiquitin (Komander et al., 
2009). 
Ubiquitin molecules can be linked through any one of the seven ubiquitin Lys 
residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63) or through the 
ubiquitin amino terminal Methionine residue (linear) to generate polyubiquitin 
chains (Figure 1. 14) (Kulathu and Komander, 2012). Although all possible 
linkages have been detected in cells, studies have largely focused on Lys48- and 
Lys63- linked homogenous chains and as such the biological  significance of other 
atypical ubiquitin chains (Lys6, Lys11, Lys27, Lys29, Lys33) is less defined 
(Kulathu and Komander, 2012, Ikeda and Dikic, 2008). 
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Figure 1.13 Ubiquitination Cascade. 
Schematic representation of the ubiquitination process (see text). Ubiquitin-activating 
enzymes (E1), ubiquitin-conjugating enzymes (E2), ubiquitin ligases (E3), Ubiquitin (Ub), 
Adenosine triphosphate (ATP), adenosine monophosphate (AMP), pyrophosphates (PPi), 
Deubiquitinase (DUB). The two major classes of ubiquitin ligases are depicted, HECT 
(Homologous to the E6-AP C-Terminal domain) and RING (Really Interesting New Gene). 
Depending on the type of ubiquitin ligase utilised, activated ubiquitin can be transferred 
directly to the substrate (RING) or following the formation of an E3-ubiquitin 
intermediate (HECT). 
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Lys48- linked ubiquitin chains were the first type of ubiquitin linkage to be 
identified and remain the best characterised. This form of ubiquitination 
typically targets the protein for degradation by the 26S proteasome, a large 
multicatalytic protease that degrades proteins into small peptides in a process 
known as proteolysis (Glickman and Ciechanover, 2002). The 26S proteasome is 
a 2.5-MDa molecular machine composed of two sub complexes,  a barrel-shaped 
20S proteolytic core complex capped at one or both ends by 19S regulatory 
complexes which recognise the ubiquitinated proteins (Voges et al., 1999). Once 
delivered to the proteasome, ubiquitinated proteins are then  deubiquitinated, 
unfolded by ATPases in the base and translocated into the 20S complex for 
degradation (Geng et al., 2012). Within the 20S core, chymotrypsin-like, trypsin-
like, and peptidylglutamyl peptide hydrolytic activities are responsible for 
attacking the target protein and cleaving it into peptide of about 4-25 residues 
(Voges et al., 1999). 
Ubiquitin meditated proteolysis is a critical regulatory mechanism that controls 
the concentration of a large number intracellular proteins which include cell 
cycle regulators such as cyclins, cyclin-dependent kinase inhibitors, and 
proteins, tumour suppressors, transcriptional activators and their inhibitors 
(Glickman and Ciechanover, 2002). Consequently, this controls a variety of 
cellular processes  involved in  cell cycle and division, differentiation and 
development, DNA repair, transcriptional regulation, transcriptional silencing 
and regulation of the immune and inflammatory responses  (Glickman and 
Ciechanover, 2002). Lys63-linked ubiquitination in contrast does not label a 
protein for destruction but rather acts as a scaffold to assemble signalling 
complexes (Wertz and Dixit, 2010, Ikeda and Dikic, 2008). Lys-63-linked 
ubiquitination thereby participates in diverse cellular processes from receptor 
endocytosis and DNA-repair processes to NF-κB activation (Ikeda and Dikic, 
2008, Wertz and Dixit, 2010) . 
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Figure 1. 14 Ubiquitin linkages 
A single Ubiquitin (Ub) moiety can be attached to the ε-amino group of lysine substrate 
at one or multiple sites yielding monoubiquitination or multi- monoubiquitination 
respectively. Ubiquitin also has seven lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, 
Lys48 and Lys63) which act as receptors for the conjugation of further ubiquitin moieties 
in the assembly of polyubiquitin chains. Branched ubiquitin chains can also form when 
two ubiquitin moieties are attached to different lysine residues of a ubiquitin that is 
already linked to a substrate protein. Adapted from (Ye and Rape, 2009). 
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1.3.2 Stimulus Induced IκB degradation  
Following the initial discovery of the IκBs, significant interest in elucidating the 
inhibitory mechanism and function of these proteins ensued. Understanding how 
NF-κB was liberated from IκB association was an obvious goal and an early 
breakthrough occurred when phosphorylation was identified as a key step in this 
regulation. Ghosh et al. reported that the addition of kinases in vitro could 
dissociate NF-κB:IκB complexes (Ghosh and Baltimore, 1990). Subsequent 
studies demonstrated that a critical step of stimulus-dependent NF-κB induction 
in vivo involved the phosphorylation of IκBα and that this was a prerequisite for 
NF-κB activation (Brown et al., 1993, Beg et al., 1993, Naumann and 
Scheidereit, 1994). Serines 32 and 36 of IκBα were identified as essential 
phosphorylation sites, later established to be mediated by the IKK complex 
(Brockman et al., 1995, Brown et al., 1995). Interestingly phosphorylation alone 
was found to be insufficient for activation and nuclear translocation of NF-κB 
(DiDonato et al., 1995, Miyamoto et al., 1994, Alkalay et al., 1995a, Finco et 
al., 1994). A second step, involving IκBα stimulus-dependent proteasomal 
degradation facilitated by β-TrCP, is required for NF-κB activation (Alkalay et 
al., 1995b, Chen et al., 1995, Yaron et al., 1998, Winston et al., 1999, Spencer 
et al., 1999). 
β–TrCP is a part of a larger family of F-box/WD40 repeat containing proteins, 
(Fbw) characterised by the presence of a 42–48 amino-acid F-box motif at the 
N-terminus and seven WD40 repeats at the C-terminus. These F-box proteins 
serve as the substrate recognition subunits of a larger SCF ubiquitin ligase 
complex, a member of the cullin-RING ligases. Substrates recognised by the β-
TrCp complex contain a characteristic degron motif in which modification of 
target serines by phosphorylation serve to rapidly distinguish the inducible 
degron motif from the non-modified sequence (Figure 1.7) (Kanarek and Ben-
Neriah, 2012, Fuchs et al., 0000). Following Lys 48-linked ubiquitination, IκBα 
is targeted for degradation by proteasome. Liberated NF-κB dimers are then 
free to translocate to the nucleus where they can bind to target promoters and 
activate transcription.  
While IκB degradation presents a sensitive system for a rapid response to a 
pathogen or harmful stimuli, prolonged NF-κB activation is potentially 
detrimental to the host. The IκBs function to not only provide inducibility to NF-
κB activity but also to prevent extended inflammatory gene expression. IκBα 
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transcription itself is regulated by NF-κB and thus is rapidly replenished 
following degradation. Newly synthesised IκBα enters the nucleus where it 
dissociates DNA bound NF-κB providing an effective negative feedback system 
to limit NF-κB dependent gene expression following a stimulus. Like IκBα, all 
classical IκBs are targeted for ubiquitination by β-TrCP following stimulus-
dependent phosphorylation but the kinetics of degradation vary significantly 
between IκBs (Hinz et al., 2012). For example, following LPS stimulation in 
Jurkat cells, IκBα is degraded in less than 15 minutes whereas IκBε degradation 
takes 60-90 minutes (Kanarek and Ben-Neriah, 2012).  In addition to different 
degradation kinetics, resynthesis of IκBβ and IκBε is also delayed compared to 
IκBα. Combined experimental and computational modelling demonstrated that 
IκBα, IκBβ and IκBε each have distinct roles that coordinate for temporal-
regulation of NF-κB activity (O'Dea and Hoffmann, 2010). Due to stimulus-
induced rapid resynthesis, IκBα provides strong negative feedback of the initial 
NF-κB response whereas IκBβ and IκBε function to control NF-κB at later time 
points (Hoffmann et al., 2002). 
 
1.3.3 Processing of NF-κB p105 to p50 
Targeting to the proteasome normally results in complete degradation of a 
protein but in remarkably rare cases, partial proteolysis by the proteasome can 
yield biologically active protein fragments  (Glickman and Ciechanover, 2002, 
Rape and Jentsch, 2002). This partial proteolysis or processing is responsible for 
the generation of the p50 and p52 subunits from the p105 and p100 precursors 
respectively. Ubiquitination of NF-κB precursors therefore presents a twofold 
mode of NF-κB regulation; complete degradation liberates sequestered NF-κB 
dimers from inhibition and processing yields the mature NF-κB subunits which 
can homo- or hetero-dimerise with other members of the rel family. 
Although several models of this proteasomal protein processing have been 
suggested, the exact mechanism is still unclear (Rape and Jentsch, 2002, Lin 
and Ghosh, 1996, Orian et al., 1999). p105 contains a glycine-rich region (GRR) 
between the RHD and the ankyrin repeats which is essential for constitutive 
processing of p105 (Figure 1.2) (Lin and Ghosh, 1996). It has been proposed that 
p105 is degraded from its C-terminal until the proteasome encounters the GRR, 
which acts as a stop signal preventing p50 degradation (Orian et al., 1999). 
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Ubiquitination is essential for both proteasomal processing and complete 
proteolysis of p105 but these may be regulated by independent mechanisms 
(Orian et al., 1995, Cohen et al., 2004). p105 is constitutively processed to p50 
in resting cells however following certain stimuli, p105 can also be targeted for 
complete degradation by the proteasome (Kanarek et al., 2010). Similar to the 
classical IκB proteins, stimulus-induced phosphorylation, targets p105 for 
ubiquitination via β-TrCp  (Cohen et al., 2004). β-TrCp mediated ubiquitination 
is dependent on IKK phosphorylation on serines 927 and 932 and triggers 
complete proteolysis of p105 by the proteasome (Figure 1.7) (Lang et al., 2003). 
In some cases, IKK phosphorylation may also induce the processing of p105 to 
p50 but this independent of β-TrCp and likely occurs by another currently 
unidentified  ubiquitin ligase (Beinke and Ley, 2004, Orian et al., 2000, 
Heissmeyer et al., 2001). 
In addition to post-translational processing from p105, it has also been proposed 
that p50 may be generated constitutively by a co-translational mechanism which 
is also dependent on the proteasome but not on ubiquitination (Lin et al., 1998, 
Lin et al., 2000). In this mechanism p50 is generated during translation of the 
Nfkb1 gene allowing the production of both p50 and p105 from the same mRNA 
which may be the source of p50 in unstimulated cells (Perkins, 2007, Chen, 
2005).  
 
 
1.3.4 Bcl-3 Inhibits p50 Ubiquitination  
Aberrant or deregulated TLR signalling can be detrimental to the host, resulting 
in inappropriate tissue damage and a variety of pathological conditions including 
autoimmunity and in severe cases septic shock.  Although the rapid induction of 
NF-κB target genes is fundamental in mounting an effective innate immune 
response, NF-κB activity must be tightly regulated in order to limit the 
magnitude and duration of TLR-mediated inflammation. In LPS tolerance for 
example, it has been shown that TLR-induced genes with diverse biological 
functions can be regulated differently following the same stimulus. NF-κB 
dependent pro-inflammatory genes that could cause excessive tissue damage if 
continually expressed are transiently silenced following repeated LPS 
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stimulation whereas NF-κB regulated genes encoding antimicrobial effectors 
that are essential for the early defence from infection remain inducible 
(Medvedev et al., 2000). 
In addition to gene-specific regulation, NF-κB activity is also intrinsically 
regulated with individual subunits having overlapping and distinct biological 
functions. p50 homodimers lack inherent transactivating potential and their role 
as transcriptional repressors of pro-inflammatory gene expression has been 
firmly established. Loss of p105 and consequently p50 impairs innate and 
adaptive immune function and Nfkb1-/- mice exhibit multifocal defects in 
immune responses (Kastenbauer and Ziegler-Heitbrock, 1999, Dennis et al., 
2008, Bohuslav et al., 1998, Wessells et al., 2004, Oakley et al., 2005, 
Elsharkawy et al., 2010, Panzer et al., 2009, Cao et al., 2006, Sha et al., 1995). 
Interestingly, a study by Cheng et.al demonstrated that a significant number of 
p50 homodimers are present in the nuclei of unstimulated macrophage, 
indicating that in addition to regulating inducible transcription, p50 may also 
play a critical role in controlling the basal expression of NF-κB target genes. 
Interestingly, this paper also showed a role for p50 homodimers in regulating 
IRF mediated transcription by binding to interferon responsive elements (IRE) in 
interferon inducible gene promoters. 
Previous studies have shown that Bcl-3 is an essential regulator of p50 
homodimers and is required to limit NF-κB transcriptional activity in a number 
of essential immune cells (Carmody et al., 2007b). Bcl-3 inhibits the 
ubiquitination and degradation of p50 homodimers thereby promoting a stable, 
p50 homodimer:DNA complex. In the absence of Bcl-3, the half-life and DNA 
binding of p50 is dramatically reduced. As a result, the promoter occupancy in 
both resting and stimulated Bcl3-/- macrophage is significantly altered. 
Chromatin immunoprecipitation (ChIP) analysis demonstrated that p50 and not 
p65 or c-Rel was present on the TNF promoter in unstimulated, wild-type 
macrophages and upon LPS stimulation p50 was transiently replaced by c-Rel 
and p65 containing dimers. In contrast, c-Rel and p65 were found to 
constitutively occupy the TNF and CXCL2 (chemokine C-X-C motif ligand 2) 
promoters in unstimulated Bcl3-/- macrophages. Furthermore, the order of the 
dimer exchange on both promoters was also disrupted following LPS. Recent 
studies have shown that NF-κB chromatin interactions are highly dynamic, 
occurring in a matter of seconds and exchange of dimers at the same promoter 
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can regulate NF-κB dependent transcription. By preventing p50 ubiquitination, 
Bcl-3 stabilises promoter bound p50 and thus in the absence of Bcl-3, an 
increased occupancy time of p65 and c-Rel containing dimers results in greater 
transcriptional output. Consequently, macrophages, dendritic cells and B cells 
deficient in Bcl-3 are hyper responsive to TLR stimulation and produce 
significantly more cytokines than wild-type cells. 
An essential role for proteasome degradation in the control of NF-κB dependent 
gene activity has already been established for p65. p65 polyubiquitination and 
degradation is required for posttranscriptional repression of the NF-κB response. 
A mutant of p65 that exhibits impaired signal-induced proteasomal degradation 
can reside on the promoters of NF-κB target genes for a longer period of time 
than the wild-type protein (Bosisio et al., 2006, Saccani et al., 2004). 
Furthermore, inhibiting USP7, a p65 deubiquitinase, inhibits recruitment of p65 
to the interleukin (IL)-6 and TNF promoters and consequently cytokine gene 
expression (Colleran et al., 2013). As with p65, DNA binding also triggers p50 
polyubiquitination thereby representing a critical mechanism in controlling 
nuclear NF-κB turnover and removal from specific promoters. Unlike p65 
however, the mechanisms regulating p50 ubiquitination and its function in TLR 
signalling are poorly understood and many questions are still outstanding. 
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1.4 Thesis Aims 
The molecular basis for the inhibition of p50 ubiquitination by Bcl-3 is unknown. 
The exact nature of the interaction between Bcl-3 and p50 has not been 
experimentally explored and it is not evident whether interaction with p50 is 
necessary for Bcl-3 mediated inhibition of cytokine expression or if other binding 
partners of Bcl-3 are also important. In addition to the NF-κB subunits, Bcl-3 
interacts with a number of regulators of transcription including -Jun and c-fos 
(Na et al., 1999), STAT1 (Jamaluddin et al., 2005), PPAR (Yang et al., 2009), 
CBP/p300 (Na et al., 1999), HDAC-1, -3 and -5 (Viatour et al., 2004), steroid 
receptor coactivator-1 (Na et al., 1999), TORC3 (Hishiki et al., 2007), retinoic 
X receptor (RXR) (Na et al., 1998), Fyn (Weyrich et al., 1998) and Lck (Zhao et 
al., 2005), insulin receptor substrate 3 (IRS3)(Kabuta et al., 2010) and Bag-1 
(Southern et al., 2012). To investigate this, we employed an immobilised 
peptide array approach to identify key regions of p50 critical for interaction 
with Bcl-3 as illustrated in chapter 3. This allowed us to generate a mutant of 
p50 incapable of interaction with Bcl-3 thereby enabling us to investigate the 
role of p50-Bcl-3 interaction in Bcl-3-mediated inhibition of p50 ubiquitination 
and repression of NF-κB target gene expression.  
As Bcl-3 is a critical negative regulation of TLR and TNFR induced gene 
expression, the second aim of this thesis was to investigate the potential of Bcl-
3 derived peptides as modulators of TLR signalling. We postulated that 
interaction with p50 mediated Bcl-3’s inhibitory activity. In chapter 4, we aimed 
to identify the minimal regions of Bcl-3 sufficient for interaction with p50 and 
from this design short peptides capable of mediating Bcl-3 function. 
Bcl3-/- mice and cells are hyper responsive to TLR and TNFR stimulation are 
defective in LPS tolerance. TLR stimulated NF-κB and MAPK signalling results in 
the production of IFNs, pro-inflammatory and effector cytokines which activate 
the innate immune response. As described in chapter 5, the final aim of this 
thesis, was to further study the role of Bcl-3 in inflammation and explore the 
possibility of NF-κB independent functions of Bcl-3 during TLR signalling, 
specifically investigating MAPK signalling in the absence of Bcl3. 
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Chapter Two 
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2 Materials and Methods 
 
2.1 MATERIALS 
2.1.1 Antibodies 
Table 3. Primary Antibodies 
Antibody and clone Cat # Supplier 
β-Actin(ac-15) A5441 Sigma Aldrich 
Bcl-3 39761 Active Motif 
c-Jun(60A8) 9165 Cell Signalling 
Phospho-c-Jun (Ser63) II 9261 Cell Signalling 
c-Myc (9E10) sc-40 Santa Cruz 
FLAG M2   F1804 Sigma Aldrich 
Glutathione-S-Transferase G7781 Sigma Aldrich 
HA (12CA5) 11583816001 Roche 
HDAC (H-51) sc-7872 Santa Cruz 
IκBα (44D4) 4812 Cell Signalling 
Phospho – IκBα (Ser32/36) (5A5) 9246 Cell Signalling 
MEK1/2 (L38C12) 4694 Cell Signalling 
Phospho-MEK1/2 (Ser217/221) 9121 Cell Signalling 
NF-κB p50 (C-19) sc-1190 Santa Cruz 
NF-κB p50 ADI-KAP-TF112 Enzo 
NF-κB p105/p50(phospho S927) ab60936 Abcam 
NF-κB p65 (C-20) sc-372 Santa Cruz 
p38 MAPK Antibody 9212 Cell Signalling 
Phospho-p38 MAPK (Thr180/Tyr182) 9211 Cell Signalling 
p44/42 MAPK(ERK1/2) 9102 Cell Signalling 
Phospho-p44/42 MAPK(ERK1/2) (Thr202/Tyr204) 9101 Cell Signalling 
Tpl-2- Cot (M20)  sc-720 Santa Cruz 
Ubiquitin VU-1 Teubu Bio 
Xpress(XP) R910-25 Invitrogen 
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Table 4. Secondary Antibodies 
Antibody and clone Cat # Supplier 
Anti- mouse IgG HRP NA931 Amersham 
Anti-rabbit IgG HRP NA934 Amersham 
Anti-goat IgG-HRP sc-2768 Sigma Aldrich 
DyLight 680 Conjugates Anti-Mouse IgG  35518 Thermo Scientific 
DyLight 800 Conjugates Anti-Mouse IgG  35521 Thermo Scientific 
DyLight 680 Conjugates Anti-Rabbit IgG  35568 Thermo Scientific 
DyLight 800 Conjugates Anti-Rabbit IgG  35571 Thermo Scientific 
Clean-Blot IP Detection Kit (HRP) 21230 Thermo Scientific 
Alexa Fluor 488 Dye Chicken Anti-Mouse IgG A2100 Invitrogen 
 
 
2.1.2 Bcl-3 Peptide Synthesis 
Table 5.  Peptide Sequences 
Peptide Sequence Modification Supplier 
BDP YGRKKRRQRRHIAVVQNNI
AAVYRILSLFKLGSREVDV
HN 
N-terminal 
FITC 
GL Biochem Ltd. (Shangai) 
BDP YGRKKRRQRRHIAVVQNNI
AAVYRILSLFKLGSREVDV
HN 
None  W.M. Keck Biotechnology 
Resource Lab (Yale) 
sBDP   YGRKKRRQRRAAVYRILSL
FKLGSR                    
None 1.W.M. Keck Biotechnology 
Resource Lab (Yale)  
2.Genscript (Hong Kong) 
mBDP     YGRKKRRQRRAAAAAILSL
FALGSA 
None 1.W.M. Keck Biotechnology 
Resource Lab (Yale)  
2.Genscript (Hong Kong) 
 
 
2.1.3 Plasmid Sources 
pGEX-6P1 was kindly provided from the McCaffrey lab, University College Cork, 
Cork. pcDNA3-Tpl2 and pcDNA3-Tpl2D270A (Rat) constructs were kindly provided 
by Steven Ley, National Institute for Medical Research, Mill Hill, London. The 
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Renella luciferase expression vector pRL-TK was purchased from Promgea.The 
pAP1-luc luciferase expression vector which contains multiple copies of the AP1 
enhancer was purchased from Clontech. The pLucp19 luciferase expression 
vector was described previously (Carmody et al., 2007a) but in summary 
the p19 promoter containing the genomic fragment −1180 to +110 of the p19 
gene and three putative NF-κB binding sites was amplified by PCR from C57BL/6 
genomic DNA and cloned into the pGL3-basic vector (Promega).  All other 
plasmids used are listed below were from Carmody lab stocks and were cloned 
using murine cDNAs. 
- pRK5-p50-FLAG 
- pEF4a-p50-XPRESS 
- pRK5-p105-FLAG 
- pEF4a-p105-XPRESS 
- pEF4a-p50-MYC 
- pcDNA3.1-Bcl-3-MYC 
- pRK5-Bcl-3-FLAG 
- pRK5-p65-FLAG 
 
 
2.1.4 DNA Sequencing 
Plasmid DNA sequencing following site-directed mutagenesis was carried out by 
GATC-Biotech Ltd. (Germany), using on site primers or primers generated by 
Eurofins MWG Operon. Sequencing results were analysed using Vector NTI 
software (Invitrogen). 
Table 6. Sequencing Primers 
Vector Forward Reverse Vector Forward Reverse 
pRK5-FLAG SP6  SV40 pEF4-Xpress T7 BGH  
pcDNA 3.1-Myc T7 SP6 pEF4-Myc T7 BGH  
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2.1.5 Mice 
Bcl3-/- C57BL/6 mice were generated as described previously described 
(Carmody et al., 2007b). Bcl3-/- C57BL/6 male mice were generously provided 
by Professor Y. Chen (University of Pennsylvania, Philadelphia, Pennsylvania, 
USA). Wild-type (WT) C57BL/6 mice were purchased from Harlan laboratories, 
UK at 6 - 8 weeks of age. Establishment of homozygous breeding was carried out 
by Doctor Christine O’Carroll (University College Cork, Cork, Ireland). Animal 
husbandry and experimental procedures were approved by the University 
College Cork Animal Experimentation Ethics Committee (AEEC). 
 
2.1.6 Reagents 
All general salts and chemicals were purchased from Sigma Aldrich UK unless 
otherwise stated. Specific biochemicals and concentrations used are indicated 
in Table 7 and described in detail in the appropriate figure legends. 
 
Table 7. List of Biochemicals 
Biochemical Concentration used Supplier 
Lipopolysaccharides from 
Escherichia coli 055:B5 
10ng/ml for BMDM 
100ng/ml RAW 264.7 
Sigma Aldrich 
TNF (recombinant mouse) 10-20ng/ml eBioscience or 
Miltenyi Biotec 
Leptomycin B 20nM Santa Cruz 
MG132 (Z-Leu-Leu-Leu-al) 20μM Sigma Aldrich 
Cyclohexamide 100μg/ml Sigma Aldrich 
 
2.1.7 Buffer Composition 
Table 8. Agarose Gel Electrophoresis Buffers 
6X Gel Loading buffer 5xTris/Borate/EDTA (TBE) 
0.4% orange G 
40% sucrose 
 
 
450mM Tris-borate 
10mM Ethylenediaminetetraacetic acid 
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Table 9. EMSA Buffers 
EMSA buffer 5% Non-denaturing Polyacrylamide 
Gel 
10mM HEPESKOH (pH7.9) 
50mM KCl 
2.5mM MgCl2 
1mM Dithiothreitol (DTT) 
10% Ficoll 
1.2µg Bovine serum albumin 
3.6 µg poly[d(I-C)] (Roche Applied 
Science) 
16.6 ml of 30% polyacrylamide solution 
10 ml of 5X TBE 
72.3 ml ddH2O 
100µl   N,N,N′,N′-Tetramethylethylene-
diamine 
1 ml Ammonium persulphate (10%) 
 
Table 10. Luciferase Assay Buffers 
Firefly luciferase  buffer Renilla luciferase buffer 
25mM Glycylglycine 
15mM Dipotassium phosphate pH 8, 
4mM Ethylenediaminetetraacetic acid 
15mM Magnesium sulphate 
75µM Luciferin 
1mM Dithiothreitol (DTT) 
0.1mM Co-Enzyme A 
2mM ATP 
1.1M Sodium chloride 
2.2mM EDTA 
220mM K2PO4 pH5.1 
0.44mg/ml bovine serum albumin, 
1.3mM Sodium Azide 
1.43µM Coelentrerazine 
 
Table 11. Lysis Buffers 
Notes: *Proteinase and phosphatase inhibitors added fresh on day of use 
 
 
 
Pull Down Lysis and Binding Buffer Radioimmunoprecipitation assay 
(RIPA)  
20mM Tris-Cl pH8.0 
200mM NaCl 
1mM EDTA pH8.0 
0.5 % NP-40 
1mM PMSF* 
2µg/ml aprotinin* 
1µg/ml pepstatin* 
 
50mM Tris-HCL pH7.4 
1% NP-40 
0.25% deoxycholate 
150mM NaCl, 1mM EDTA 
1mM PMSF* 
1mM NaF* 
1mM Na3VO4* 
2µg/ml aprotinin* 
1µg/ml pepstatin* 
2µg/ml leupeptin* 
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Table 12. Glutathione S-transferases (GST)  Protein Purification 
Lysis/ Binding Buffer Wash Buffer Elution Buffer 
50mM Tris pH8.5 
150mM NaCl 
1mM DTT* 
50mM Tris pH8.5 
500mM NaCl 
1mM DTT* 
150mM Tris pH8.5 
150mM NaCl 
10mM Glutathione 
 
Notes: Lysis/binding buffer adjusted pH to 8.5 and wash buffer to pH 7.5 (dependant 
on the Isoelectric point (pI) of purified protein – pH cannot be similar to protein pI). 
Buffers prepared day before use. *DTT added on day of use 
 
 
 
Table 13. Column Regeneration Buffers 
Glutathione Regeneration Buffer  1 Glutathione Regeneration Buffer  2 
0.1M Tris-HCl 
0.5M NaCl 
Filtered – pH8.5 
0.1M Sodium Acetate 
0.5M NaCl 
Filtered – pH4.5 
 
 
 
Table 14. Kinase Assay Buffer 
MEK Kinase Assay Buffer 
50mM Tris pH7.5 
150mM NaCl 
5mM β-glycerophosphate 
2mM DTT 
0.1mM Sodium vanadate 
10mM MgCl2 
1mM ethylene glycol tetraacetic acid  
0.01% Brij-35 
 
 
Table 15. Electrophoresis Buffers for Western Blotting 
1X Tris-glycine Running Buffer 1X Tris-glycine Transfer Buffer 
25mM Tris 
250mM glycine 
0.1% SDS 
 
(Electrophoresis grade reagents) 
48mM Tris Base 
39mM glycine  
0.0375% SDS 
20% methanol 
(Electrophoresis grade reagents) 
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Table 16. SDS PAGE Sample Buffer 
2X SDS Sample Buffer 
100mM Tris-Cl(pH6.8) 
4% (w/v) SDS 
0.2% (w/v) bromophenol blue 
20% (w/v) glycerol 
200mM β-mercaptoethanol 
 
Table 17. Tris-glycine SDS-Polyacrylamide Gels  
Gel 5% Stacking  8% Resolving 10% Resolving 
Volume 
H20 
30% acrylamide 
1.0M Tris(pH6.8) 
1.5M Tris(pH8.8) 
10%SDS 
10% ammoninumpersulfate 
TEMED 
1ml     
0.68 
0.17 
0.13 
- 
0.01 
0.01 
0.001 
5ml 
2.3 
1.3 
- 
1.3 
0.05 
0.05 
0.003 
5ml 
1.9 
1.7 
- 
1.3 
0.05 
0.05 
0.002 
 
 
Table 18. Media  
Super optimal broth (SOB) 1L SOB with catabolite repression (SOC) 
20g  Tryptone  
5g Yeast Extract   
0.5g NaCl  
10ml 250mM KCl  
pH 7.0  
-Autoclave  
-Add 5ml sterile 2M MgCl2 prior to use 
SOC is identical SOB with the addition of 
20mM glucose. 
 
-Allow autoclaved SOB to cool to 60°C.  
-Add 20 mL of sterile 1M glucose 
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2.2 METHODS 
2.2.1 Cell Culture 
2.2.1.1  Maintenance  
Human embryonic kidney 293T (HEK293T) and RAW 264.7 cells were cultured in 
high glucose Dulbecco's Modified Eagle Medium (DMEM) (Sigma) containing 10% 
Fetal Bovine Serum (FBS)(Gibco), 2mM glutamine (Sigma), and 100U/ml 
penicillin/ streptomycin (Sigma). NIH 3T3 and  Nfkb1-/-MEF cells were cultured 
in DMEM containing 10% Iron Fortified Bovine Calf Serum (BCS)(Sigma), 2mM 
glutamine, and 100U/ml penicillin/streptomycin. p105WT and p105 RKR MEFs cells 
were cultured in DMEM containing 10% Iron Fortified Bovine Calf Serum, 2mM 
glutamine, 100U/ml penicillin/streptomycin and 200μg/ml Zeocin. All cells 
were maintained at 37ºC in a humidified environment with 5% CO2. Cells were 
subcultured three times per week following mechanical (RAW 264.7) or 
enzymatic detachment (HEK293T, NIHMEF,  Nfkb1-/-MEF, p105WT and p105 RKR 
MEF)  with 0.05% Trypsin-EDTA solution (Gibco). 
 
2.2.1.2 Stable Cell Line Generation 
2.2.1.2.1 Determining Zeocin sensitivity 
The minimal concentration of Zeosin (Invivogen) required to kill the 
untransfected parental cell line was determined by generating a kill curve. Cells 
were plated at 25% confluency  grown for 24 hours. Media was removed and 
replaced with fresh  media containing varying concentrations of Zeocin from 
0μg/ml-1000μg/ml. Selective media was replenished every 3-4 days and the 
percentage of surviving cells was monitored over time. The concentration of 
Zeocin that killed all cells within the desired time (1-2 weeks) was determined 
to be 200μg/ml. 
 
2.2.1.2.2 Stable transfection 
7ug of pEF4-p105-XP  and pEF4-p105RKR-XP constructs were linearised with PvuI 
restriction enzyme (New England Biolabs [NEB]). Plasmid were linearised to 
decrease the likelihood of the vector integrating into the genome in a way that 
disrupted the gene of interest. DNA was purified with Qiaquik PCR purification 
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kit and eluted in 30 μl. Nfkb1-/-MEF (7x105/10cm dish) were transfected with 
purified plasmid (20μl) using 15μl Attratene (Qiagen) according to 
manufacturer’s instructions. 48 hours post transfection cells were trypsinised, 
diluted 1/4 in a 10cm dish and subjected to selection pressure with 200 μg/ml 
Zeocin.  To confirm transient transfection, whole cell lysates were prepared of 
the remaining cells and analysed by western blot with anti-Xpress for p105WT 
and p105 RKR expression. 
Media containing 200μg/ml Zeocin (selective media) was replenished every 3-4 
days until all negative control cells (untransfected) were dead ~13 days. In order 
to clonally select stable transfectants, serial dilutions of trypsinised cultures 
were generated in 96-well plates. Whole cell lysates were prepared of the 
remaining cells and analysed by western blot with anti-p50 to confirm stable 
transfection of mixed population. Selective media was replenished every 3-4 
days until colonies were visible. As Zeocin is not effective when cells are at 
confluencey, depending on size, single colonies were transferred (following 
trpysinisation) to a new well of 96- or 24-well plate. Selective media was 
replenished every 3-4 until cells were near confluency. Negative or low 
expressing clones were discarded and positive clones were expanded and 
cryopreserved. 
 
2.2.1.3 Bone Marrow Derived Macrophage 
2.2.1.3.1 Bone marrow isolation 
Bone marrow was isolated from C57BL6/J mice at 8-12 weeks old for generation 
of primary bone marrow derived macrophages (BMDM) in vitro. Mice were 
sacrificed by Co2 asphyxiation and cervical dislocation. Hind legs were removed 
at the hip joint and excess tissue removed from the femur and tibia bones. In 
sterile culture, bones were cleaned in sterile phosphate buffered saline (PBS) 
(Gibco) and 70% ethanol. Bones were then cut at each extremity and flushed 
with cold PBS using a 21 gauge needle and syringe. Isolated bone marrow was 
collected in sterile PBS and re-suspended to generate a single cell suspension. 
Debris was removed by passing bone marrow suspension through a 70μM cell 
strainer The bone marrow suspension was washed twice in BMDM culture media 
(DMEM, 10% FBS, 1% penicillin/streptomycin, 1% L-Glutamine) and centrifuged 
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at 4°C at 300 x g for 5 minutes. Bone marrow was typically pooled from three 
mice. 
2.2.1.3.2 BMDM Differentiation and stimulation experiments 
Following isolation or recovery from cryopreservation, bone marrow was 
cultured in BMDM culture media supplemented with 30% L929 conditioned media 
(BMDM differentiation media) in sterile untreated petri dishes, for seven days. 
Differentiation media was replaced on day 3 and any non- adherent cells were 
removed. By day 7 adherent monocytes/macrophage progenitors were 
differentiated into BMDMs. BMDMs were removed from petri dishes by incubating 
with 5mM EDTA in sterile PBS at 37°C for 5 minutes. Cells were washed twice in 
BMDM culture media at 4°C for 5 minutes at 300 x g. Cells were re-suspended 
in BMDM culture media with no L929 supplement and replated  overnight in 
tissue culture treated dishes for subsequent experiments. For LPS stimulation 
experiments, LPS was added in a step-wise fashion and al were samples 
harvested at the same time at the experiment endpoint.  
 
2.2.2 Protein Methodologies 
2.2.2.1 Protein Extraction 
2.2.2.1.1 Non denaturing whole cell extracts 
Cell culture media was aspirated and tissue culture plates gently washed with 
4ºC PBS. Cells were detached with 4ºC PBS Cells and pelleted at 11,000g for 45 
seconds. Pellets were re-suspended in 20-200μl radioimmunoprecipitation assay 
(RIPA) buffer ( 
Table 11). Re-suspended pellets were incubated on ice for 30 minutes and 
vortexed every 5 minutes. Lysate was cleared by centrifugation at 16,000g for 
10 mins at 4ºC. Supernatants were collected and analysed immediately or stored 
at -20 ºC or -80 ºC for long term storage. 
 
2.2.2.1.2 Denaturing whole cell extracts 
Cells were incubated with 10mM n-ethylmaleimide (NEM) for 30 seconds before 
cells before harvested. Cell culture media was aspirated and tissue culture 
plates gently washed with 4ºC PBS containing 10mM NEM. Cells were detached 
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with 4ºC PBS containing 10mM NEM and pelleted at 11,000g for 45 seconds. 
Pellets were re-suspended in 100μl 1%SDS and boiled for 5 minutes at 95ºC.  Cell 
pellet was disrupted by sonication for 5-15 seconds (30% amplitude and 50% duty 
cycle) using a Bandelin SONOPULS ultrasonic homogeniser HD 2070 with the MS 
73 microtip. Lysate was cleared by centrifugation at 16,000g for 10 mins at 4ºC. 
Supernatants were collected and analysed immediately or stored at -20 ºC or -
80 ºC. 
 
2.2.2.1.3 Nuclear /Cytoplasmic Extracts 
Nuclear and cytoplasmic extractions were carried out using Active Motif nuclear 
extract kit according to manufacturer’s instructions with one deviation. For 
10cm dish, cytoplasmic fractions were extracted in 200μl of lysis buffer and 
nuclear fractions extracted in 20μl of lysis buffer. 
 
2.2.2.2 Quantification 
Whole cell, cytoplasmic and nuclear protein extracts were quantified by 
Bradford assay. 1μl of cellular extract was diluted in 1ml 1X Bradford assay 
reagent (Bio-Rad).  Samples were assayed in triplicate using a 
spectrophotometric 96-well plate reader and absorbance measured at 595nM. A 
6 point standard curve between 0-9ug/ml of bovine serum albumin was 
generated to determine unknown protein concentrations.  
 
2.2.2.3 Western Blotting 
Protein preparations were separated by denaturing sodium dodecyl sulphate 
(SDS) polyacrylamide gel electrophoresis (PAGE) using the Mini-PROTEAN Tetra 
Cell system (Bio-Rad).  Cellular extracts dilued in 2X or 5X SDS sample buffer 
were routinely resolved using 10% acrylamide gels and immunoprecipitated  
proteins were resolved using 10% acrylamide gels for interaction studies and 8% 
acrylamide gels for ubiquitination assays (Table 17). Gels were run at 100-120V 
for 90-120 minutes in 1X Tris-glycine Running Buffer (Table 15). Resolved 
proteins were transferred to Amersham Hybond ECL Nitrocellulose Membrane 
(GE Healthcare) using the Mini Trans-Blot Electrophoretic Transfer sytem (Bio-
Rad)  and 1X Tris-glycine Transfer Buffer (Table 15). Nitrocelluose membranes 
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were incubated in a 5%  non-fat milk (Marvel)/PBS-T solution to block 
nonspecific binding to the membrane. For endogenous ubiquitination assays, 
nitrocellulose membranes were incubated in 0.5% glutaraldehyde/PBS pH 7.0 
for 20 min and washed  in PBS-T three times prior to blocking.  
Nitrocellulose membranes were then probed with primary antibodies in either 
5% milk/PBS-T or 5% BSA/PBS-T overnight at 4°C or 1-2 hours at room 
temperature and secondary antibodies in 5% milk/PBS-T for 1 hour at room 
temperature. Three 5-minute washes in PBS-T were performed after each 
antibody incubation.  
The method used to detect bound protein was dependent on the type of 
secondary antibody used (HRP-conjugated or Dylight 680 or 800-conjugated). 
For HRP-conjugated secondary antiobodies, bound protein was detected with 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) or 
WesternBright ECL chemiluminescent HRP substrate (Advansta). Lowly abundant 
proteins were detected with higher sensity ECL substrates, SuperSignal West 
Femto Chemiluminescent Substrate (Thermo Scientific) or WesternBright Sirius  
chemiluminescent HRP substrate (Advansta). For Dylight-conjugated secondary 
antibodies, membranes were scanned using the LI-COR Odyssey infrared 
scanner. 
In the case of multiple antibody reprobes for proteins of similar or identical 
sizes, membranes were stripped using a commercially available stripping buffer, 
Restore Western Blot Stripping Buffer (Thermo Scientific) as per instructions. 
For clarity, Western blots are presented as cropped images throughout this 
thesis, however an example of a full length Western Blot for individual assays 
are available in Appendix 7.12. 
 
2.2.3 Functional Assays 
2.2.3.1 EMSA 
IR-800 dye (DY782) labelled NF-κB consensus double stranded oligonucleotides 
5'AGTTGAGGGGACTTTCCCAGGC–3', 3'TCAACTCCCCTGAAAGGGTCCG5'  were 
purchased from Eurofins MWG Operon. Binding reactions were prepared with 
EMSA buffer (Table 9) containing 5µg of nuclear extract and 10ng 
oligonucleotides in a 30 µl reaction volume and incubated at room temperature 
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for 15 mins. Binding reactions were resolved on a 5% non-denaturing 
polyacrylamide gel (Table 9) at 300V at 4°C in 0.5x TBE (Table 8). Gels were 
visualised using LI-COR odyssey. All EMSAs were carried out with nuclear 
extracts from HEK293T transiently transfected with p50 or p50 mutant 
expression constructs. As a negative control, a DNA binding defective p50 
mutant in which critical residues for DNA binding, Y57 and D60 were mutated 
to alanine and aspartic acid respectively (p50 Y57A, D60E) was included. Cropped 
EMSAs are presents throughout figures, see Appendix 7, Figure 7.5 for an 
example of a full EMSA image. 
  
2.2.3.2 GST Pull-down Assay 
HEK293T cells were transiently transfected with p50WT- FLAG or p50RKR- FLAG. 
Whole cells lysates were extracted from cells resuspended in Pull-down lysis and 
binding buffer. Equal concentrations of lysates were  precleared in 1ml of Pull-
down lysis and binding buffer ( 
Table 11) with 50μl GSH-agarose (Sigma)  for 2 hours rotating at 4°C. GST or 
GST-Bcl-3 were incubated with precleared lysates and were affinity purified 
with 50μl GSH-agarose for 2 hours rotating at 4°C. Following wash steps, pull 
down complexes were eluted from the beads with 2X SDS sample buffer and 
analysed by western blot. 
 
2.2.3.3 Immunoprecipitation 
Following transient transfection whole cell lystates were prepared as per 
2.2.2.1.1 from 6cm or 10cm dishes (see Table 22). Equivalent concentrations of 
lysates were re-suspended in a total of 1ml of RIPA.   Samples were  pre-cleared 
with 20μl of a 50% slurry of protein G agarose/salmon sperm DNA (Millipore) for 
30 minutes rotating at 4°C. The pre-cleared lysate was removed from the 
agarose beads following centrifugation at 14,000g  for 2 minutes. 20μl of fresh 
protein G agarose beads  were added to the pre-cleared lysate and 
immunoprecipitated with 1-5μl primary antibody (anti-FLAG and anti- 
XPRESS:1μl or anti-MYC:3μl) overnight at 4°C rotating. Beads were pelleted at 
11,000g  for 10 seconds, the supernatant was discarded and beads were washed 
in 1ml of RIPA buffer by inverting 10 times. Wash step was repeated twice. To 
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elute immunoprecipitates, beads were resuspended in 20-40μl 2X SDS sample 
buffer and boiled for 5 minutes at 95°C . Samples were vortexed for 10 seconds 
and elutates removed from the beads following centrifugation at  16,000g  for 
2 minutes. Eluates were stored short term at -20°C or analysed immediately by 
western blot (see section 2.2.2.3). For endogenous immunoprecipitation of p50 
from p105 and p105 RKR MEFS, assays were carried out as above using 3 x 10cm 
dishes (1.5x106 cells per dish) per sample using 5ul anti-p50 for 
immunoprecipitation (Enzo). 
 
2.2.3.4 Dual Luciferase Assay 
RAW 264.7 and Nfkb1-/- MEF were transiently transfected (see Table 22) with 
the pLucp19 or pAP1-Luc plasmid for 24 hours . Cotransfection of the Renella-
luciferase expression vector pRL-TK (Promega) was used as an internal control 
for all reporter assay. If additional plasmids were required, the total plamid 
concentration was kept constant between samples with the addition of an 
empty expression vector.  Cells were then cultured with or without 100 ng/ml 
LPS (Sigma) or 20ng/ml TNF (eBiosciences) for an additional 8 hours before  
harvest. Cells were washed once with 4°C PBS and either lysed immediately in 
100μl 1x passive lysis buffer (Promega) in the plate or plates were stored at -
80°C following the addition of 100μl 1x passive lysis buffer. 10µl of fresh or 
thawed lysate was added to 50µl of firefly luciferase assay buffer (Table 10) 
and a 10 second measurement was performed on a GloMax 20/20 luminometer 
to determine the luciferase activity. 50µl of Renella assay buffer (Table 10 ) 
was added and Renella luciferase activity measured as previous. For all samples 
the firefly luciferase activity was divided by that of the Renella luciferase 
activity to normalise for the transfection efficiency as previously described 
(Dyer et al., 2000). 
 
2.2.3.5 MEK Kinase Assay 
Tpl-2-MYC was immunoprecipitated as described in section 2.2.3.3. Essentially, 
whole cell lysates were prepared from 293T cells transfected with 1μg pcDNA3-
Tpl-2-MYC in the presence or absence of 1μg pRK5-Bcl-3-FLAG. Equivalent 
concentrations of lysates were re-suspended in a total of 1ml of RIPA. Samples 
were pre-cleared as in section 2.2.3.3.  The pre-cleared lysate was removed 
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from the agarose beads following centrifugation at 14,000g for 2 minutes. 20μl 
of fresh protein G agarose beads were added to the pre-cleared lysate and 
immunoprecipitated with 3μl anti-MYC rotating overnight at 4°C. Beads were 
pelleted at 11,000g for 10 seconds, the supernatant was discarded and beads 
were washed in 1ml of RIPA buffer ( 
Table 11) by inverting 10 times. Wash step was repeated twice.  Beads were 
then washed twice in 1ml MEK kinase assay buffer (Table 14). Beads were 
incubated at 30°C with occasional agitation for 15 minutes in 20μl of MEK kinase 
assay buffer containing 1μg recombinant inactive MEK1 20μl (Millipore) and 2mM 
adenosine triphosphate (ATP). Beads were pelleted at 11,000g for 10 seconds 
and the supernatant was removed, added to 20μl 2X SDS sample buffer and 
analysed by western blot for phosphorylated MEK. Immunoprecipitates were also 
eluted from the beads as per section 2.2.3.3 and analysed by western blot. 
 
2.2.3.6 Ubiquitination Assay 
Denaturing whole cell lysates were prepared from 6cm or 10cm dishes (see 
Table 22)  as described in section 2.2.2.1.2. Equivalent volumes of lysates were 
re-suspended in a total of 1ml of RIPA buffer supplemented with 20mM NEM. 
Samples were pre-cleared and immunoprecipitated overnight as in section 
2.2.3.3.  Eluates were stored short term at -20°C or analysed immediately by 
western blot (see section 2.2.2.3). For endogenous p50 ubiquitination assays, 
assays were carried out as above using 3 x 10cm dishes (1.5x106 cells per dish) 
per sample using 5ul anti-p50 (Enzo). IP samples were resolved by SDS PAGE (8%) 
and transferred to nitrocellulose membrane. Prior to blocking, nitrocellulose 
membranes were incubated in 0.5% glutaraldehyde/PBS pH 7.0 solution for 20 
min , followed by 3 washes  in PBS-T.  
 
2.2.4 Immunofluorescence  
NIH3T3 cells were transiently transfected for 24 hours in a 6cm dish (see Table 
22) before replating 40,000 cells per well in 4-well chamber slide (Lab-Tek, 
Nunc). 24 hours later, cells were left untreated or treated with 20nM LMB for 2 
hours before harvest. Tissue culture media was discarded and slides washed x3 
with PST-T. Cells were fixed by the addition of ice cold 1:1 methanol/acetone 
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solution and incubating at -20°C for 5 minutes. Slides were washed x3 with PST-
T. Cells were blocked in 1% BSA/PBS-T for 1 hour. Cells were stained with 1/500 
anti-MYC in 1% BSA/PBS-T overnight at 4°C. Slides were washed x5 with PST-T. 
Cells were stained with 1/800 anti-mouse AF488 secondary antibody 1% 
BSA/PBS-T at room temperature for 1 hour. Slides were washed x5 with PBS-T. 
Coverslips were mounted onto slides with vectashield mounting medium with 
DAPI (Vector Labs). 
 
2.2.5 GST Protein Purification  
BL21 Codon Plus cells (provided by McCaffery Lab university College Cork, Cork) 
were transformed with pGEX6p1, pGEX6p1-p50 or pGEX6p1-Bcl-3 and plated 
onto LB agar containing 50μg/ml ampicillin and chloramphenicol. Plates were 
incubated overnight at 37°C. A single colony was isolated and incubated 
overnight in 5ml of L Broth containing 50μg/ml ampicillin and chloramphenicol. 
Cultures were incubated shaking 220-240 rpm at 37°C. 5ml of overnight culture 
was added to 700ml L Broth containing 50μg/ml ampicillin in a Belco flask.  
Cultures were grown shaking 220-240 rpm at 37°C to an OD 600 of 1.0-2.0. Before 
induction, 1ml aliquot was pelleted by centrifugation at 1000g for 5 minutes and 
resuspended in 1X SDS sample buffer, boiled at 95°C for minutes and stored at 
-20°C (uninduced). Volume in μl of 1x sample buffer used = OD600x200. Cultures 
were induced with 1mM IPTG (GST, GST-p50) or 0.1mM IPTG (GST-Bcl-3) and 
incubated overnight shaking 220-240rpm at 20°C. Following induction a 1ml 
aliquot was prepared as uninduced sample above. Cultures were centrifuged at 
4,000g for 15 minutes at 4°C. Pellets were frozen at -20°C. 
Pellets were thawed on ice and resuspended in 70ml of cold lysis buffer (Table 
12) supplemented with two complete, mini, EDTA-free protease inhibitor 
cocktail tablets (Roche Applied Science). The resuspended pellet was sonicated 
for 30 minutes with 5 minutes pulses, and 5 minute rest between each pulses (1 
hour total run time).  Lysates were cleared by centrifugation at 15,000g for 30 
minutes at 4°C. 50μl of supernatant was added to 50ul 2X SDS sample buffer 
(Table 16) boiled at 95°C for 5 minutes and stored at -20°C (soluble fraction). 
Pellets were resuspend in 70ml of lysis buffer and an insoluble sample was 
prepared as soluble fraction above. Subsequent steps were carried out at 4°C. 
Glutathione agarose (Sigma) in the purification column was equilibrated with 
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binding buffer (Table 12).The cleared supernatant was added to the 
Glutathione agarose and incubated for 1 hour rocking before passing through 
the column. Glutathione agarose was washed overnight with 2L of wash buffer 
adjusted to pH 7.5. Six elutions were performed by incubating the Glutathione 
agarose with 4ml elution buffer (Table 12) and passed through the purification 
column. Elutions were aliquoted, snap frozen and stored at -80°C.  Elutions 
were analysed by SDS PAGE. 
 
2.2.6 Spot synthesis of Peptides and Overlay Analysis 
Spot synthesis of peptides was carried out in collaboration with Dr. Kiely, 
(University of Limerick, Limerick, Ireland). Peptide libraries of p50 (sequences 
provided in Appendix 7.1 and 7.2) and Bcl-3 (Appendix 7.5 and 7.6 ) were 
generated by automatic SPOT synthesis as previously described (Kramer and 
Schneider-Mergener, 1998) and synthesised on continuous cellulose membrane 
supports on Whatman 50 cellulose using Fmoc (N-(9-flurenylmethoxycarbonyl) 
chemistry with the AutoSpot-Robot ASS 222 (IntavisBioanalytical Instruments).  
Arrays were activated by incubation in 100% Ethanol for 5 minutes, equilibrated 
in Tris buffered saline (TBS) with 0.05% Tween20 (TBS-T) for 10 minutes and 
blocked with a 5% non-fat milk (Marvel)/TBS-T solution  for 1 hour at room 
temperature. The interaction of GST and GST-Bcl3 or GST-p50 was investigated 
by overlaying the cellulose membrane with 10ug/ml of each recombinant 
protein in 1% Milk/TBS-T overnight at 4°C in. Arrays were washed a total of 3 
times for 5 minutes in TBS-T before immunoblotting with anti-GST primary 
antibody for 2 hours and Anti-rabbit IgG HRP for 1 hour.  Arrays were washed as 
previous following each antibody incubation and bound protein was detected 
with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific).  
Arrays were incubated in peptide array stripping buffer(2% SDS, 62mM Tris 
pH6.8, 20mM DTT) for 30 minutes at 70°C and washed twice in TBS-T for 10 
minutes to remove bound protein. Specific alanine scanning substitution arrays 
were generated using the same synthesis procedure. GST and GST-Bcl3 or GST-
p50 were incubated with the substitution arrays as previous and immunoblotted 
with anti-GST and a IR-800 conjugated anti-rabbit secondary.  Substitution 
arrays were scanned on  the LI-COR odyssey to detect bound protein. 
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2.2.7 Site-directed Mutagenesis 
Site-directed mutagenesis (SDM) of p50 and p105 was performed using Quick-
change I, II and lightening site-directed mutagenesis kits (Stratagene) as per 
instructions. SDM oligonucleotides were designed using the QuikChange Primer 
Design online tool: 
(http://www.genomics.agilent.com/primerDesignProgram.jsp). 
HPLC grade oligo-nucleotides were purchased from Eurofins MWG Operon. 
Concentrations of oligonucleotides and templates as follows: Oligonucleotides 
125ng  and Template: 100ng. 
- SDM for p50DFSPT was performed  by Aisling McCann (University College 
Cork). 
- SDM for p50K315A,K317A was performed by Jennifer O’Donnell (University 
College Cork). 
- SDM for p50K315A,Y316A,K317A.  was performed by Diarmuid Glavin (University 
College Cork). 
  
Table 19. p50 SDM Oligonucleotide Sequences 
Mutant oligonucleotides Sequences 5’-3’ 
 
p50KRM 
 
5-gccccgaatgcatccaacctggcaatcgtggcagcggacagaacagcaggatgtgt-3 
5-acacatcctgctgttctgtccgctgccacgattgccaggttggatgcattcggggc-3 
 
Template: pRK5-p50-FLAG 
 
p50KRM,DBM 
 
5-ggatttcgattccgcgctgtgtgtgacggcccatcacacgga-3 
5-tccgtgtgatgggccgtcacacacagcgcggaatcgaaatcc-3 
 
Template: pRK5-p50KRM-FLAG 
 
p50DFSPT 
5-ggagtttgggaaggatttggggccgctgccgccgcggatgttcatagacagtttgc-3 
5-gcaaactgtctatgaacatccgcggcggcagcggccccaaatccttcccaaactcc-3 
 
Template: pRK5-p50KRM-FLAG 
 
p50Y316F 
5-cattgtcttcaaaacgccaaagtttaaggatgtcaacattacaaagc-3 
5-gctttgtaatgttgacatccttaaactttggcgttttgaagacaatg-3 
 
Template: pRK5-p50-FLAG 
 
p50RKR 
5-
tgaaatcaaagacaaagaggaagtgcaagcggcagcccagaagcttatgccgaacttct 
cgg-3 
5-ccgagaagttcggcataagcttctgggctgccgcttgcacttcctctttgtctttgatt 
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tca-3 
 
Template: pRK5-p50-FLAG 
Template: pEF4-p50-MYC 
 
p50K363A 
5-gtgcaaaggaaacgccaggcgcttatgccgaacttctc-3 
5-gagaagttcggcataagcgcctggcgtttcctttgcac-3 
 
Template: pRK5-p50-FLAG 
p50K128R 5-gtaacagcaggacccagggacatggtggttg-3 
5-caaccaccatgtccctgggtcctgctgttac-3 
 
Template: pEF4-p50-XPRESS 
 
p50Y316A  
 
5-ccattgtcttcaaaacgccaaaggctaaggatgtcaacattacaaagc-3 
5-gctttgtaatgttgacatccttagcctttggcgttttgaagacaatgg-3 
 
Template: pRK5-p50-FLAG 
 
p50K315A,Y316A,K317A
  
5-tgtcttcaaaacgccagcggctgcggatgtcaacattaca-3 
5-tgtaatgttgacatccgcagccgctggcgttttgaagaca-3 
 
Template: pRK5-p50K315A,K317A -FLAG  
 
p50K315A,K317A 
5'cagtttgccattgtcttcaaaacgccagcgtatgcggatgtcaacattacaaagccagc-
3 
5-gctggctttgtaatgttgacatccgcatacgctggcgttttgaagacaatggcaaactg-
3 
 
Template: pRK5-p50-FLAG 
 
 
 
 
Table 20. p105 SDM Oligonucleotide Sequences 
Mutant oligonucleotides Sequences 5’-3’ 
 
p105K315A,K317A 
5-cagtttgccattgtcttcaaaacgccagcgtatgcggatgtcaacattacaaagccagc-3 
5-gctggctttgtaatgttgacatccgcatacgctggcgttttgaagacaatggcaaactg-3 
 
Template:pEF4-p105-Xpress 
 
p105 KRM 
 
5-gccccgaatgcatccaacctggcaatcgtggcagcggacagaacagcaggatgtgt-3 
5-acacatcctgctgttctgtccgctgccacgattgccaggttggatgcattcggggc-3 
 
Template:pEF4-p105-Xpress 
 
p105RKR 
5-tgaaatcaaagacaaagaggaagtgcaagcggcagcccagaagcttatgccgaac 
ttctcgg-3 
5-ccgagaagttcggcataagcttctgggctgccgcttgcacttcctctttgtctttgat 
ttca-3 
 
Template: pEF4-p105-XPRESS 
 
p105K128R 
5-gtaacagcaggacccagggacatggtggttg-3 
5-caaccaccatgtccctgggtcctgctgttac-3 
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Template: pEF4-p105-XPRESS 
2.2.8 Molecular Biology Techniques 
2.2.8.1 Preparation of Chemically Competent Cells 
Adapted from  (Sambrook and Russell) Escherichia coli (E.coli) DH5α  were 
streaked onto LB agar and incubated overnight (16-20 hours). A single colony 
was isolated and incubated with 100 ml of Lysogeny broth (LB) in a 1L flask at 
37°C with agitation. The OD600 of the culture was measured every 15-20 minutes 
and harvested at OD600 of 0.35. For efficient transformation it is essential that 
the number of viable cells not exceed 108cells/ml which is equivalent to OD600 
~ 0.4 for most strains of E.coli. Bacterial cells were transferred to 50ml 
centrifuge tubes and incubated on ice for 10 minutes. Cells were recovered by 
centrifugation at 2700g for 10 minutes at 4°C. Medium was decanted and tubes 
inverted for 1 minute to ensure all media was removed. Pellets were 
resuspended by gentle swirling in 30 ml ice-cold MgCl2-CaCl2solution (80mM 
MgCl2, 20mM CaCl2).  Cells were recovered by centrifugation at 2700g for 10 
minutes at 4°C. Medium was decanted and tubes inverted for 1 minute to ensure 
all media was removed. Pellets were resuspended by gentle swirling in 4 ml ice-
cold 0.1 M CaCl2 solution for each 50 ml of original culture. 
To prepare frozen stocks of competent cells, 70μl of Dimethyl sulfoxide (DMSO) 
was added per 2ml of resuspended cells and mixed gently.  Following 15 minutes 
incubation on ice, an additional 70ul of DMSO was added to each suspension and 
returned to ice. Cells were quickly dispensed into aliquots into chilled, sterile 
microfuge tubes and immediately snap-frozen in liquid nitrogen. Competent 
cells were stored at -80°C. 
 
2.2.8.2 DNA transformation for Routine Plasmid Preparation 
10-20 μl of competent bacteria (as prepared in 2.2.8.1) were thawed on ice. 
Following the addition of 10ng of plasmid DNA, competent cells were incubated 
on ice for a further 2 minutes. Bacteria were heat shocked in a 37°C water bath 
for 1 minute and returned to ice immediately. Cells were recovered in 100μl of 
super optimal broth with catabolite repression (SOC) media (Table 18) and 
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transferred to LB agar containing of 50μg/ml ampicillin. Agar plates were 
incubated over night at 37°C. 
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2.2.8.3 Plasmid Extraction 
2.2.8.3.1 Midiprep 
A single colony was inoculated into 2ml LB containing 50μg/ml ampicillin.  
Starter cultures were incubated at 37°C shaking for 6-8 hours. 100 ml LB 
containing 50μg/ml ampicillin was then spiked with 100μl of the starter culture 
and incubated at 37°C shaking for 16-20 hours. Plasmid DNA was extracted using 
PureYield Plasmid Midiprep System (Promega) according to manufacturer’s 
instructions. Plasmid concentration and purity was determined using a 
NanoDrop spectrophotometer.  
2.2.8.3.2 Miniprep 
5 ml LB containing 50μg/ml ampicillin was inoculated with a single colony and 
incubated at 37°C shaking for 16-21 hours. Plasmid DNA was extracted using 
Wizard Plus SV Mini-Prep (Promega) or  PureYield Plasmid Miniprep System 
(Promega) according to manufacturer’s instructions.  
 
2.2.8.4 Transfection 
Cell lines were transiently transfected as per manufacturer’s instructions, cells 
were transfected for 24 hours for all assays with the exception of 
immunofluorescence which is described in detail in section 2.2.4.  Transfection 
reagents and ratios of plasmid to transfection reagent used for each cell type 
are described in Table 21. Assay specific transfection conditions are described 
in Table 22. Within an experiment total plasmid concentrations were kept 
constant between samples with the addition of an empty expression vector. 
Table 21. Transfection Conditions 
Cell line Transfection Reagent Supplier Plasmid(μg): 
Reagent(μl) 
RAW 264.7 X-tremeGENE HP 
Attractene 
Roche 
Qiagen 
1:2 
1:3 
HEK293T Turbofect 
X-tremeGENE HP 
Fermentas 
Roche 
1:2 
1:3 
NIH3T3 Attractene Qiagen 1:3 
Nfkb1-/-MEF Attractene Qiagen 1:3 
p105WT MEF 
p105 RKR MEF 
Attractene Qiagen 1:3 
 
 70 
 
Table 22. Assay Specific Transfection Conditions 
Assay 
Type 
Cell 
Number 
Cell 
Type 
Plasmid 
Concentration 
Co-IP 2 x106 per 6cm dish 
or 
5 x106 per 10cm dish 
HEK 293T 
 
HEK 293T 
1ug of each plasmid 
 
2ug of each plasmid 
EMSA 2 x106 per 6cm dish HEK 293T 1ug of each plasmid 
Immuno-
fluorescence 
3.5 x105 per 10cm dish NIH 3T3 1ug of each plasmid 
Luciferase 
assay 
1x105 per well  
(24 well plate) 
 
 
 
 
 
 
 
 
 
RAW 264.7 
 
 
 
 
 
 
 
 
 
 
100ng of luciferase 
reporter and 10ng of 
Renella reporter used 
per sample. 
The concentration of 
additional plasmids 
were dependent on the 
individual experiment 
and are detailed in 
figure legends. 
 
Luciferase 
assay 
2.5x104  per well 
(24 well plate) 
 
Nfkb1-/- MEF 
 
As above 
Kinase assay 2 x106 per 6cm dish 
 
HEK 293T 1ug of each plasmid 
 
Ubiquitination 
assay 
2 x106  per 6cm dish 
or 
5 x106 per 10cm dish 
HEK 293T 
 
HEK 293T 
1ug of each plasmid 
 
2ug of each plasmid 
 
2.2.8.5 Sub cloning 
To generate GST expression vectors. Murine Bcl-3 and p50 cDNAs were subcloned 
from pRK5-Bcl-3-FLAG and pRK5-p50-FLAG vectors respectively into pGEX-6p1. 
NEB supplied all restriction enzymes. 20μl restriction digests were performed 
with 1μg plasmid DNA and 10 units of BamH1 and Sal1 as per manufacturer’s 
instructions. DNA fragments were resolved on 1% agarose gel, excised and 
purified with Wizard SV Gel and PCR Clean-Up System (Promega). Ligation 
reactions were performed with T4 DNA ligase (NEB) using a 1:6 molar ratio of 
vector to insert in 10μl, overnight at 16°C. 1μl of ligation reaction was 
transformed into NovaBlue Singles Competent Cells (Novagen) as per 
manufacturer’s instructions. 
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2.2.8.6 Gene expression analysis 
For real-time PCR, total RNA was isolated using RNeasy kits (Qiagen) and 
reversely transcribed using cDyNAmo cDNA synthesis kit (Thermo scientific) or 
NanoScript reverse transcription kit (Primer Design) as per manufacturer’s 
instructions. Real-time PCR was performed with SensiMix SYBR master mix or 
PerfeCTa SYBR Green SuperMix with ROX using QuantiTect Primer Assays 
(Qiagen). Data were normalised to 18s Gene expression changes calculated using 
the 2-∆∆CT method. 
 
Table 23. Thermo cycling conditions 
                                             Cycle              Temperature           Time 
SensiMix SYBR master mix 
 
Roche lightcycler 480 
384well format 
 
1 95°C 10 minutes 
 
40-45 
95°C 
60°C 
72°C 
15 seconds 
30 seconds 
15 seconds 
PerfeCTa SYBR Green 
SuperMix 
 
Applied Biosystems 7500 
Fast Real-Time PCR System  
96 well format 
1 95°C 20 seconds 
40 
95°C 
60°C 
3 seconds 
30 seconds 
 
Table 24. QuantiTect Primer Assays 
Gene Product Number  Gene Product Number 
Ccl2 QT00167832  ILβ QT01048355 
cFos QT00147308  IL6 QT00098875 
Cxcl2 QT00113253  IκBα QT00134421 
Egr1 QT00265846  Ptgs2 QT00165347 
IL10 QT00106169  Tnf QT00104006 
IL12b QT00153643  Ccl2 QT00167832 
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2.2.9 Bioinformatic tools 
2.2.9.1 Hydrophobicity analysis 
Hydrophobicity analysis was performed on the murine  p50 protein sequence 
using  the Cowan and Whittaker Hydrophobicity scale (Cowan and Whittaker, 
1990) and  BioAnnotator (Vector NTI, Invitrogen). 
 
Table 25. Amino Acid Hydrophobicity Values 
Amino Acid Hydrophobicity Values 
Ala:0.420 Gln:-0.960 Leu: 1.800 Ser:-0.640 
Arg:-1.560 Glu:-0.370 Lys:-2.030 Thr:-0.260 
Asn:-1.030 Gly: 0.000 Met: 1.180 Trp: 1.460 
Asp:-0.510 His:-2.280 Phe: 1.740 Tyr: 0.510 
Cys:  0.840 Ile:  1.810 Pro: 0.860 Val: 1.340 
 
 
2.2.9.2 Crystal structure analysis 
Protein crystal structures were analysed with 3D Molecule Viewer (Vector NTI, 
Invitrogen). p50 crystal structure with predicted C-and N-terminal domains was 
modelled using Phyre2 (Structural Bioinformatics Group, Imperial College 
London) (Kelley and Sternberg, 2009). Confidence in the model: 332 residues 
(83%) modelled at >90% accuracy.  
Protein data bank (PDB) structures used:  
 Structure of NF-kappa b p50 homodimer bound to a kappa b site 
(Ghosh et al., 1995) 
 Crystal Structure Of The Ankyrin Repeat Domain Of Bcl-3: A 
Unique Member Of The Ikappa b Protein Family (Michel et al., 
2001). 
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2.2.9.3 Similarity index 
Similarity index of the ARD of murine IκB family members was determined with 
AlignX software (Vector NTI, Invitrogen) following multiple sequence alignment. 
Residues are scored based on the similarity value. Identical residues =1, similar 
residues = 0.5 and weakly similar residues = 0.2.  
 
Table 26. Residue conservation table 
Residue 
 
Strong 
Similarity 
Weak 
Similarity 
 Residue 
 
Strong 
Similarity 
Weak 
Similarity 
A GS CTV  M ILV F 
B    N Q DEGHKRST 
C  AS  P  ST 
D E GHKNQRS  Q N DEHKRS 
E D HKNQRS  R K DEHNQ 
F WY HILM  S AT CDEGKNPQ 
G A DNS  T S AKNPV 
H Y DEFKNQR  V ILM AT 
I LMV F  W FY  
K R DEHNQST  Y FHW  
L IMV F  Z   
 
 
2.2.9.4 Multiple sequence alignment 
Multiple sequence alignment of the ANK repeat domains of murine IκB family 
members was performed using AlignX software (Vector NTI, Invitrogen) and gaps 
manually adjusted based on secondary structure as per (Basith et al., 2013).
  
Table 27. IκB sequence Identifiers 
Protein Reference Sequence ID  Protein Reference Sequence ID 
Bcl-3 NP_291079.2  IκBζ NP_001152866.1 
IκBα EDL36726.1  IκBNS NP_742154.1 
IκBβ NP_035038.2  p100 NP_001170840.1 
IκBε NP_032716.2  p105 NP_032715.2 
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2.2.9.5 Protein structure prediction software  
A number of web based protein prediction software tools were utilised in this 
study and are summarised in Table 28.  
 
Table 28. Web servers for structure predication 
Prediction 
Tool 
Server name Server location and  
web address 
Reference  
3D structure  
 
Phyre2 
 
 
Structural Bioinformatics Group, 
Imperial College, London. 
http://www.sbg.bio.ic.ac.uk/ph
yre2 
 
(Kelley and 
Sternberg, 
2009) 
Surface 
accessibility 
and 
secondary 
structure  
Predictprotein 
 
 
 
 
 
 
 
NetSurfP 
 
Rost Lab, Bioinformatics and 
Computational Biology 
Department,  Technical University 
of Munich. 
https://www.predictprotein.org/ 
 
 
Centre for Biological Sequence 
Analysis, CBS, Department of 
Systems Biology. 
The Technical University of 
Denmark. 
http://www.cbs.dtu.dk/services
/NetSurfP 
 
(Rost et al., 
2004) 
 
 
 
 
 
(Petersen et 
al., 2009) 
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Chapter Three 
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3 Investigation of the molecular 
determinants of NF-κB p50 
ubiquitination 
 
3.1 ABSTRACT 
Bcl-3 is an essential negative regulator of NF-κB during TLR and TNF Receptor 
signalling. Bcl-3 interacts with a number of transcriptional regulators including 
homodimers of the NF-κB p50 subunit. Deletion of Bcl-3 results in increased NF-
κB p50 ubiquitination and increased inflammatory gene expression. We 
employed immobilised peptide array technology to define a region of p50 
required for the formation of a Bcl-3:p50 homodimer immunosuppressor 
complex.  Key amino acids of p50 critical for interaction with Bcl-3 and are 
essential for Bcl-3 mediated inhibition of inflammatory gene expression were 
identified. Bcl-3 is unable to interact with p50 when these amino acids are 
mutated, rendering it incapable of inhibiting the transcriptional activity of NF-
κB. Nfkb1-/- cells reconstituted with mutated p50 precursor, p105, recapitulate 
the Bcl3-/- phenotype and are hyper-responsive to TNF stimulation as measured 
by inflammatory gene expression. Our study demonstrates that interaction with 
p50 essential for the anti-inflammatory properties of Bcl-3 and further highlights 
the importance of p50 homodimer stability in the control of NF-κB target gene 
expression.  
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3.2 INTRODUCTION 
Bcl-3 is a critical regulator of NF-κB during TLR-induced gene expression and 
recent work has shown that Bcl-3 mediated stabilisation of p50 is required for 
limiting NF-κB transcriptional activity (Carmody et al., 2007b). Supported by 
increased levels of p50 ubiquitination in Bcl3-/- macrophages, Bcl-3 over 
expression blocks p50 homodimer ubiquitination and subsequent degradation 
(Carmody et al., 2007b). This inhibition of ubiquitination extends the half-life 
of p50 thereby stabilising a DNA bound p50 homodimer complex. DNA binding 
triggers p50 ubiquitination, thus in the absence of Bcl-3 this p50:DNA complex 
is short lived, permitting an increase in promoter occupancy of active NF-κB 
dimers. In unstimulated macrophage, p50 homodimers occupy the promoters of 
Tnf and Cxcl2 genes, however in Bcl3-/-  cells , these promoters are bound by 
cRel and p65 (Carmody et al., 2007b). This altered dimer equilibrium results in 
increased NF-κB transcriptional activity and proinflammatory gene expression 
(Carmody et al., 2007b). p50 ubiquitination is  therefore a critical regulatory 
step of NF-κB gene expression following TLR activation. The precise mechanism 
of p50 ubiquitination following TLR signalling and its role in innate immunity is 
however yet to be elucidated. 
In 1995, the structure of murine and human NF-κB p50 homodimer bound to DNA 
was determined independently by two group (Ghosh et al., 1995, Muller et al., 
1995). Although the orientation of the N-terminal domains varied slightly due to 
different half site spacing, both structures show identical protein folds (Müller 
and Harrison, 1995). Not surprisingly the structure of IκBα:NF-κB heterodimer 
complex quickly followed  but remains the only resolved structure of an IκB 
protein bound to NF-κB p50 complex to date (Huxford et al., 1998, Jacobs and 
Harrison, 1998). Due to the homologous nature of IκB proteins, this complex 
provided a template for the available models of a DNA bound Bcl-3:p50 
homodimer complex (Michel et al., 2001, Manavalan et al., 2010). Michel et al. 
superimposed the crystal structures of  Bcl-3 and a p50 homodimer onto the 
IκBα:NF-κB complex (Michel et al., 2001),  whereas Manavalan et al. performed 
a molecular docking approach (Manavalan et al., 2010). While in silico methods 
provide an excellent basis to study protein-protein interactions these 
approaches have significant limitations. Unlike the predicted Bcl-3:p50 
homodimer complex, the solved IκBα:NF-κB structure is not a DNA bound 
complex and DNA biding can directly alter p50 conformation (Müller et al., 
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1996). Docking models also predict complexes based on individual structures 
and may not account for conformational changes of bound and unbound 
proteins. Both approaches predicted specific p50:Bcl-3 interacting residues but 
neither were confirmed experimentally.  
Peptide arrays provide an excellent tool to aid in the investigation of protein 
interaction domains through epitope mapping (Geysen et al., 1987, Frank and 
Overwin, 1996). This strategy involves synthesising a library of overlapping 
peptides that span the entire protein of interest.  There are many methods 
available to prepare peptides arrays but one of  the most common technique 
used for synthesising peptides directly on a solid support is the SPOT-synthesis 
technique. The SPOT method allows simultaneous multiple short peptides to be 
synthesised on a variety of solid supports (Frank, 1992). Ronald Frank developed 
the system in 1990 based on Merrifield’s solid phase peptide chemistry  and 
earlier work by Frank et al. describing parallel synthesis of large numbers of 
oligonucleotides on cellulose filter disks (Frank et al., 1983). Originally 
developed as a manual method, the SPOT-synthesis technique has been 
commercially adapted allowing reliable high throughput automatic synthesis of 
peptide arrays. The range of applications are growing (reviewed in (Reineke et 
al., 2001, Frank, 2002)) but peptide arrays are commonly used to map B and T 
cell epitopes, characterise enzyme substrates and study protein-protein 
interactions.  
 
 
Figure 3.1 Schematic representation of peptide scanning using SPOT synthesis 
technology 
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Peptides are synthesised on cellulose membranes in a cyclic procedure where 
essentially during each cycle, a single 9-Fluorenylmethoxycarbonyl (Fmoc)-
protected (Carpino and Han, 1972) amino acid is coupled to a growing peptide 
chain bound to the solid support. Following  Fmoc deprotection and 
dimethylformamide and ethanol wash steps, the process  is repeated until the 
entire peptide is assembled. Peptide length and offset number are determined 
by the user but ideally longer peptides with a short offset will yield a greater 
chance of epitope hits. This approach is ideally suited for continuous epitope 
regions, mapping of partial discontinuous binding sites although limited, is 
possible. Following synthesis the peptide array is then incubated with a binding 
partner for example cell extract or recombinant protein.  Detection of the 
peptide-protein complex can be performed by a number of methods, dependent 
on the specific assay. Typically, an antibody based approach is used in which a 
primary antibody against the partner protein or fused tag coupled with a 
secondary antibody is used (Kiely et al., 2009, Colleran et al., 2013). 
In this chapter, we investigated the mechanisms through which Bcl-3 inhibits 
p50 ubiquitination specifically aiming to determine if interaction with p50 is 
necessary for Bcl-3 mediated inhibition of p50 ubiquitination and repression of 
NF-κB transcriptional activity. A peptide array approach was utilised to identify 
key regions of p50 required for interaction with Bcl-3. Using site-directed 
mutagenesis, we generated a p50 mutant incapable of interaction with Bcl-3. 
Our data demonstrates that interaction between Bcl-3 and p50 is required for 
Bcl-3-mediated inhibition of p50 ubiquitination and the anti-inflammatory 
properties of Bcl-3. During this study, we also identified a number of residues 
of p50 critical in regulating p50 ubiquitination. 
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3.3 RESULTS 
3.3.1 Identification of the Bcl-3 Interacting Regions of p50 
Using Peptide Arrays 
3.3.1.1 Expression and Purification of Recombinant Bcl-3 
Recombinant Bcl-3 was constructed by inserting murine Bcl-3 cDNA into the 
multiple cloning site of pGEX6p1 (Figure 3.2 A).  The pGEX vector series allows 
inducible expression of GST fusion proteins in E.coli. Expression of the fusion 
protein is under the control of the tac promoter, which is induced by addition 
of IPTG. E.coli BL21 CodonPlus were transformed with pGEX-6p1 or pGEX-6p1-
Bcl-3.  GST proteins were induced overnight at 20°C with optimised 
concentrations of IPTG 1.0mM or 0.1mM for GST or GST-Bcl-3, respectively.  The 
lower concentration of IPTG resulted in a reduced yield of Bcl-3 fusion protein 
but was required to express a soluble intact protein as higher IPTG 
concentrations induced expression of an insoluble form of Bcl-3. Recombinant 
proteins were then affinity-purified against GSH-agarose and eluted with 
glutathione over a number of elutions (Figure 3.2 B).  The suitability of GST-Bcl-
3 for use as a p50 peptide library probe was established using a GST pull-down 
assay. GST or GST-Bcl-3 were incubated with a whole cell lysate overexpressing 
FLAG tagged p50 and affinity purified with GSH agarose. p50-FLAG bound 
specifically to purified GST-Bcl-3, but not GST indicating a functional Bcl-3 
fusion protein. (Figure 3.2 C). 
 
3.3.1.2 Bcl-3 Binds to Distinct Peptides on a p50 Peptide Array 
The crystal structures of Bcl-3 and p50 homodimers have been resolved 
independently and computational modelling of a Bcl-3:p50 homodimer complex 
indicates that Bcl-3 makes a number of contacts with amino acids in both 
subunits of a p50 homodimer (Michel et al., 2001, Manavalan et al., 2010). In 
order to experimentally identify the regions of p50 mediating interaction with 
Bcl-3, an immobilised peptide array based technique using recombinant GST-
Bcl-3 protein as a probe was employed. Specifically, a library of overlapping 
peptides 18 amino acids in length, each shifted by 3 amino acids and 
encompassing the entire sequence of p50, was SPOT-synthesised on 
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nitrocellulose membranes to generate p50 peptide arrays (see Appendix 7.1 for 
peptide library). p50 peptide arrays were then probed with either GST or GST-
Bcl-3 and bound protein was detected by immunoblotting with anti-GST 
antibody (Figure 3.3A). GST-Bcl-3 bound specifically to a number of peptides on 
the p50 peptide array suggesting that Bcl-3 probably makes a substantial number 
of contacts with p50. This is not surprising as it is likely Bcl-3 will make unique 
contacts on both p50 subunits (Michel et al., 2001, Manavalan et al., 2010). 
These stretches of peptides were examined further and using the available 
crystal structure of a p50 homodimer bound to DNA, many peptides were 
excluded from additional analysis. Protein-protein interactions are dependent 
on exposed residues to create a binding interface, many of the positive Bcl-3 
peptides identified from the peptide array however did not appear to be 
exposed and therefore were unlikely to be available for binding with Bcl-3. 
Furthermore, peptides that contained residues involved in DNA binding were 
also excluded as mutation of these amino acids would likely result in substantial 
changes in the properties of p50, for example peptides 12-17 contain several 
p50 amino acids that make direct contacts with DNA (Muller et al., 1995). The 
full p50 peptide array and alanine scanning data is available in Appendixes 7.1-
7.3. 
Four regions of positive Bcl-3 binding were however considered to be of 
particular interest (Figure 3.3 B). Regions R1-R3 are highlighted on the crystal 
structure of p50 (Figure 3.3 C). R1 spans both the DNA binding and dimerisation 
domains of the RHD whereas R2 and R3 are contained within the dimerisation 
domain of p50. Residues from region R4 lie in extreme C-terminus of the RHD 
and are not represented in the currently available structures of p50. 
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Figure 3.2 Cloning and purification of recombinant Bcl-3. 
(A) Murine Bcl-3 was ligated via  BamH1 and Sal1 restriction sites into pGEX6p1 to 
produce a GST-Bcl-3 expression vector. (B) Escherichia coli BL21 CodonPlus were 
transformed with pGEX-6p1 or pGEX-6p1-Bcl-3.  GST and GST-Bcl-3 were  induced with 
the addition of  IPTG. Recombinant proteins were affinity-purified against GSH-agarose 
and eluted with glutathione. (C) p50 binds specifically to GST-Bcl3 in a GST pull down 
assay. Purified bacterial recombinant GST or GST-Bcl-3 was incubated with a HEK293 
whole cell lysate overexpressing FLAG-p50 and were affinity purified with GSH agarose. 
Pull down complexes were immunoblotted with anti-FLAG and anti-GST . 
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Figure 3.3 Identification of Bcl-3 interacting regions on p50 using peptide arrays. 
(A) Peptide arrays of immobilised overlapping 18-mer peptides, each shifted to the right 
by 3 amino acids encompassing the entire p50 sequence were generated.  Arrays were 
probed with GST or GST-Bcl-3 and detected by immunoblotting with anti-GST antibody. 
GST-Bcl-3 binding to p50 peptides is shown and is representative of duplicate arrays. 
(B) Table indicating GST- Bcl-3 positive binding regions of interest with corresponding 
p50 amino acids. (C) Schematic representation of GST-Bcl-3 binding regions R1-R4 on 
p50.  (D) p50 homodimer crystal structure with R1-R3 shaded in blue. For clarity, each 
region is highlighted on only one subunit. Murine p50 amino acid numbering (B-D). 
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3.3.1.3 Alanine Substitution Arrays Identify Key Interacting 
Residues on p50 
In order to identify individual amino acids within these regions of p50 that are 
essential for Bcl-3 binding a series of alanine-scanning arrays were generated.  
Alanine scanning arrays were derived from the positive 18-mer parent peptides 
of region R1-R4. For each parent peptide, 18 new peptides were generated.  
Each peptide contained a single successive alanine substitution of the original 
peptide (see Appendix 7.2 for alanine substitution library).  The alanine 
scanning array was again incubated with GST-Bcl-3 prior to staining with anti-
GST antibody. Detection of GST-Bcl-3 binding was then performed using near 
infra-red IR-Dye-conjugated secondary antibody to facilitate quantification of 
GST-Bcl-3 binding to specific peptides using an infra-red scanner. In each case 
the binding of GST-Bcl-3 to the substituted peptide was calculated with respect 
to the parent peptide contained on the same array. Substitution of amino acids 
that resulted in significantly decreased Bcl-3 binding i.e. less than 50% binding 
of the parent peptide were  considered to be strong candidates for interaction.  
These data indicated a number of key residues in each of the four regions R1 –
R4 which were subsequently mutated through site-directed mutagenesis (SDM) 
of full length p50. 
 
3.3.2 Lys 249, Arg252 and Met 253 are Critical for p50 
Stability 
3.3.2.1 Alanine Substitution Analysis of Bcl-3 Binding Region R1  
The first region of the p50 array to be investigated was  R1, a  30 residue stretch 
corresponding to amino acids 232-261 of p50 (Figure 3.4 A).  An alanine scanning 
approach was then employed to identify the specific amino acids within R1 that 
may be required for interaction with Bcl-3. The 18 amino acids of p50-derivied 
peptides 78, 80 and 82 were sequentially substituted with alanine and probed 
with GST-Bcl-3. Bcl-3 binding was detected by immuoblottting and quantified 
by densitometry and represented as a percentage binding of the control parent 
peptide (Figure 3.4 B).  These data demonstrate that alanine substitutions at 
Lys 249, Arg252 and Met 253 significantly decreased GST-Bcl-3 binding when 
compared to the parent p50 peptide.  Direct interaction with Bcl-3 requires 
contributing amino acids to be present on the outer surface of p50. Examination 
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of the crystal structure of p50 homodimer bound to DNA reveals that indeed Lys 
249, Arg252 and Met 253 are surfaced exposed and available for binding (Figure 
3.4 C). 
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Figure 3.4 Alanine substitution analysis of Bcl-3 binding Region R1. 
(A) Sequences of peptides 78-82 of region 1 are shown with Lys249, Arg252 and Met253 
underlined. (B) The 18 amino acids of p50-derivied peptides 78, 80 and 82 were 
sequentially substituted with alanine and probed with GST-Bcl-3. Bcl-3 binding was 
quantified by densitometry and represented as a percentage binding of the control 
parent peptide. Substitution of amino acids Lys249, Arg252 and Met253 (denoted with 
*) resulted in a decrease of ≥ 50%  in Bcl-3 binding and are represented on p50 crystal 
structure in (C) . Murine p50 amino acid numbering (A-C).   
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3.3.2.2 Characterisation of p50KRM  
In order to evaluate the contribution of residues Lys 249, Arg252 and Met 253 of 
p50 to interaction with Bcl-3, a p50 mutant in which Lys 249, Arg252 and Met 
253 were mutated to alanine (p50KRM) was generated. The interaction of this 
p50KRM mutant with Bcl-3 was then assessed by co-transfection in 293T cells 
(Figure 3.5 A).  Bcl-3 was weakly detectable in immunoprecipitates of p50KRM 
but was significantly decreased compared to levels purifying with p50, 
suggesting that Lys 249, Arg 252 and Met 253 promote p50 interaction with Bcl-
3. Bcl-3 is a predominantly nuclear protein and thus changes in the subcellular 
localisation of p50 can in directly affect the ability of Bcl-3 to bind p50. 
Therefore nuclear and cytoplasmic fractions of cells transfected with p50 or 
p50KRM were generated and protein levels analysed by immunoblot.  As 
demonstrated in Figure 3.5 B, subcellular fractionation revealed that p50KRM 
localised to the nucleus to similar levels as p50, indicating that the mutation of 
the amino acids Lys 249, Arg 252 and Met 253 to alanine does not disrupt the 
nuclear localisation of p50. These data was supported by an analysis of the DNA 
binding activity of p50KRM using EMSA which incorporated a double stranded 
oligonucleotide probe containing the NF-κB consensus DNA binding sequence 
and nuclear extracts from 293T cells transfected with expression vectors for p50  
or p50KRM. No significant differences were seen in the DNA binding activity of 
p50RKR compared to wild type p50 (Figure 3.5 C).Together these data 
demonstrate that reduced binding of p50KRM to Bcl-3 is not due to a change in 
nuclear localisation or DNA binding properties resulting from the mutation. 
 
3.3.2.3 Mutation of Lys 249, Arg 252 and Met 253 Disrupt p50 
Stability 
Previous studies indicated that Bcl-3 negatively regulates NF-κB through 
inhibition of p50 homodimer ubiquitination and subsequent proteasome 
degradation (Carmody et al., 2007b). We next wanted to determine whether 
Lys 249, Arg252 and Met 253 are important for Bcl-3 mediated inhibition of p50 
ubiquitination. A ubiquitination assay in 293T cells transfected with HA-tagged 
ubiquitin, p50 or p50KRM, with or without Bcl-3 was performed. Following 
denaturing lysis, p50 was immunoprecipitated with anti-FLAG and 
immunoblotted with anti-HA antibody. Strikingly this analysis revealed a huge 
increase in the ubiquitination of p50KRM relative to wild type p50 (Figure 3.6 A).  
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Overexpression of Bcl-3 effectively blocked p50 ubiquitination and although the 
levels of ubiquitination of p50KRM  were substantially increased Bcl-3 was also 
able to inhibit p50KRM ubiquitination , as evident upon lighter exposure of the 
Western blot. 
Ubiquitination of p50 is closely linked to its degradation indicating that a hyper 
ubiquitinated form of p50 would have reduced stability and function. To 
investigate this, a luciferase reporter assay incorporating the Bcl-3 regulated 
NF-κB-dependent IL-23p19 gene promoter was employed (Carmody et al., 
2007a). p50 homodimers are generally considered repressors of NF-κB 
transcription. Dose-dependent analysis of p50 and p50KRM expression on IL-23p19 
reporter activity was performed by transfecting low but increasing amounts of 
p50 or p50KRM expression vectors in RAW 264.7 cells. Total plasmid was kept 
constant by including appropriate amounts of an empty plasmid expression 
vector. Following LPS stimulation, a dose dependent inhibition of reporter 
activity following transfection with p50 but not with p50KRM was observed (Figure 
3.6 B). Furthermore mutation of these residues in p105, the p50 precursor, 
produced a very unstable form of p50 as p50 processed from mutated p105 
(p105KRM) was almost undetectable by immunoblot (Figure 3.6 C). Together 
these data demonstrate that although important, Lys 249, Arg252 and Met253 
of p50 are not essential for Bcl-3 binding. The hyper-ubiquitination and 
instability of p50 generated form p105 suggest that these residues may be 
critical in regulating p50 stability independently of Bcl-3. 
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Figure 3.5 Characterisation of p50KRM.  
(A) HEK293T cells were transfected with pRK5-p50-FLAG(p50) or pRK5-p50-FLAG in 
which Lys249, Arg252 and Met253 of p50 are mutated to alanine (p50KRM ) with or without 
pcDNA3.1‐Bcl‐3-MYC (Bcl-3). Whole cell lysates were immunoprecipitated (IP) with anti-
FLAG and analysed by western blot (WB) with the indicated antibodies. Immunoblotting 
with anti-β-actin was used as a loading control. (B) Nuclear (Nuc) and cytoplasmic (Cyto) 
extracts were prepared from HEK293T cells transfected with expression plasmids as 
indicated. p50 and p50KRM subcellular localisation were analysed by WB with anti-FLAG. 
(C) HEK293T cells were transfected with expression plasmids as indicated. Nuclear 
extracts were prepared from the transfected cells and tested in an Electrophoretic 
Mobility Shift Assay (EMSA) using the consensus NF‐κB binding nucleotide. As a negative 
control, in addition to the KRM mutation, residues critical for DNA binding, Y57 and D60 
were mutated to alanine and aspartic acid respectively (p50 KRM,DBM). DNA binding mutant 
(DBM). 
 90 
 
 
Figure 3.6 Lys 249, Arg 252 and Met 253 are critical for p50 stability.  
(A) HEK293T cells were transfected as indicated with pRK5-p50-FLAG(p50) or pRK5-p50-
FLAG in which Lys249, Arg252 and Met253 of p50 are mutated to alanine (p50KRM ) with 
or without pcDNA3.1‐Bcl‐3-MYC (Bcl-3). p50/p50KRM ubiquitination was determined by IP 
from whole cell lysates with anti-FLAG and WB with anti-HA for HA-ubiquitin. Bcl-3 can 
inhibit p50KRM ubiquitination (Lower Exposure). (B) RAW 264.7 cells were transiently 
transfected with the pLucp19 plasmid expression vector with increasing amounts 
(1.25,2.5 and 5ng) of p50 or  p50KRM for 24 hours and cultured with or without 100 ng/ml 
LPS for an additional 8 hours before luciferase activity was measured. The total amount 
of plasmid was constant across all samples by adjusting the amount of empty vector. 
The Renella luciferase expression vector pRL-TK was used as an internal control to 
normalise the transfection efficiency across all samples. IL23 p19 reporter activity is 
represented as fold increase over untreated (UNT) cells transfected with pLucp19 
plasmid and empty vector expression (mock). Transfections were performed in triplicate 
per experiment and data shown are means + SEM and are representative of independent 
experiments. Statistical significance between corresponding p50 and p50KRM mutant 
reporter activities was determined by Student’s t test; P<0.05 (*), P<0.01 (**), 
P<0.001(***). (C) HEK293T cells were transfected with p105 or p105 in which Lys 249, 
Arg 252 and Met 253 were mutated to alanine and analysed by western blot.   
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3.3.3 Alanine Substitution Analysis of Bcl-3 Binding Region 
R2  
A similar approach was carried out to analyse Bcl-3 binding region R2 of p50. 
Alanine scanning arrays of spots 91-97 were generated as in Figure 3.5. Bcl-3 
binding was detected by immuoblottting and represented as a percentage 
binding of the control parent peptide (Figure 3.7 B). The alanine substitution 
array identified a number of amino acids that when mutated to alanine 
significantly reduced Bcl-3 binding (Figure 3.7 B). Specifically a stretch of 5 
amino acids of p50 DFSPT 297-301 were considered to be of particular interest 
as, equivalent amino acids in p65 make contact with IκBα as part of a p50 
heterodimer (Huxford et al., 1998, Jacobs and Harrison, 1998). These amino 
acids are surface exposed and available for binding (Figure 3.7 C).  
 
3.3.3.1 p50DFSPT Emulates p50KRM Phenotype 
When Asp297, Phe298, Ser299, Pro300 and Thr301 were mutated to alanine  
(p50DFSPT), Bcl-3 binding was drastically reduced. The interaction of p50DFSPT and 
Bcl-3 was assessed by co-transfection in 293T cells.  Bcl-3 was readily detectable 
in p50 immunoprecipitates in contrast to almost undetectable levels with 
p50DFSPT (Figure 3.8 A). These mutations did not affect the nuclear localisation 
or DNA binding activity of p50DFSPT compared to wild type p50  (Figure 3.8 B). 
Interestingly, these mutations also lead to a hyper ubiquitinated phenotype 
similar to that seen for p50KRM, which was also sensitive to inhibition by Bcl-3 
(Figure 3.9 A). As with p50KRM , p50DFSPT was next tested in in an IL-23p19 
luciferase reporter assay.  Following LPS stimulation a dose dependent inhibition 
of reporter activity following transfection with p50 but not with p50DFSPT was 
observed (Figure 3.9 B).   
 
3.3.3.2 Potential R1/R2 Binding Interface  
As both p50KRM and p50DFSPT mutants displayed apparent identical phenotypes, 
the crystal structure of these regions was further analysed. The amino acid 
sequence information of a protein determines its three-dimensional structure, 
however due to complex folding mechanisms; distinct regions of a protein’s one-
dimensional sequence can be adjacent on the crystal structure.  The p50 RHD 
 92 
 
folds into two domains and although Lys 249, Arg252 and Met 253 and  Asp297-
Thr 301 are both in the C terminus they are located at opposite sides of the 
three-dimensional p50 structure (Figure 3.10 B).  p50  is stable only as part of 
an NF-κB  dimer  and two p50 subunits bind asymmetrically to produce a p50 
homodimer (Figure 3.10 A).  When visualised as part of the complete structure, 
it is evident that these regions on opposite subunits complement each other to 
produce an interface on each side of the p50 homodimer (Figure 3.10 E). This 
suggests that this region may be critical in the stability/ubiquitination of p50 
independent of Bcl-3. 
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Figure 3.7 Alanine substitution analysis of Bcl-3 binding Region R2.  
(A) Sequences of peptides 94-98 of p50 region 2 are shown with amino acids Asp297, 
Phe298, Ser299, Pro300 and Thr301 underlined. (B) The 18 amino acids of p50-derivied  
peptides 95 and 97 were sequentially substituted with alanine and probed with GST-Bcl-
3. Bcl-3 binding was quantified by densitometry and represented as a percentage 
binding of the control parent peptide. Substitution of amino acids Asp297, Phe298, 
Ser299, Pro300 and Thr301 (denoted with *) resulted in a decrease of ≥ 50%  in Bcl-3 
binding and are represented on thr p50 crystal structure in (C). Murine p50 amino acid 
numbering (A-C). 
 
 94 
 
  
 
 
Figure 3.8 Asp 297, Phe 298, Ser 299, Pro 300 and Thr 301 of p50 are required for 
interaction with Bcl-3. 
(A) HEK293T cells were transfected as indicated with pRK5-p50-FLAG(p50) or pRK5-p50-
FLAG in which Asp 297, Phe 298, Ser 299, Pro 300 and Thr 301 of p50 are mutated to 
alanine (p50DFSPT) with or without pcDNA3.1‐Bcl‐3-MYC (Bcl-3). Whole cell lysates were 
immunoprecipitated (IP) with anti-FLAG and analysed by western blot (WB) with the 
indicated antibodies. Immunoblotting with anti-β-actin was used as a loading control. 
(B) HEK293T cells were transfected with expression plasmids as indicated. Nuclear 
extracts were prepared from the transfected cells and tested in an Electrophoretic 
Mobility Shift Assay (EMSA) using the consensus NF‐κB binding nucleotide. Nuclear inputs 
were analysed by WB with anti-FLAG. 
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Figure 3.9 p50DFSPT emulates p50KRM. 
(A) HEK293T cells were transfected as indicated with pRK5-p50-FLAG(p50) or pRK5-p50-
FLAG in which Asp 297, Phe 298, Ser 299, Pro 300 and Thr 301 of p50 are mutated to 
alanine (p50DFSPT) with or without pcDNA3.1‐Bcl‐3-MYC (Bcl-3). p50/p50DFSPT 
ubiquitination was determined by IP from whole cell lysates with anti-FLAG and WB with 
anti-HA for HA-ubiquitin. (B) RAW 264.7 cells were transiently transfected with the 
pLucp19 plasmid and with empty expression vector or expression vectors containing 
increasing amounts (1.25,2.5 and 5ng)  of p50 or  p50DFSPT for 24 hours and cultured with 
or without 100 ng/ml LPS for an additional 8 hours before luciferase activity was 
measured. IL23 p19 reporter activity was determined as in Figure 3.6. Transfections 
were performed in triplicate and data shown are means + SEM and are representative 
of independent experiments. Statistical significance between corresponding p50 and 
p50DFSPT mutant reporter activities was determined by Student’s t test; P<0.05 (*), 
P<0.01 (**), P<0.001(***). 
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Figure 3.10 Potential R1/R2 binding interfaces of p50 homodimer.  
(A) Amino (N)- and Carboxyl (C)- termini of  subunit A (yellow) and B (green) of the p50 
homodimer (murine). (B-D) Top view of dimer rotated 90° on its y- axis. (B) Region R1 
and R2 of subunit A shaded in blue. (C) Amino acids of region R1 indicated on both 
subunits A and B. (D) Amino acids of region R2 indicated on both subunits A and B. (E) 
Detailed top view of R1/R2 interface. 
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3.3.4 Regulation of p50 Ubiquitination by Tyrosine 316 
Based on the alanine scanning arrays of peptides 103 and 105 a three amino acid 
motif, KYK in loop 5 of p50 appeared to be a potential Bcl-3 binding region. 
Individual mutation of Lys315 and Lys317 to alanine in the substitution array 
reduced Bcl-3 binding by at least 50% (Figure 3.11 B). A number of mutants 
(p50K315A,K317A, p50Y316A and p50Y316F) of this region were made with various 
phenotypes each characterised below. 
 
3.3.4.1 p50 Lys 315 and Lys 317 are not essential for interaction 
with  Bcl-3 
A mutant of p50 in which Lys 315 and Lys 317 were mutated to alanine 
(p50K315A,K317A) retained the ability to interact with Bcl-3. Reduced levels of Bcl-
3 immunoprecipitated with p50K315A,K317A however this correlates with decreased 
expression of Bcl-3 when co-transfected with this mutant. Co-
immunoprecipitation with increasing levels of Bcl-3 demonstrated that 
p50K315A,K317A interacted dose dependently with Bcl-3 similar to wild type p50 
(Figure 3.12 A). Although this mutation had no effect on Bcl-3 binding, the 
ubiquitination of this mutant was significantly reduced (Figure 3.12 B). This 
reduction of ubiquitination was not due to a defect in DNA binding as 
p50K315A,K317A bound to an NF-κB probe with similar levels to wild type p50 (Figure 
3.12 C). Previous data generated in the lab in which Lys 315 and Lys 317 were 
mutated to arginine, another positively charged,  polar, amino acid  showed no 
reduction in ubiquitination. This suggested that neither lysine was directly 
ubiquitinated or that this defect was due to a possible structural change or 
alternation in the interaction with the ubiquitination machinery.  
 
3.3.4.2 Tyr 316 is critical for negative regulation of p50 
ubiquitination  
To further elucidate the role of this region in regulating p50 ubiquitination Tyr 
316 was mutated to alanine (p50Y316A).  Surprisingly p50Y316A was ubiquitinated 
to an even greater extent than wild type p50 as opposed to a reduction as seen 
again with p50K315A,K317A (Figure 3.13 A). Tyrosine contains a bulky aromatic side 
chain which is completely absent in alanine, therefore a second Tyr 316 mutant 
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in which tyrosine was mutated to phenylalanine p50Y316F was made. As with 
tyrosine, phenylalanine contains a large benzyl side chain, but it does not 
contain a hydroxyl group, essentially a non phosphorylatable tyrosine.  This 
version of p50 was also hyper-ubiquitinated compared to wild type p50 (Figure 
3.13 B). A double mutant, p50 K315A,Y316A,K317A was also hyper ubiquitinated and 
was unable to inhibit LPS induced IL23p19 reporter activity as effectively wild 
type p50 (Figure 3.13 C). Collectively these data suggest that Tyr 316 is essential 
for negatively regulating p50 ubiquitination. As the tyrosine to phenylalanine 
mutation (p50Y316F) did not rescue the hyper-ubiquitination phenotype of 
p50Y316A, this suggests that phosphorylation at Tyr 316   may play a role in 
blocking ubiquitination of p50. 
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Figure 3.11 Alanine substitution analysis of Bcl-3 binding Region R3. 
(A) Sequences of peptides 100-105 of region R3 are shown and Lys315, Tyr316 and Lys137 
underlined. (B) The 18 amino acids of p50-derivied peptides 103 and 105 were 
sequentially substituted with alanine and probed with GST-Bcl-3. Bcl-3 binding was 
quantified by densitometry and represented as a percentage binding of the control 
parent peptide. Substitution of amino acids Lys315, Tyr316 and Lys137 (denoted with *) 
resulted in *) resulted in a decrease of ≥ 50%  of Bcl-3 in Bcl-3 binding and are 
represented on p50 crystal structure in (C). Murine amino acid numbering (A-C). 
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Figure 3.12 p50 Lys 315 and Lys 317 are not required for interaction with Bcl-3.  
(A)  HEK293T cells were transfected as indicated with pRK5-p50-FLAG(p50) or pRK5-p50-
FLAG in which in which Lys 315 and 317 were mutated to alanine (p50K315A,K317A) with or 
without increasing concentrations of pcDNA3.1‐Bcl‐3-MYC (Bcl-3). The total amount of 
plasmid was constant across all samples by adjusting the amount of empty vector. (B) 
p50/p50K315A,K317A ubiquitination was determined by IP from whole cell lysates with anti-
FLAG and WB with anti-HA for HA-ubiquitin. (C) HEK293T cells were transfected as 
indicated with p50, p50K315A,K317A or p50 in which in which Tyr 57  and Asp 60  were 
mutated to alanine and glutamic acid respectively(p50 Y57A,D60E). Nuclear extracts were 
prepared from the transfected cells and tested in an Electrophoretic Mobility Shift Assay 
(EMSA) using the consensus NF‐κB binding nucleotide. Nuclear inputs were analysed by 
WB with anti-FLAG.  
  
 101 
 
 
 
 
Figure 3.13 KYK motif regulates p50 ubiquitination. 
(A,B) HEK293T cells were transfected as indicated with pRK5-p50-FLAG(p50) or pRK5-
p50-FLAG in which Tyr 316 was mutated to alanine (p50Y316A) or phenylalanine (p50Y316F). 
p50Y316A and p50Y316F ubiquitination was determined by IP from whole cell lysates with 
anti-FLAG and WB with anti-HA for HA-ubiquitin. (C) RAW 264.7 cells were transiently 
transfected with the pLucp19 plasmid and with empty expression vector or expression 
vectors containing increasing amounts (1.25,2.5 and 5ng) of p50, p50K315A,K317A or 
p50K315A,Y316A,K317A  for 24 hours and cultured with or without 100 ng/ml LPS for an 
additional 8 hours before luciferase activity was measured. IL23p19 reporter activity 
was determined as in Figure 3.6. Transfections were performed in triplicate and data 
shown are means + SEM and are representative of independent experiments. Statistical 
significance between corresponding p50 and p50K316A,Y316A,K317A mutant reporter activities 
was determined by Student’s t test; P<0.05 (*), P<0.01 (**), P<0.001(***).  
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3.3.5 Inhibition of transcription by Bcl-3 Requires 
Interaction with NF-κB p50 
3.3.5.1 Alanine substitution analysis of Bcl-3 binding Region R4 
Alanine scanning arrays of spots 115, 117, 119 and 121 were generated as in 
figure 3.5. Bcl-3 binding was detected by immunoblotting and represented as a 
percentage binding of the control parent peptide (Figure 3.14 B). Substitution 
of Arg359, Lys360 and Arg361 resulted in a large decrease of at least 50% in Bcl-
3 binding, confirmed by independent arrays.   
 
3.3.5.2 Surface exposure prediction of Arg359, Lys360, Arg361 
The identified residues lie in the extreme C-terminal region of the RHD of p50 
and are not represented in the currently available structures of p50. However, 
hydrophobicity analysis of the primary structure of p50 indicated that these 
residues are in a region of low hydrophobicity (Cowan and Whittaker, 1990) 
(Figure 3.15 A).  Hydrophobicity of an amino acid is correlated with its average 
surface exposure and typically polar residues tend to occur at the surface of a 
folded protein. The solvent accessibility of this region  was also analysed using  
Predictprotein (Rost et al., 2004) a profile based neural network secondary 
structure prediction programme. This method predicted that Arg359, Lys360, 
Arg361 are exposed residues, exposed Arg359 and Lys360 was also was 
confirmed by NetSurfP (Petersen et al., 2009) an independent prediction 
programme (Figure 3.15 B). Using Phyre2 (Kelley and Sternberg, 2009) homology 
modelling, a predicted three-dimensional structure of the entire p50 protein 
was generated (Figure 3.15 C).  Together with the hydrophobicity index, these 
prediction tools suggest that residues Arg359, Lys360, Arg361 are exposed and 
likely to be available for interaction with Bcl-3.  
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Figure 3.14 Alanine substitution analysis of Bcl-3 binding Region R4.  
(A) Sequences of peptides 113-121 of R4 are shown and Arg359, Lys360 and Arg361 
underlined. (B) The 18 amino acids of p50-derivied peptides 115,117,119 and 121 were 
sequentially substituted with alanine and a peptide arrays  probed with GST-Bcl-3. Bcl-
3 binding was quantified by densitometry and represented as a percentage binding of 
the control parent peptide. Substitution of amino acids Arg359, Lys360 and Arg361 with 
alanine (*) resulted in a decrease of ≥ 50%  of Bcl-3 binding. Murine amino acid 
numbering (A-B). 
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Figure 3.15 Surface Exposure prediction of  Arg359, Lys360 and Arg361. 
(A) Hydrophobicity analysis of p50 using Cowan and Whittaker Hydrophobicity scale 
(Cowan and Whittaker, 1990), positive values are hydrophobic. Amino acids 359-361 
highlighted. (B) Solvent accessibility analysis of amino acids 359-361. Predictprotein 
(Rost et al., 2004) relative solvent accessibility (RSA) in 3 states: B=Burried 0-9%, I = 
intermediate 9-36%,  and E=exposed 36-100% exposure. Reliability index (RI) for RSA 
prediction (0=low to 9=high). NetSurfP (Petersen et al., 2009) RSA in 2 states B=buried 
< 25% and E=exposed >25% exposure.  Z-fit score for RSA prediction.(C) Hypothetical 
model of the entire p50 subunit using Phyre2 (Kelley and Sternberg, 2009) with R4 
indicated. Murine amino acid numbering (A-C). 
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3.3.5.3 Arg359, Lys360 and Arg361 are essential for interaction 
with Bcl-3 
We next generated a mutant of p50 in which  Arg359, Lys360 and Arg361 were 
mutated to alanine(p50RKR) and assessed the contribution of these residues to 
Bcl-3 interaction by co transfection in 293T cells. Bcl-3 was undetectable in 
immunoprecipitates of p50RKR while Bcl-3 was readily detectable in 
immunoprecipitates of wild type p50 (Figure 3.16 A). Additionally the binding 
of p50RKR mutant with purified GST-Bcl-3 was evaluated in a GST-pull down 
assay. As expected, GST-Bcl-3 pull-down readily purified p50, however, p50RKR 
protein was not detectable following GST-Bcl-3 pull-down from p50RKR 
containing lysates (Figure 3.16 B).  
 
3.3.5.4 p50RKR retains p50WT properties of nuclear translocation, 
dimerisation and DNA binding 
In order to rule out an indirect effect of Arg359, Lys360 and Arg361 mutation on 
the ability of the p50RKR mutant to interact with Bcl-3 additional 
characterisation of p50RKR mutant protein were out. Homodimerisation of p50RKR 
was assessed by co-transfection of 293T cells with FLAG-tagged and Myc-tagged 
p50RKR or FLAG-tagged and MYC tagged p50. Lysates were immunoprecipitated 
using anti-FLAG antibody and immunoblotted with anti-MYC antibody. This 
analysis demonstrated no significant differences in the formation of homodimers 
by p50RKR when compared to wild type p50  protein (Figure 3.17A). 
We next assessed the heterodimerisation of p50RKR using a similar approach. 
MYC- tagged p50 or p50RKR was co-expressed with FLAG-tagged NF-κB p65 and 
lysates immunoprecipitated using anti-FLAG antibody. Immunoblot analysis of 
FLAG-p65 immunoprecipitates demonstrated no differences in the levels of 
p50RKR co-immunoprecipitating with p65 relative to p50 indicating that the 
p50RKR mutation has no effect on heterodimerisation with p65 (Figure 3.17 B). 
IκBα has a high affinity for p65:p50 heterodimers and so the levels of 
endogenous IκBα in p65 immunoprecipitates from cells expressing p50 or p50RKR 
were also assessed. No significant differences in the amount of IκBα co-
immunoprecipitating with p65 was found between cells expressing p50 or p50RKR 
(Figure 3.17 B). Similarly, no difference in the levels of p50RKR interacting with 
p105 relative to p50 in cells co-transfected with p105 and p50 WT or p50RKR were 
observed, as assessed by immunoprecipitation (Figure 3.17 C). Together these 
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data demonstrate that the p50RKR mutation does not alter p50 dimerisation or 
interaction with IκBα or p105 proteins.  
The amino acids 359 to 361 of p50 have previously been indicated to function in 
the nuclear translocation of p50 (Latimer et al., 1998). Since Bcl-3 is 
predominant nuclear in localisation it was important to rule out that lack of 
nuclear p50RKR prevented the interaction with Bcl-3 in co-transfected cells. To 
address this, nuclear and cytoplasmic fractions of cells transfected with p50RKR 
or p50 were generated and analysed protein levels by immunoblot. As 
demonstrated in Figure 3.18 A, subcellular fractionation revealed that p50RKR 
translocated to the nucleus to similar levels as wild type p50, indicating that 
the mutation of the amino acids 359-361 to alanine does not disrupt the nuclear 
localisation of p50. This data was supported by an analysis of the DNA binding 
activity of p50RKR in which no significant differences between wild type p50 and  
p50RKR DNA binding tested by EMSA  (Figure 3.18 B). Taken together, these data 
reveal that the p50RKR mutant is defective in binding to Bcl-3 but retains the p50 
WT properties of nuclear translocation, dimerisation and DNA binding. 
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Figure 3.16 Arg359, Lys360 and Arg361 of p50 are essential for interaction with Bcl-
3.  
(A) HEK293T cells were transfected as indicated with pRK5-p50-FLAG (p50) or pRK5-p50-
FLAG in which Arg359, Lys360 and Arg361 were mutated to alanine (p50RKR) with or 
without pcDNA3.1-Bcl-3-MYC (Bcl-3).  Whole cell lysates were immunoprecipitated (IP) 
with anti-FLAG and analysed by western blot (WB) with the indicated antibodies. 
Immunoblotting with anti-β-actin was used as a loading control. (B) Purified bacterial 
recombinant GST or GST-Bcl3 was incubated with a whole cell lysate overexpressing p50 
or p50RKR and were affinity purified with GSH agarose. Pull down complexes were 
analysed by western blot with anti-FLAG and anti-GST antibodies.  
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Figure 3.17 Mutation of Arg 359, Lys 360 and Arg 361 does not affect the 
dimerisation properties of p50.  
p50RKR  can form homodimers and heterodimers with p65 and p105. (A) HEK293T cells 
were transfected as indicated with  pRK5-p50-FLAG and pEF4a-p50-MYC (p50) or pRK5-
p50-FLAG and pEF4a-p50-MYC in which Arg359, Lys360 and Arg361 of p50 were mutated 
to alanine (p50RKR). FLAG-p50 or FLAG-p50RKR  were immunoprecipitated (IP) from whole 
cell lysates with anti-FLAG and analysed by western blot (WB) with anti-MYC for MYC–
p50 and p50RKR. (B) HEK293T cells were transfected as indicated with pRK5-p65-FLAG 
(p65) and  pEF4a-p50-MYC (p50) or pEF4a- p50RKR –MYC (p50RKR). FLAG-p65 was 
immunoprecipitated (IP) from whole cell lysates with anti-FLAG and analysed by western 
blot (WB) with anti-MYC for MYC–p50 and p50RKR. (C) HEK293T cells were transfected as 
indicated with pRK5-p105-FLAG (p105) and  pEF4a-p50-MYC (p50) or pEF4a-p50 pEF4a- 
p50RKR -MYC (p50RKR). FLAG-p50 or FLAG- p50RKR  were immunoprecipitated (IP) from 
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whole cell lysates with anti-MYC and analysed by western blot (WB) with anti-FLAG for 
p105. 
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Figure 3.18 p50RKR can bind DNA and translocate to the nucleus.  
(A) HEK293T cells were transfected as indicated with  pRK5-p50-FLAG or pRK5-p50-FLAG 
in which Arg359, Lys360 and Arg361 of p50 were mutated to alanine (p50RKR). Nuclear 
(N) and cytoplasmic (C) extracts were prepared and  fractions were analysed by Western 
blot (WB) with anti-FLAG for p50 and p50RKR. (B) HEK293T cells were transfected as 
indicated with  p50 or p50RKR . Nuclear extracts were prepared and tested in an 
Electrophoretic Mobility Shift Assay (EMSA) using the consensus NF‐κB binding 
nucleotide. 
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3.3.5.5 Bcl-3 inhibits ubiquitination through interaction with p50 
The ubiquitination of p50 is significantly increased in Bcl3-/- cells and 
overexpression of Bcl-3 inhibits p50 ubiquitination (Carmody et al., 2007b). To 
establish whether the inhibition of p50 ubiquitination by Bcl-3 requires 
interaction with p50, a ubiquitination assay was performed in 293T cells 
transfected with HA-tagged ubiquitin, p50 or p50RKR, with or without Bcl-3. In 
contrast to the complete inhibition of p50 ubiquitination by Bcl-3, the 
expression of Bcl-3 failed to inhibit the ubiquitination of p50RKR (Figure 3.19 A). 
These data demonstrate that the interaction of Bcl-3 with p50 is required for 
Bcl-3 mediated inhibition of p50 ubiquitination. p50 ubiquitination leads to 
degradation by the proteasome and thereby controlling p50 protein stability. 
Next, the stability of p50RKR was assessed by treating p50 or p50RKR expressing 
cells with the protein synthesis inhibitor cyclohexamide and monitoring protein 
levels over a short time period by immunoblotting. This analysis demonstrated 
that p50RKR is significantly less stable than p50 and has a half-life less than 50% 
that of wild type p50 (Figure 3.19 B). These data demonstrate that interaction 
with Bcl-3 is critical for the regulation of p50 ubiquitination and protein 
stability. 
 
3.3.5.6 Arg359, Lys360 and Arg361 of p50 are critical for negative 
regulation of NF-κB dependent gene expression 
It has been proposed that Bcl-3 regulates NF-κB mediated transcription through 
inhibition of p50 homodimer ubiquitination and proteasomal degradation. 
However, additional p50-independent functions of Bcl-3 in regulating 
transcription can not be ruled out in studies employing Bcl3-/- cells. Our findings 
that interaction with Bcl-3 is important for the regulation of p50 ubiquitination 
and stability led us to examine the regulation of gene transcription by p50RKR.  
To investigate this, a luciferase reporter assay incorporating the NF-κB-
dependent IL-23p19 gene promoter was employed (Carmody et al., 2007a). In 
agreement with previous reports (Muhlbauer et al., 2008) , Bcl-3 expression 
inhibited the reporter activity in RAW 264.7 macrophage cells following 
stimulation with LPS. Similarly, overexpression of both p50 and p50RKR inhibited 
LPS-induced reporter activity. However, whereas co-expression of p50 with Bcl-
3 completely abolished LPS-induced reporter activity, the co-expression of 
 112 
 
p50RKR with Bcl-3 failed to inhibit reporter activity below the level seen when 
either are expressed alone (Figure 3.20 A). Next, dose-dependent analysis of 
p50  and p50RKR expression on IL-23p19 reporter activity was performed by 
transfecting increasing, but low amounts of p50 or p50RKR expression vector in 
Nfkb1-/- mouse embryonic fibroblast cells (MEFs). Here a dose dependent 
inhibition of reporter activity following transfection with p50 but not with p50RKR 
was observed (Figure 3.20 B). Similar results were obtained when Nfkb1-/- MEFs 
were transfected with an expression vector for wild type p105 or p105 
containing alanine substitutions at position 359-361 (p105RKR) (Figure 3.20 C). 
Together these data demonstrate that the interaction between Bcl-3 and p50 is 
critical for the negative regulation of NF-κB target genes by both of these 
factors. 
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Figure 3.19 Arg359, Lys360 and Arg361 of p50 are critical for protein stability. 
 
(A) Bcl‐3 cannot block p50RKR ubiquitination.  HEK293T cells were transfected as 
indicated with  pRK5-p50-FLAG or pRK5-p50-FLAG in which Arg359, Lys360 and Arg361 
of p50 were mutated to alanine (p50RKR). p50/ p50RKR ubiquitination was determined by 
IP from whole cell lysates with anti-FLAG and WB with anti-HA for HA-ubiquitin. (B) 
Reduced half-life of p50RKR. HEK293T cells were transfected with p50 or p50RKR. 
Following 24 hours transfection cells were treated with 100ug/ml cyclohexamide (CHX) 
and harvested at the indicated times following treatment. For each sample p50 protein 
levels were quantified by densitometry and normalised with β-actin. Graph represents 
western blot shown. The half-life (t1/2) of p50 and p50
RKR was calculated from three 
independent experiments and is presented as ± SD. 
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Figure 3.20 Arg359, Lys360 and Arg361 of p50 are critical for negative regulation of 
NF-κB dependent gene expression. 
(A) Bcl-3 is unable to synergise with p50RKR to inhibit LPS induced activation of IL23 p19 
reporter activity. RAW 264.7 cells were transiently transfected with the pLucp19 
plasmid and with empty expression vector or pRK5-p50-FLAG or pRK5-p50-FLAG in which 
Arg359, Lys360 and Arg361 of p50 were mutated to alanine (p50RKR) (5ng) and pcDNA3.1-
Bcl3-MYC (Bcl-3) (2.5ng). Following 24 hours transfection  cells were cultured with or 
without 100 ng/ml LPS for an additional 8 hours before luciferase activity was measured. 
(B,C) Nfkb1-/- MEFs cells were transiently transfected with the pLucp19 plasmid and 
increasing amount of expression vectors containing p50 or  p50RKR (1.25,2.5 and 5ng)  (B) 
or peF4a-p105-Xpress or peF4a-p105-Xpress in which Arg359, Lys360 and Arg361 of 105 
were mutated to alanine p105RKR (200,300 and 400ng) (C). The total amount of plasmid 
was constant across all samples by adjusting the amount of empty vector used. Cells 
were transfected for 24 hours and cultured with or without 20 ng/ml TNF for an 
additional 8 hours before luciferase activity were measured. IL23p19 reporter activity 
was determined as in Figure 3.6. Transfections were performed in triplicate and data 
shown are means + SEM and are representative of independent experiments Statistical 
significance between corresponding p50 and p50DFSPT mutant reporter activities was 
determined by Student’s t test; P<0.05 (*), P<0.01 (**), P<0.001(***). 
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3.3.6 p105RKR Expression Recapitulates Bcl3-/- Phenotype 
In order to further analyse the lack of p50:Bcl-3 complex formation in the 
context of an inflammatory signal, Nfkb1-/- MEFs were reconstituted with 
expression vectors for p105 or p105RKR. Stably transfected cells were clonally 
selected for equivalent expression of p105 and p105RKR (Figure 3.21 A). No 
differences in the activation of the NF-κB pathway by TNF between p105 and 
p105RKR cells were found as determined by IκBα phosphorylation and degradation 
(Figure 3.21 B). TNF-induced nuclear localisation of p50 and p65 was not 
significantly altered in p105RKR cells relative to p105 wild type cells. However, 
p105RKR cells had significantly reduced p50 protein levels compared to p105 cells 
(Figure 3.21 C), reflecting the reduced stability of p50RKR (Figure 3.19 B). In 
agreement with over expression analysis (Figure 3.16), endogenous Bcl-3 failed 
to co-immunoprecipitate with p50RKR in TNF stimulated cells, whereas TNF-
inducible interaction with wild-type p50 was readily detectable (Figure 3.22 A). 
Consequently, endogenous ubiquitination of p50RKR in both untreated and TNF-
stimulated cells was elevated relative to p50WT (Figure 3.21 B). Realtime-PCR 
analysis of TNF-induced gene expression revealed that p105RKR cells express 
significantly higher levels of the NF-B target genes Tnf, IL6, Ccl2 and Cxcl2 
when compared to p105 wild type cells (Figure 3.21 C). This hyper-
responsiveness towards TNF stimulation in p105RKR cells correlates with the 
increased ubiquitination and reduced half-life of the p50RKR protein and 
importantly recapitulates the hyper-responsiveness of Bcl3-/- cells. Together 
these data demonstrate that interaction with Bcl-3 is essential for p50 
homodimer repressor function and suggests that repression of transcription by 
Bcl-3 is dependent on interaction with p50 homodimers. 
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Figure 3.21 Normal upstream signalling and NF-κB nuclear translocation of p105RKR 
MEFs. 
(A) Nfkb1-/- MEF cells were stably transfected with expression vectors encoding p105WT 
or p105RKR. (B) p105WT or p105RKR MEFs were stimulated with 20ng/ml TNF for the 
indicated times prior to lysis. Whole cell extracts were analysed by western blotting for 
phosphorylated IκBα and total IκBα. (C) p105WT or p105RKR MEFs were stimulated with 
20ng/ml TNF for the indicated times prior to lysis. Nuclear and cytoplasmic extracts 
were prepared and analysed for p50 and p65 proteins by western blot. 
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Figure 3.22 p105RKR MEFs are hyper-responsive to TNF stimulation. 
(A) p105WT or p105RKR MEFs were left untreated (-) or stimulated  with 10ng/ml TNF (+) 
for 1 hour. Following stimulation cells were pre-treated with 20μM MG132 for 30 minutes 
prior to harvest. p50WT and p50RKR were immunoprecipitated (IP) from whole cell lysates 
and analysed by western blot (WB) with anti-Bcl-3 antibody for endogenous Bcl-3. (B) 
Endogenous ubiquitination assay. p105WT or p105RKR MEFs were treated as in (A). p50WT 
and p50RKR were immunoprecipitated (IP) from whole cell lysates and ubiquitination was 
determined by western blot (WB) with anti-ubiquitin (Ub). (C) p105WT or p105RKR MEFs 
were stimulated with 20ng/ml TNF. Gene expression levels were determined by real-
time PCR. Data shown are means ± SEM of replicate samples and are representative of 
three independent experiments. 
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3.3.7 Ubiquitination of p50 at Lysine 128 
p50 homodimer binding to DNA is a critical  step which triggers its 
ubiquitination, leading to its subsequent degradation (Carmody et al., 2007b). 
TLR4 activation triggers p50 ubiquitination and we hypothesise that this 
ubiquitination is required for NF-κB mediated expression of inflammatory gens 
following TLR stimulation (Carmody et al., 2007b). Ubiquitination of p65 has 
previously been shown to play an essential role in the regulation of NF-κB 
dependent gene activity and post-transcriptional repression of the NF-κB 
response (Bosisio et al., 2006, Saccani et al., 2004). Ubiquitination resistant p65 
resides on the  promoters of NF-κB target genes longer than the wild-type 
protein (Bosisio et al., 2006, Saccani et al., 2004). Little is known about the 
mechanisms regulating p50 ubiquitination, for example a ubiquitin ligase for p50 
has not been identified, whereas three ubiquitin ligases have been reported for 
p65 thus far (Maine et al., 2007, Tanaka et al., 2007, Ryo et al., 2003). As shown 
in the previous section, Bcl-3 prevents p50 ubiquitination and this action is 
dependent on interaction with p50. p50 which cannot interact with is hyper-
ubiquitinated and has a significantly reduced half-life relative to wild type p50. 
p105RKR MEFS are hyper responsive to stimulation with TNF, further highlighting 
the significance of p50 homodimer stability in the control of NF-κB target gene 
expression. In order to further investigate the role of p50 ubiquitination in TLR 
signalling we aimed to identify the lysine(s) required for ubiquitination with the 
goal of generating a ubiquitination resistant version of p50 which should have 
profound effects TLR activation and NF-κB-mediated inflammatory responses. 
A target protein can be mono or poly-ubiquitinated and attachment of ubiquitin 
can occur at a single or multiple lysine residues. p50 is ubiquitinated via lysine 
48-mediated poly-ubiquitination (Carmody et al., 2007b) (Appendix 7.4). 
Preliminary data previously generated in the lab suggested that this 
ubiquitination occurs at a single lysine substrate as ubiquitination assays carried 
out with a ubiquitin mutant incapable of forming K48-linked polyubiquitin chains 
produced a single ubiquitination band corresponding to 58 kDA, p50 modified 
with one ubiquitin. In order to identify the specific lysine modified during p50 
ubiquitination, a series of lysine to arginine mutants were generated and tested 
in the p50 ubiquitination assay as previously outlined. Mutation of lysine to 
arginine, another positively charged, polar amino acid, conserves some of the 
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biochemical properties of the amino acid, but unlike lysine, ubiquitin can not 
be conjugated to an arginine. 
Mutation of lysine 128 of p50 to arginine (p50K128R) dramatically reduced p50 
ubiquitination suggesting that this lysine may be the target of ubiquitination on 
p50. (Figure 3.23 A). To investigate the effect of this mutation  on the regulation 
of transcription, a IL23p19 reporter assay was employed as previous. Dose-
dependent analysis of p105 and p105 in which Lys128 was mutated to arginine 
(p105K128R) expression on IL-23p19 reporter activity was performed by 
transfecting increasing, but low amounts of these expression vectors in Nfkb1-/- 
MEFs (Figure 3.23 B). At lower concentrations, p105K128R was significantly more 
effective than wild type p105 at reducing TNF simulated reporter activity. 
Crystal structure analysis revealed Lys128 is surface exposed and likely 
accessible for binding by ubiquitin machinery (Figure 3.23 C), furthermore 
Lys128 is also highly conserved among a number of species (Figure 3.23 D). 
Taken together, these data suggest that Lys128 is the major ubiquitinated lysine 
in p50 and in keeping with our hypothesis, a ubiquitin-resistant p50 mutant may 
be a stronger repressor of NF-κB dependent transcription.  
  
 120 
 
 
 
 
Figure 3.23 p50 is ubiquitinated at Lysine 128.  
(A) HEK293T cells were transfected with pEF4a-p50-Xpress or pEF4a-p50-Xpress in which 
Lys 128 of p50 was mutated to arginine (p50K128R). All cells were also transfected with 
ubiquitin-HA expression vector. p50 or p50K128 ubiquitination was determined by 
immunoprecipitation (IP) from whole cell lysates with anti-Xpress (XP) and WB with anti-
HA for HA tagged ubiquitin. (B) NF-KB1-/- MEFs cells were transiently transfected with 
the pLucp19 plasmid and increasing amount (200,300 and 400ng) of pEF4a-p105-Xpress 
or pEF4a-p105-Xpress in which Lys 128 of p105 was mutated to arginine p105128R. The 
total amount of plasmid was constant across all samples by adjusting the amount of 
empty vector used. Cells were transfected for 24 hours and cultured with or without 20 
ng/ml TNF for an additional 8 hours before luciferase activity were measured. IL23p19 
reporter activity was determined as in Figure 3.6. (C) Crystal structure of p50 
homodimer with Lys 128 highlighted in blue. (D) Lysine 128 (bold) in p50 is highly 
conserved across species,  identical residues are shaded in green. Murine amino acids 
numbering used  (A-D). 
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3.4 DISCUSSION 
Bcl-3 is an IB protein that regulates NF-B-dependent gene expression through 
interaction with NF-B p50 and p52 homodimers. Bcl-3 also interacts with a 
number of non NF-κB subunits that regulate transcription (Zhao et al., 2005, 
Yang et al., 2009, Weyrich et al., 1998, Viatour et al., 2004, Southern et al., 
2012, Na et al., 1999, Na et al., 1998, Kabuta et al., 2010, Jamaluddin et al., 
2005, Hishiki et al., 2007). The contribution of these factors to immune 
regulation by Bcl-3 has not been determined. Previous studies have 
demonstrated that Bcl-3 regulates p50 homodimer stability through the 
inhibition of ubiquitination and subsequent proteasomal mediated degradation 
(Carmody et al., 2007b). However, studies employing Bcl3-/- cells and mice do 
not exclude the possibility that Bcl-3 may also function through p50-
independent mechanisms to regulate gene expression. This study describes the 
experimental characterisation of the interaction between p50 and Bcl-3 and 
demonstrates for the first time that interaction between Bcl-3 and p50 is 
required for the stability of p50 homodimers and is necessary for the anti-
inflammatory function of Bcl-3.  
A peptide array approach was employed to identify residues of p50 necessary 
for interaction with Bcl-3. Peptide arrays provide an efficient tool to map 
protein interaction domains of known binding partners. A large library of 
immobilised peptides can be screened simultaneously on a single array, rapidly 
reducing the vast number of potential binding sites within a complex. This 
approach is also advantageous over traditional deletional mutagenic approaches 
where significant portions of a protein are disrupted. Mutations in the p50 RHD 
for example, could affect DNA binding and dimerisation, artefactually  inhibiting 
a p50-Bcl-3 complex (Ghosh et al., 1995, Sengchanthalangsy et al., 1999). In 
this study, a series of overlapping peptides with high affinity for purified 
recombinant Bcl-3 were identified. Four regions R1-R4, located in the C 
terminus of p50, were considered to be strong candidates for interaction with 
Bcl-3. To further increase the resolution of these potential binding sites, a series 
of alanine substitution arrays were generated. These arrays identified a number 
of potentially key amino acids, subsequently mutated in full length p50, in order 
to verify their contribution to Bcl-3 binding. 
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Although mutation of Lys249, Arg253 and M253 to alanine (p50KRM) did not 
completely inhibit interaction, Bcl-3 binding affinity was significantly reduced. 
The hypothetical model of Manavalan et al. published after this data was 
generated , further supports the role of these amino acids in Bcl-3 binding 
(Manavalan et al., 2010) (Table 29). Using a molecular docking approach based 
on the available crystal structure of IκBα bound to an NF-κB heterodimer, they 
predicted residues 249-257 of p50 to be directly involved in Bcl-3 interaction.  
Nevertheless, Bcl-3 overexpression was able to inhibit p50KRM ubiquitination, 
however the huge increase in ubiquitination of this mutant relative to wild-type 
p50 was unexpected. Not surprisingly, p50KRM processed from p105 in which 
these residues were mutated, was inherently unstable. Moreover p50KRM failed 
to inhibit IL-23p19 reporter activity following LPS stimulation. Based on the 
solved crystal structure Lys249, Arg253 and M253 of p50 also contribute to IκBα  
binding part of a p65 heterodimer (Jacobs and Harrison, 1998). Reconstitution 
of Nfkb1-/- cells with p105KRM would therefore result in disrupted p50:Bcl-3 and 
p50/p65:IκBα complexs, the effects of which, would be indistinguishable from 
one another. Thus, further characterisation of this mutant in was not 
performed. 
 
Table 29. Comparison of Hypothetical Models of p50:Bcl-3 binding 
Model p50 Subunit Interacting Residues 
Manavalan  
Complex A 
Subunit A Lys74, Lys249, Ile250, Val251, Arg252, Met253, Asp254, 
Arg255, Thr256, Ala257, Pro324, Ser326, Val327, Phe328, 
Glu341, Pro342, Pro344, Phe345, Leu346, Tyr348 
  Subunit B Arg255, Cys259, Thr261, Gly262, Gly263, Glu264 ,Glu265, 
Tyr267, Ser299, Thr301, Asp302, Val310, Lys312, Glu350 
 Manavalan  
Complex B 
Subunit A Glu73, Lys 74, Tyr248, Lys 249, Val251, Arg252, Met 253, 
Asp254, Thr256, Pro324, Ser326, Lys343, Pro344, Phe345, 
Leu346, Tyr348,  
  Subunit B Gly263, Glu254, Glu265, Tyr26, Asp297, Ser299, Thr301, 
Lys312,Thr313 
 Michel    Tyr263, Asp297, Pro300, Thr301, Lys315 
 
Table comparing the hypothetical models of p50 and Bcl-3 interaction. There are three 
predicted models of interaction, Manavalan complex A and B (Manavalan et al., 2010)  
and Michel (Michel et al., 2001). Putative Bcl-3 interacting residues of p50 identified by 
peptide array are underlined. 
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Interestingly, the p50DFSPT mutant  had an almost identical phenotype to p50KRM. 
Despite very reduced levels of Bcl-3 binding, overexpression of Bcl-3 was still 
partially capable of inhibiting p50DFSPT ubiquitination. Although Lys249, Arg253 
and M253 (R1) and Asp297, Phe 298, Ser 299, Pro300 and Thr 301(R2) reside on 
opposite sides of a p50 subunit, they form a potential interface on each side of 
a p50 homodimer. While differing in the precise amino acids, both 
computational models of a p50:Bcl-3 complex predicted amino acids within this 
DFSPT region  to be important for interaction with Bcl-3. Furthermore 
Manavalan et al predicted these amino acids were also important for interaction 
with IκBNS, another nuclear IκB protein. The structures of the IκB proteins are  
very homologous (Figure 1.4),  Bcl-3 and IκBα for example, share 35% sequence 
identity within the ARD (Michel et al., 2001). These data suggests that regions 
R1 and R2 provide an important binding interface for multiple IκB protein, 
mutation of which severely disrupts p50 stability and function. 
Another region important in regulating p50 ubiquitination identified from the 
peptide array was a three amino acid stretch, Lys315 , Tyr316  and Lys317. 
Mutation of lysines  315 and 317 to alanine in full length p50 did not have a 
significant effect on Bcl-3 binding. This suggests that these amino acids are not 
essential for interaction with Bcl-3 but does not rule out the contribution of this 
region to Bcl-3 binding. Recombinant Bcl-3 bound to a number of peptides 
representing amino acids 298-330 (R3). It is possible that these peptides 
represent artificial binding sites not represented in full-length p50. However, 
as Lys312, Thr313 and Lys315 were predicted to contact Bcl-3 in Manavalan et 
al. el (Manavalan et al., 2010) and Michel et el (Michel et al., 2001) models, it 
is likely that Bcl-3 makes contacts in this region. 
Unlike immobilised peptides on an array, binding sites are not static and are 
considerably flexible.  Critical amino acids tightly packed within protein-protein 
interfaces are considered hot spots (Clackson T, 1995) and these hot spots 
cluster within a hot region, contributing cooperatively to the stability of a 
complex (Keskin et al., 2005). Thus, Lys 315 and Lys 317 could be just two of a 
number of contacting amino acids within this potential hot region, mutation of 
which is insufficient to disrupt Bcl-3 binding. A recent Study (Moreira et al., 
2007)  of  the Alanine Scanning Energetics database (ASEdb) (Thorn and Bogan, 
2001) estimated that only 9.5% of interfacial residues to be hot spots. 
Therefore, it is also possible that Lys 315 and Lys 317 are contained within a hot 
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region but under physiological conditions are not the critical contacting amino 
acids. 
Although mutation of Lys 315 and Lys317 had no effect on Bcl-3 binding, these 
mutations did alter the ubiquitination status of p50. p50K315A,K317A  ubiquitination 
was significantly reduced when compared to wild type p50. Previous work in the 
lab in which Lys 315 and Lys 317 were mutated to arginine, showed no reduction 
in ubiquitination. This suggested that p50 was not ubiquitinated on Lys315 or 
Lys317 but rather this defect was due to a structural change in this region. 
Tyr316 is flanked by these two lysines and when mutated to alanine, also 
increases the ubiquitination of p50. Tyrosine is a polar amino acid with a bulky 
benzyl side chain and substitution with alanine, a much smaller amino acid could 
create a significant hole and alter protein confirmation. Mutation to 
phenylalanine however also resulted in a similar hyper-ubiquitinated 
phenotype.  
Post-translational modification of tyrosine is a widely established mechanism 
for regulating signal transduction and cellular processes such as proliferation 
and differentiation. Within the NF-κB pathway, IκBα and p65 are phosphorylated 
and nitrated on tyrosine residues respectively (Imbert et al., 1996, Park et al., 
2005) but no known tyrosine modifications on p50 have been established to 
date. Collectively these data suggest an essential role for Tyr316 in negatively 
regulating p50 ubiquitination, either through post-translational modification or 
interaction with an unknown binding partner. Lysines 315 and 317 may act to 
hinder binding to Tyr316 and when mutated to alanine actually increase binding 
affinity, resulting in decreased ubiquitination. This  mechanism of attenuation 
by neighbouring residues in a hot spot has previously been reported for the 
human growth factor receptor complex (Keskin et al., 2005). Further 
investigation into the possible posttranslational modification of Tyr316 and its 
role in regulating p50 ubiquitination need to be investigated.   
The final region identified by the peptide array to contribute to Bcl-3 binding 
was peptides 115-121, corresponding to amino acids 337 to 378 at the extreme 
C-terminal region of p50. The serial substitution of amino acids 355 to 372 with 
alanine as immobilised peptide identified Arg359, Lys360 and Arg361 as 
essential residues for interaction with Bcl-3. Subsequently, the mutation of 
Arg359, Lys360 and Arg361 to alanine in full length p50 blocked the interaction 
with purified, recombinant Bcl-3. The region of p50 containing Arg359, Lys360 
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and Arg361 is C terminal to previously identified ankyrin repeat domain 
interaction sites determined from the crystal structure of a p65:p50 
heterodimer complexed with IκBα (Jacobs and Harrison, 1998). Unfortunately, 
the amino acids 359 to 361 are not represented on the crystal structures of p50 
containing complexes and so no structural data is available. However, a 
hydrophobicity plot reveals that these amino acids lie in a region of low 
hydrophobicity and thus are expected to be available for interaction with Bcl-
3.  
Importantly, mutation of these amino acids does not alter the hetero- or 
homodimer formation properties of p50, or interfere with DNA binding of p50. 
This allows us to rule out the loss of repressor function of p50RKR homodimers 
due to lack of dimerisation or DNA binding. Moreover, despite being located in 
a region previously reported to be important for nuclear localisation (Latimer 
et al., 1998), the mutation of Arg359, Lys360 and Arg361 to alanine had no 
effect on the nuclear localisation of p50 as monitored by sub-cellular 
fractionation analysis and DNA binding assays. Our data suggests that additional 
sequences of p50 are important in its nuclear translocation. The mutation of 
Arg359, Lys360 and Arg361 in p50 (p50RKR) functionally recapitulates the 
previously described phenotype of Bcl3-/- cells. Thus, p50RKR undergoes increased 
ubiquitination corresponding to a reduced half-life and cells expressing p50RKR 
display increased NF-κB transcriptional activity relative to wild type p50. 
Critically, Bcl-3 is unable to rescue the increased NF-κB activity in p50RKR 
expressing cells. NF-κB transactivation is not inhibited by overexpression of Bcl-
3 in cells expressing p50RKR and Bcl-3 is unable to inhibit p50RKR ubiquitination. 
Recent studies have highlighted the role of p50 in regulating transcriptional 
programmes during inflammation during TLR and interferon-induced responses 
(Yan et al., 2012, Cheng et al., 2011). Our data further highlights the 
importance of Bcl-3 and p50 interaction in the regulation of the inflammatory 
response, which is independent of Bcl-3 interaction with other transcriptional 
regulators. 
TLR activation triggers p50 homodimer ubiquitination however the precise 
sequences involved in regulation its ubiquitination and degradation are 
unknown. p50 Lys128 is highly conserved across species and mutation to arginine 
dramatically reduced p50 ubiquitination. Arginine, like lysine is a positive polar 
amino acid but cannot be modified with ubiquitin. This suggests a critical role 
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for Lys128 in p50 homodimer ubiquitination. Ubiquitination removes inhibitory 
homodimers from target promoters allowing activation of NF-κB target genes, a 
critical step in the regulation of TLR activation. Expression of a ubiquitination-
resistant p50 mutant should therefore result in reduced inflammatory response. 
Initial studies over expressing p105K128R  in a luciferase IL-23p19 gene promoter 
assay supports this theory as  p105K128R  was significantly more effective than 
wild type p105 at inhibiting reporter activation following TNF simulation. Nfkb1-
/- MEFS stably expressing either p105 or p105K128R have also been generated and 
these will provide an excellent tool in determining the role of p50 ubiquitination 
in innate immunity. Gene expression analysis and chromatin 
immunoprecipitation studies in these cells will provide a further insight into the 
mechanism of p50 ubiquitination in TLR signalling. 
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Chapter Four 
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4 Characterisation of a Bcl-3 derived 
NF-κB inhibitory peptide 
 
 
4.1 ABSTRACT 
Bcl-3 regulates NF-κB dependent transcription through interaction with 
homodimers of NF-κB subunits, p50 and p52. Bcl-3 inhibits p50 ubiquitination 
and subsequent degradation, stabilises inhibitory p50 homodimers and 
negatively regulates TLR-induced NF-κB-dependent inflammatory gene 
expression.  Bcl-3 interaction with p50 is necessary for the inhibition of 
ubiquitination and the negative regulation of pro-inflammatory gene expression. 
Immobilised peptide arrays were employed to experimentally characterise the 
interaction between Bcl-3 and p50. A number of short peptides derived from 
Bcl-3 capable of binding to p50 with high affinity were identified.  We generated 
a cell permeable peptide representing the outer helix and linker domains of Bcl-
3 ANK1, a region poorly conserved among IκB proteins. The Bcl-3 derived 
peptide (BDP) effectively inhibited LPS induced NF-κB activity in vitro. This 
inhibitory activity was significantly reduced when key amino acids required for 
p50 interaction were mutated. This study provides a basis for the development 
of Bcl-3 derived therapies for the treatment of inflammatory diseases.  
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4.2 INTRODUCTION 
NF-κB controls the transcription of hundreds of genes critical for the 
inflammatory response, aberrant activity of which underlies the 
pathophysiology of a number of human diseases. Ubiquitination and proteasomal 
degradation of NF-κB represents a major limiting factor in the control of the 
NF-κB transcriptional response (Bosisio et al., 2006, Saccani et al., 2004, 
Carmody et al., 2007b, Wertz and Dixit, 2010, Colleran et al., 2013). Thus, 
ubiquitin based drug discovery presents a promising field for the development 
of novel therapies for the treatment of many immunological diseases and 
cancers. However when compared to inhibitors of kinases for example, the 
limited success of such drugs is apparent.  To date the proteasome inhibitor 
bortezomin (Velcade, Millenium Pharmaceuticals) is the only FDA approved drug 
targeting the ubiquitin system, while currently there are 24 small molecule 
kinase inhibitors approved by the FDA, with hundreds in clinical trials. 
The complexity of the ubiquitination system is such that establishment of 
selective inhibitors of the ubiquitin pathway for clinical use is challenging. Many 
experimental inhibitors of the ubiquitin/proteasome pathway are available and 
include inhibitors of specific E1, E2, E3 and DUP enzymes which provide valuable 
tools to study the ubiquitin system (Brownell et al., 2010, Ceccarelli et al., 
2011, Yang et al., 2007, Issaeva et al., 2004, Michel Espinoza-Fonseca, 2005, 
Colland et al., 2009). Due to the broad specificity of the enzymes involved in 
conjugating ubiquitin to a substrate, inhibition of enzyme activity is likely to 
affect a number of cellular proteins. For example, the ubiquitin E3 ligase β-
TrCP mediates the degradation of IκBα (Suzuki et al., 1999) and the proteasome 
dependent processing of p105 (Orian et al., 2000), thereby activating the NF-κB 
pathway. However β-TrCP can also inhibit the Wnt pathway through association 
with β-catenin (Latres et al., 1999). As a consequence much work has focused 
on inhibiting E3 substrate binding for specific E3 substrate pairs (Cohen and 
Tcherpakov, 2010). Inhibitors of the interaction between p53 and two of it’s E3 
ligases COP1 (Yamada et al., 2013) and MDM2 (Vassilev et al., 2004) have already 
been developed  with the latter currently in clinical trials for the treatment 
leukaemia and retinoblastoma. 
A current exciting strategy in the intracellular delivery of bioactive material is 
through a process called peptide transduction. This involves the covalent or non 
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covalent conjugation of molecular ‘cargoes’ (peptides, proteins, DNA, siRNA 
(Sterghios Moschos, 2006)) to small peptides that can translocate the plasma 
membrane (Järver and Langel, 2006). These natural and synthetic cell-
penetrating peptides (CPP), also called protein transduction domains (PTD) are 
relatively short peptides, 5–40 amino acids in length, with the ability to gain 
access to the cell interior (Langel, 2006). CPPs vary in size, sequence, charge 
and origin but can be classified by physical-chemical properties into 3 main 
groups; cationic, amphiathic and hydrophobic (Milletti, 2012). Cationic and 
amphiathic CPPs have been utilised extensively in the development of inhibitors 
of NF-κB signalling and have been used effectively in vitro and some in vivo 
models (Orange and May, 2008). The NEMO binding domain (NBD) peptide (May 
et al., 2000) is probably the most widely studied NF-κB CPP inhibitor to date 
and has been used successfully to inhibit inflammation in a wide range of models 
including, dextran sulphate sodium (DSS) induced colitis, arthritis, and  in 
models of lung inflammation (Orange and May, 2008).  This peptide blocks the 
association of NEMO with the IKK complex thereby inhibiting cytokine-induced 
NF-κB activation and NF-κB–dependent gene expression (May et al., 2000).  
The first CPP discovered was derived from the human immunodeficiency virus 
(HIV)-1 TAT protein, a 86 amino acid protein which can translocate through the 
plasma membrane and transactivate the viral genome (Frankel and Pabo, 1988). 
Further studies identified the minimal domain required for this translocation 
activity to a cluster of basic amino acids 47-57, YGYKKRRQRR (Vivès et al., 
1997). Early work by Fawell et al. (Fawell et al., 1994) illustrated the huge 
potential of the TAT peptide in conferring cell penetrating properties to an 
attached cargo. They demonstrated delivery of a TAT (37-72)-β-galactosidase 
conjugate to a number of tissues including the heart, liver and spleen following 
intravenous (i.v) injection. More recent work investigating the kinetics of a TAT 
fusion into the mouse, detailed distribution in all tissues following portal vein 
(i.v.),intraperitoneal (i.p.) and oral administration (Cai et al., 2006). The exact 
mechanism of cellular uptake utilised by CPPs has not been fully elucidated but 
reports suggest that a number of mechanisms (extensively reviewed in (Madani 
et al., 2011)) may be involved which are dependent on the class and 
concentration of the CPP and the attached molecular cargo (Tünnemann et al., 
2006). Initial studies proposed an energy independent mechanism of 
internalisation by the TAT peptide however it is now clear endocytosis is 
involved (Richard et al., 2003, Tünnemann et al., 2006, Vendeville et al., 2004).  
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Figure 4.1 Proposed mechanisms of cellular uptake of cell penetrating peptides. 
The exact mechanism of cellular uptake of cell penetrating peptides(CPP) is currently 
unknown however a number of mechanism have been proposed. Peptides are thought 
to transverse the plasma membrane through energy independent (direct translocation 
or through pore formation) and energy dependent (clathrin or caveolae mediated 
endocytosis and macropintcytosis). 
 
The NF-κB transcriptional response is tightly regulated by a number of processes 
including the phosphorylation, ubiquitination and subsequent proteasomal 
degradation of NF-κB. Through inhibition of p50 ubiquitination, Bcl-3 stabilises 
a p50 homodimer:DNA complex that suppresses inflammatory gene expression 
(Carmody et al., 2007b). This complex prevents the binding of the 
transcriptionally active NF-κB subunits on the promoters of NF-κB target genes, 
however the precise mechanism of Bcl-3 mediated regulation of p50 homodimer 
ubiquitination is unknown. As shown in chapter 3, Bcl-3 interaction with p50 is 
critical step. Nfkb1-/- MEFs reconstituted with a version of p50 that can no longer 
bind Bcl-3 are hyper responsive to TNF stimulation, further highlighting the 
importance of Bcl-3-p50 interaction in the control NF-κB–associated 
inflammation. p50 homodimer ubiquitination thus signifies a critical step in the 
regulation of TLR signalling and presents of novel therapeutic targets in the 
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control of NF-κB mediated gene expression. Interaction with p50 is essential for 
Bcl-3 mediated inhibition of p50 ubiquitination and thus the anti-inflammatory 
properties of Bcl-3. In this chapter, we identified the regions of Bcl-3 that are 
necessary and sufficient to bind p50 and from this designed short mimetic 
peptides capable of mediating Bcl-3 function i.e. inhibiting NF-κB mediated 
inflammatory gene expression.  
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4.3  RESULTS 
4.3.1 Identification p50 Binding Peptides 
4.3.1.1 Cloning and Purification of Recombinant p50  
To experimentally identify the minimum regions of Bcl-3 sufficient to bind p50, 
a peptide array based technique using recombinant GST-p50 protein as a probe 
was employed. Recombinant p50 was constructed by inserting murine p50 cDNA 
into the multiple cloning site of pGEX6p1. (Figure 4.2 A)  E.coli  BL21 CodonPlus 
were transformed with either pGEX-6p1 or pGEX-6p1-p50 and  GST fusion 
proteins were induced overnight at 20°C with 1.0mM IPTG. Recombinant 
proteins were then affinity-purified using GSH-agarose and eluted with 
Glutathione over a number of elutions.  (Figure 4.2 B).  The suitability of GST-
p50 for use as a Bcl-3 peptide library probe was established using a GST pulldown 
assay. GST or GST-p50 was incubated with a whole cell lysate overexpressing 
Bcl-3 and affinity purified with GSH agarose. Bcl-3 bound specifically to purified 
GST-p50, but not GST indicating a functional p50 fusion protein. (Figure 4.2 C). 
 
4.3.1.2 Bcl-3 Peptide Array 
A library of overlapping peptides 18 amino acids in length, each shifted by 4 
amino acids and encompassing the entire sequence of Bcl-3, was Spot-
synthesised on a cellulose membrane to generate the  Bcl-3 peptide array (see 
Appendix 7.5 for Bcl-3 peptide library). Arrays were probed with either GST as 
a control or GST-p50, positive binding was detected by immunoblotting with 
anti-GST antibody (Figure 4.3 A). GST-p50 bound specifically to a number of Bcl-
3 peptides representing the N terminus and ANK repeats 1, 6 and 7 of Bcl-3 
(Figure 4.3 C). In order to identify amino acids within these peptides essential 
for binding to p50, a series of alanine scanning arrays were generated. Arrays 
were derived from the positive 18-mer parent peptide of interest and 18 new 
peptides containing a single successive alanine substitution were generated (see 
Appendix 7.6 for alanine substitution library). The alanine scanning array was 
again incubated with GST-p50 prior to immunoblotting with anti-GST antibody. 
Detection of GST-p50 binding was then performed using near infra red IR-Dye-
conjugated secondary antibody to facilitate quantification of GST-p50 binding 
to specific peptides using an infra red scanner (Figure 4.4). The binding of GST-
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p50 to the substituted peptide was calculated and represented as a percentage 
binding of the control parent peptide contained on the same array (see Appendix 
7.7 for full alanine substitution binding data). Substitution of amino acids that 
resulted in significantly decreased Bcl-3 binding i.e. less than 50% binding, are 
underlined. 
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Figure 4.2 Bcl-3 binds specifically to recombinant GST-p50.  
(A) Murine p50 cDNA was ligated via  BamH1 and Sal1 restriction sites into pGEX6p1 to 
produce a GST-p50 expression vector. (B) Escherichia coli BL21 CodonPlus were 
transformed with pGEX-6p1-p50 and  expression of GST-p50 was  induced with the 
addition of  IPTG. Recombinant proteins were affinity-purified against GSH-agarose and 
eluted with glutathione. (C) Bcl-3 binds specifically to GST-p50 in a GST pull down assay. 
Purified bacterial recombinant GST or GST-p50 was incubated with a whole  cell lysate 
from HEK293 cells transfected with empty vector (Mock) or FLAG-Bcl-3 (Bcl-3) and 
affinity purified with GSH agarose. Pull down complexes were immunoblotted with anti-
FLAG and anti-GST antibodies. 
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Figure 4.3 Bcl-3 peptide array identifies p50 interacting peptides. 
(A) Peptide arrays of immobilised overlapping 18-mer peptides, each shifted to the right 
by 3 amino acids encompassing the entire Bcl-3 sequence were generated.  Arrays were 
probed with GST or GST-p50 and detected by immunoblotting with anti-GST antibody. 
GST-p50 binding to Bcl-3 peptides is shown (black spots) and is representative of 
duplicate arrays. (B) Crystal structure of human Bcl-3 ankyrin repeat domain with beta 
(β)- hairpin and inner (α1) and outer alpha helices  indicated. (C) Schematic 
representation of murine Bcl-3 with ANK repeats 1-7 indicated and table of Bcl-3 
peptides 1-109 with corresponding Bcl-3 structural region. 
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Figure 4.4 Alanine substitution analysis of positive p50 binding Bcl-3 peptides.  
(A) The 18 amino acids of Bcl-3-derivied peptides of interest were sequentially 
substituted with alanine and probed with GST-p50 and detected by immunoblotting with 
anti-GST antibody.  p50 binding was quantified by densitometry and calculated as a 
percentage binding of the parent unsubstituted peptide on the same array. The full 
substitution peptide array data is available Appendix 7.7 . Alanine substitution of an 
amino acid that significantly decreased (≤ 50% of parent peptide)  p50 binding  is 
underlined.  
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4.3.2 Bioinformatic and Structural Analysis of p50 
Interacting Sites 
As there is no available crystal structure for a p50:Bcl-3 complex, previous 
studies have used in silico modelling and molecular docking techniques based 
on the solved NF-κB heterodimer:IκBα complex to predict sites of p50 and Bcl-
3 interaction (Manavalan et al., 2010, Michel et al., 2001). As detailed in chapter 
3, these methods are limited by the available, incomplete Bcl-3 and p50 crystal 
structures. To determine the correlation of these methods with sites 
experimentally determined in this study, we aligned the putative interacting 
amino acids determined by peptide array and computational modelling. The 
peptide array detected two unique potential binding regions not identified by 
the three available computational models, representing residues in ANK1 and 
the unstructured N-terminus (Figure 4.5 and Figure 4.6). Considerable overlap 
between all methods occurred in ANK6 and ANK7, further validating the use of 
peptide arrays to investigate Bcl-3-p50 binding.   
 
Figure 4.5 Structural representations of putative p50 interacting residues. 
Human Bcl-3 crystal structure with unique p50 interacting residues determined by 
peptide array in blue,those predicted by combined in silico models (Manavalan complex 
A, complex B) (Manavalan et al., 2010) and Michel (Michel et al., 2001))  in green and 
overlapping residues identified by both methods in red. As the murine Bcl-3 structure is 
unsolved, corresponding human residues are indicated.    
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Figure 4.6 Schematic representation of putative p50 interacting residues 
determined by peptide array. 
(A) For Bcl-3 alanine scanning array, p50 binding was quantified by densitometry and 
calculated as a percentage binding of the parent unsubsitituted peptide, full alanine 
scanning peptide data is available in Appendix 7.7. The unstructured extreme N-
terminal of murine Bcl-3 is presented and alanine substitution of amino acids that 
decreased p50 binding by ≥ 50% are shaded in yellow and ≥40% shaded in grey. (B) 
Alignmnet of the seven ANK repeats of Bcl-3 with a schematic indicating the conserved 
structural features of the each ANK repeat within the ANK repeat domain. Putative p50 
binding residues of Bcl-3 were identified as in A and compared with the interacting 
residues predicted by the three currently available in silico models (shaded in yellow), 
Manavalan complex A (ManavalanA), complex B (ManavalanB) (Manavalan et al., 2010) 
and Michel (Michel et al., 2001). Human Bcl-3 amino acid numbering was used for 
Manavalan complex A and B and Michel in silico  models and murine Bcl-3 amino acid 
numbering for Bcl-3 array. 
  
 
 141 
 
 
 
In order to identify Bcl-3 specific sequences, the protein sequences of a number 
of IκB proteins were analysed. Multiple sequence alignment of Bcl-3 homologs 
was performed and gaps were manually adjusted based on secondary structure 
elements (see Appendix 7.8 for full alignment). The ARD of IκB proteins is highly 
conserved and this analysis identified a consensus residue at almost 80% of all 
positions within this domain however, the potential p50 binding region 
identified by the Bcl-3 peptide array encompassing Bcl-3 amino acids 144-158, 
is within an area of low similarity to other IκB proteins (Figure 4.7 A). While no 
identical residues occur across all six proteins in this region, a consensus 
sequence can be calculated (Figure 4.7 B). Bcl-3 however shows little similarity 
to this motif, with only two identical residues shared with the consensus 
sequence. These data indicate that this short putative p50 binding region is 
specific to Bcl-3 and not conserved among other IκB family members. 
 
 
 
Figure 4.7 Multiple sequence alignment of IκB proteins.  
(A) Similarity index of ANK1-ANK7 of the ARD of murine IκB family members, Bcl-3, IκBα, 
IκBβ, IκBε, IκBNS, p100 and p105. Similarity scoring: identical amino acids=1, similar 
residues=0.5 and weakly similar residues =0.2 (Table 26). Bcl-3 144-158 shaded in black. 
(B) Section of multiple sequence alignment of murine IκB family members, Bcl-3, IκBα, 
IκBβ, IκBε, IκBNS, p100 and p105 (see Appendix 7.8 for full alignment). Colour coding: 
non similar amino acids black on white background, conservative amino acids black on 
green background, block of similar amino acids dark blue on blue background and weakly 
similar amino acids green on white background. Only identical and similar amino acids 
were used in consensus calculation. 
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4.3.3 Bcl-3 Derived Peptide    
4.3.3.1 Design and synthesis 
A short Bcl-3 derived peptide (BDP) was designed to span both α-helices of ANK1 
and the first β-sheet of ANK2 (Figure 4.8 B), incorporating the putative p50 
binding region identified by the peptide array (Figure 4.8 C). The derived 
peptide consisted of the region H135-N164 of Bcl-3 fused with the cell 
permeable HIV-TAT peptide to mediate cellular uptake  without transfection 
(Figure 4.8 A). A Fluorescein isothiocyanate (FITC) tag was also conjugated to 
the N-terminus to visualise peptide internalisation by the cell.  
 
4.3.3.2 Peptide characterisation  
As the BDP was labelled with a C-terminal FITC tag, peptide uptake was easily 
assessed by immunofluorescence and flow cytometry analysis. Following 2 hours 
of peptide treatment, 98% of cells were FITC positive by flow cytometry analysis 
(Figure 4.9 A) and the peptide predominantly localised to the nucleus (Figure 
4.9 B). These data indicate that the BDP is effectively internalised by cells and 
can translocate to the nucleus, where Bcl-3 is localised. To investigate the 
potential of this peptide to regulate TLR function in vitro, a luciferase reporter 
assay incorporating the Bcl-3 regulated NF-κB-dependent IL-23p19 gene 
promoter was employed (Carmody et al., 2007a, Muhlbauer et al., 2008). RAW 
264.7 cells were cotransfected with firefly IL-23p19 and Renella luciferase 
expression vectors, with or without Bcl-3. Following 24 hours transfection, cells 
were pre-treated with BDP before stimulation with LPS for 8 hours (Figure 4.9 
C). To exclude any nonspecific effects due to peptide transduction, cells were 
also pre-treated with a mutant NEMO binding domain peptide (mNBD) as an 
additional control. The mNBD peptide contains mutations of two critical IKKβ 
interacting amino acids within in the NEMO binding domain necessary for 
inhibition of NF-κB activation (Tas et al., 2005). In agreement with previous 
reports (Muhlbauer et al., 2008), Bcl-3 expression inhibited IL-23p19 reporter 
activity in RAW 264.7 cells following stimulation with LPS. As expected the 
mNBD peptide had no significant effect on reporter activity while the BDP 
inhibited reporter activity to equivalent levels as seen with over expressed Bcl-
3.  
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Figure 4.8 Design of Bcl-3 derived cell permeable peptide.  
(A) Schematic representation of murine Bcl-3 with the Bcl-3 derived peptide 
corresponding to Bcl-3 amino acids 135-164 indicated. Sequence of peptide 35 and 36 
(144-158) identified as positive p50 binding peptides in Figure 4.3 are underlined. (B) 
Bcl-3 crystal structure with residues corresponding to the BDP shaded in blue. (C) 
Sequences of Bcl-3 peptides 33-40 from Bcl-3 peptide array with corresponding Bcl-3 
amino acids indicated. * denotes positive p50 binding peptides identified in Figure 4.3. 
Sequence of BDP underlined with 144-158 in italics. 
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Figure 4.9 BDP can translocate to the nucleus and inhibit IL-23p19 reporter activity. 
Work carried out by Dr Amy Colleran (University College Cork, Cork, Ireland) (A)  Flow 
cytometry analysis of RAW 264.7 following treatment with 2 μM FITC labelled BDP or 
DMSO control for 2 hours. (B) Immunofluorescence analysis of HeLa cells treated with  
20 μM FITC labelled BDP  for 2.5 hours. (C) RAW 264.7 cells were transiently transfected 
with the pLucp19 plasmid and Bcl-3 expression vector (Bcl-3) or with empty vector 
(Mock,BDP,mNBP) for 24 hours. Cells were left untreated (Mock, Bcl-3) or pre-treated 
with 20μM peptide as indicated for 1.5 hours before stimulation with 100ng/ml LPS. 
Cells were cultured for an additional 8 hours before luciferase activity was measured. 
The Renella luciferase expression vector pRL-TK was used as an internal control to 
normalise the transfection efficiency across all samples. IL-23p19 reporter activity is 
represented as fold increase over untreated (UNT) cells transfected with pLucp19 
plasmid and empty vector expression (Mock). Transfections were performed in triplicate 
per experiment and data shown are means + SEM and are representative of independent 
experiments. Statistical significance was determined by Student’s t test; P<0.05 (*), 
P<0.01 (**), P<0.001(***).  
 145 
 
4.3.3.3 Peptide optimization 
Preliminary characterisation of the BDP in the RAW 264.7 cell line identified a 
novel peptide with the ability mimic Bcl-3 in vitro. Cargo size can effect uptake 
and cell toxicity of a peptide (Tünnemann et al., 2006) . Thus, the initial BDP 
sequence was refined to produce a more effective peptide for in vivo use to 
study Bcl-3 function and regulation of TLR activation (Figure 4.10A).  The new 
short Bcl-3 derived peptide (sBDP) consisted of only Bcl-3 amino acids 144-158 
(corresponding to peptides 35 and 36) fused with the HIV TAT CPP. The sBDP 
represents the outer helix and linker domains of Bcl-3 ANK1 (Figure 4.10 B). A 
mutant sBDP was also designed to establish an additional control for peptide 
transduction. The mutant peptide was identical to the wild type sequence apart 
from alanine substitutions of essential p50 interacting amino acids determined 
by the alanine scanning array (Figure 4.11 A and B).  The mutated amino acids 
are highlighted on the human Bcl-3 structure which are identical or highly 
conserved in the murine sequence (Figure 4.11 B). The sBDP and mBDP were 
tested as before in the IL-23p19 luciferase reporter assay. RAW 264.7 cells were 
either pre-treated with sBDP or mBDP before stimulation with LPS. Expression 
of Bcl-3 and transduction with sBDP inhibited IL-23p19 reporter activity while 
the mutant peptide had no effect on reporter activity (Figure 4.11D). These 
data demonstrates that the inhibitory activity of BDP is contained within the 
144-158 region and that this activity is dependent on the key amino acids 
required for peptide interaction with p50. 
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Figure 4.10  Sequence of the shortened Bcl-3 derived cell permeable peptide. 
(A) Schematic representation of the full length (BDP) and shortened (sBDP) Bcl-3 derived 
peptide sequences with corresponding murine Bcl-3 amino acids indicated. The N-
terminal HIV TAT sequence is coloured in purple. (B) Human Bcl-3 crystal structure with 
residues 144-158 corresponding to the sBDP sequence are in shaded blue. 
 
 
 147 
 
 
Figure 4.11 sBDP inhibits IL-23p19 luciferase reporter activity. 
(A) Alanine substitution analysis of positive peptide p50 binding Bcl-3 peptide 35, 
identified in Figure 4.3.  The 18 amino acids of Bcl-3-derivied peptide 35 were 
sequentially substituted with alanine and probed with GST-p50 and detected by 
immunoblotting with anti-GST antibody.  p50 binding was quantified by densitometry 
and calculated as a percentage binding of the parent unsubsitituted peptide on the same 
array. (B) Sequences of short BDP (sBDP) and mutated short BDP (mBDP) with alanine 
substitutions underlined. (C) Top view of human Bcl-3 crystal structure with residues 
corresponding  sBDP shaded in blue and residues mutated in mBDP shaded in yellow. (D) 
RAW 264.7 cells were transiently transfected with the pLucp19 plasmid and Bcl-3 
expression vector (Bcl-3) or with empty vector (Mock, sBDP, mBDP) for 24 hours. Cells 
were left untreated (Mock, Bcl-3) or pre-treated with 20μM peptide as indicated for 2 
hours before stimulation with 100ng/ml LPS for an additional 18 hours. Transfections 
were performed in triplicate per experiment and data shown are means + SEM and are 
representative of independent experiments. IL-23p19 reporter activity was determined 
as in Figure 4.9. Statistical significance was determined by Student’s t test; P<0.05 (*), 
P<0.01 (**), P<0.001(***).   
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4.4 DISCUSSION 
Bcl-3 mediated inhibition of p50 homodimer ubiquitination results in a stable 
p50:Bcl-3 repressor complex bound to the promoters of NF-κB target genes. 
Interaction with p50 is necessary and sufficient for this anti-inflammatory 
function of Bcl-3. In order to further investigate the role of this complex in the 
regulation of NF-κB mediated gene transcription, a Bcl-3 peptomimetic strategy 
was employed. A peptide array approach was utilised to identify short peptides 
of Bcl-3 capable of binding p50.  A number of positive interactions between 
recombinant p50 and Bcl-3 peptides representing the N terminus, ANK1, ANK6 
and ANK7 were observed.  Following alanine substitution analysis, critical 
residues within these peptides were identified. Considerable overlap between 
interacting residues determined by peptide array and those predicted from 
computation modelling occurred in ANK6 and ANK7, further supporting peptide 
array as a method to identify critical p50 binding regions.   
As the Bcl-3 p50 crystal structure is unsolved, in silico models are developed 
based on the p50/p65:IκBα complex. These computational complexes are 
limited by the available crystal structure of a p50 homodimer bound to DNA and 
the ARD of Bcl-3. The extreme N- and C-terminal domains of both p50 and Bcl-
3 are not represented in the current resolved structures and thus the predicted 
complexes do not account for interactions in these domains. This may explain 
the differences observed between interacting amino acids predicted by in silico 
modelling and those determined by peptide array. Comparison of the predicted 
structure of a complete p50 subunit to Manavlan et al. modelled Bcl-3:p50 
complex, it is likely the N-terminal domain of Bcl-3 makes additional contacts 
with the extreme C terminus of p50, previously determined to be important for 
binding in chapter1 (Figure 4.12). 
Residues 144-158 of Bcl-3, comprising the outer alpha helix and linker region of 
ANK1 were considered to contain a putative p50 binding domain. The ARD of the 
IκB proteins are highly conserved, for instance Bcl-3 and IκBα share almost 34% 
sequence identity between ANK1-6. However, multiple sequence alignment of 
this region of Bcl-3 (144-158) illustrates an area of low similarity between all 
IκB proteins. The most significant structural differences between nuclear and 
cytoplasmic IκB proteins occur in the N- and C-termini (Basith et al., 2013, 
Manavalan et al., 2010, Michel et al., 2001). Although the ARDs of IκB proteins 
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typically represent a series of conserved ANK repeats, ANK1 deviates from the 
other ANK repeats of Bcl-3. Compared to the consensus sequence, the outer 
alpha helix of ANK 1 is extended by four amino acids, three of which (GSR) 
contribute to the polarity of this region (Michel et al., 2001) and A145 and R148 
replace the hydrophobic residues observed at these positions in other repeats. 
Analysis of the ARD of multiple IκB family members by  Basith et al. and  
Manavalan et al. identified residues contained within ANK1 involved in flexibility 
and functional divergence (Figure 4. 13) (Basith et al., 2013, Manavalan et al., 
2010, Michel et al., 2001). ANK1 of Bcl-3 has also been implicated in the survival 
of activated T and B cells  (Mitchell et al., 2002). Taken together, these data 
suggested this region of ANK1 would be an ideal candidate in developing a Bcl-
3 specific mimetic peptide as it represents a structurally unique, flexible 
domain capable of binding p50. 
 
 
 
Figure 4.12 Comparison of Bcl-3:p50 complex with complete p50 structure. 
In silico model of a predicted of a DNA bound Bcl-3:p50 homodimer complex (Manavalan 
et al., 2010) and the predicted structure of a complete p50 subunit including the 
unstructured extreme N- and C-terminal domains (N and C respectively) determined by 
homology modelling with Phyre 2.  
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Figure 4. 13 Structural analysis of Bcl-3 ANK repeat 1.  
Teal shading represent flexible residues (Manavalan et al., 2010), purple shading 
represent residues involved in type II divergence (radical biochemical changes between 
the IκB subfamilies) (Basith et al., 2013) and underlined amino acids are replaced by 
hydrophobic residues in all other ANK repeats. The extension of the outer α-helix is 
indicated. The corresponding murine sequence representing sBDP is underlined. 
 
The initial Bcl-3 derived peptide consisted of a HIV-TAT CPP fused to 30 derived 
amino acids (135-164) of Bcl-3, encompassing the putative p50 binding domain 
(144-158) with 6-9 N- and C-terminal flanking residues. The N-terminal FITC tag 
allowed visualisation of peptide uptake and consistent with previous reports for 
HIV-TAT conjugated peptides, the BDP translocated to the nucleus, the site of 
Bcl-3:p50 interaction. In an in vitro luciferase reporter assay, the peptide 
inhibited expression of the pro-inflammatory cytokine IL-23p19 to equivalent 
levels as that seen with Bcl-3 overexpression. These results provide proof of 
principle for Bcl-3 mimetic peptides as regulators of NF-κB. The BDP was further 
reduced in size to contain only 15 Bcl-3 amino acids (144-158) fused with the 
HIV-TAT CPP. A mutant version of this short peptide was also designed, where 
critical p50 binding residues determined by alanine substitution peptide array 
analysis were mutated to alanine. This short peptide retained the functional 
properties of the parent BDP however the mutant peptide had no significant 
effect on IL-23p19 reporter activity. These data further support the importance 
of Bcl-3:p50 interaction for Bcl-3 mediated inhibition NF-κB activity and 
inflammatory gene expression. 
NF-κB regulates the transcription of a number of genes critical for the 
inflammatory response and is considered a potential therapeutic target in a 
range of human diseases where inflammation plays a role. Hundreds inhibitors 
of NF-κB activation have been described (Gilmore and Herscovitch, 0000) but 
are limited by broad specificity. Inhibition of NF-κB mediated transcription may 
represent a more specific strategy in the control of NF-κB signalling. For 
example,  anti-inflammatory peptide-6 (AIP6), a peptide designed to bind p65 
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and inhibit DNA binding, was shown to inhibit the transcriptional activity of p65 
and production of proinflamatory mediators including TNF while having no 
effect IκBα phosphorylation or nuclear localisation of p65 (Wang et al., 2011). 
The peptides described here were designed to mimic Bcl-3 function, by 
suppressing NF-κB regulated transcription, thus representing a potential gene 
specific inhibitor of inflammation. These mimetic peptides can modulate TLR 
mediated function in vitro however; their potential in vivo is yet to be 
established. The ability of these peptides to rescue the phenotype of Bcl3-/- cells 
and as possible inhibitors of NF-κB in models of LPS induced septic shock should 
next be determined. Bcl-3 derived peptides provide a valuable tool for further 
analysis of Bcl-3 function and the development of Bcl-3 based therapeutic 
agents for inflammatory disease. 
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Chapter Five 
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5 Identification of Tpl-2 as novel binding 
partner of Bcl-3 
 
5.1 ABSTRACT 
The IκB protein, Bcl-3 is an essential negative regulator of NF-κB during TLR and 
TNFR signalling. Here we report a novel role for Bcl-3 as an inhibitor of MAPK 
signalling. MAP kinases are serine/threonine-specific protein kinases activated 
by a three tiered protein kinase pathway. The best characterised of these MAP 
kinases, ERK1/2 regulate a number of cellular processes such as differentiation, 
proliferation and inflammatory gene expression. The MAP kinase kinase kinase, 
Tpl-2, mediates ERK1/2 activation during innate immune responses triggered by 
TLRs and TNF. We have identified Bcl-3 as a novel regulator of Tpl-2 mediated 
activation of ERK1/2. Following LPS stimulation, Bcl-3 deficient macrophages 
demonstrate increased phosphorylation of ERK1/2 and increased expression of 
a number of ERK dependent genes. Furthermore, Bcl-3 overexpression inhibits 
TPL-2 MEK-kinase activity and Tpl-2 mediated ERK1/2 activation, supporting the 
role of Bcl-3 as a negative regulator of MAPK signalling. Bcl-3 interacts with TPL-
2 independently of p105, an essential regulator of TPL-2 activation. Our data 
establishes Bcl-3 as a critical regulator of both MAPK and NF-kB activity 
following TLR  activation. We identify Bcl-3 as a unique member of the IκB 
family which co-ordinates MAPK and NF-kB activity in the innate immune 
response. 
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5.2 INTRODUCTION 
Engagement of all TLRs activate a common pathway culminating in the 
activation of NF-κB and MAPKs p38, JNK and ERK1/2 (Figure 1.9) (Barton and 
Medzhitov, 2003). ERK1 (or MAPK3), the first MAPK to be discovered, was 
identified over 20 years ago as a 43 kDa protein kinase characterised by its 
ability to phosphorylate microtubule-associated protein-2 (MAP2) (Boulton et 
al., 1990). Shortly  after, a 41 kDa ERK-related protein/serine kinase sharing 
90% sequence identity to ERK1 was described  and named ERK2 (or MAPK1) 
(Boulton et al., 1991, Keshet and Seger, 2010).  ERK1/2 are ubiquitously 
expressed and over one hundred nuclear and cytoplasmic ERK substrates have 
now been identified, regulating cellular processes such as proliferation, 
differentiation and cell cycle progression. ERK1/2 are activated following 
stepwise phosphorylation of two sites, threonine and tyrosine by the dual-
specificity MAP2Ks, MEK1 and MEK2 (Ferrell and Bhatt, 1997). A number of 
MAP3Ks can initiate MAPK signalling by activating MEK1 and MEK 2 however, the 
specific MAP3K utilised, is cell type- and stimulus-dependent. For example, the 
ERK cascade is primarily initiated by the MAK3K, RAF however, in innate 
responses, Tpl-2 plays a dominant role.  Tpl-2 mediates ERK1/2 activation by all 
TLRs and some members of the TNFR superfamily in primary macrophages 
(Banerjee et al., 2006, Eliopoulos et al., 2003). In macrophages, Tpl-2 
specifically mediates activation of ERK1/2 but not MAPKs, p38 and JNK following 
LPS induction (Dumitru et al., 2000). Although Tpl-2 is the sole MAP3K 
repsonsilble for ERK1/2 activation in macrophages, the mechanisms involved in 
Tpl-2 regulation are still poorly understood. 
Activation and function of Tpl-2 requires at least two regulatory steps, 
phosphorylation of Thr 290 in the activation loop of its kinase domain and also 
at Ser 400 in its C-terminus (Gantke et al., 2011). Different kinases have been 
reported to be responsible for these phosphorylation steps but this may be 
dependent on the different experimental systems utilised. Stafford et al. and 
Lucian et al suggest that Tpl-2 autophosphorylates on Thr 270 in 293T cells, 
whereas Cho et al. report this phosphorylation is controlled by IKKβ in RAW264.7 
macrophages  (Stafford et al., 2006, Luciano et al., 2004, Cho et al., 2005). 
Recently  Roget et al. demonstrated that Tpl-2 Ser 400 phosphorylation is 
mediated by IKKβ in macrophages (Roget et al., 2012). These phosphorylation 
steps are thought activate Tpl-2-MEK kinase activity by inducing conformational 
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changes in the inhibitory C-terminal domain, which facilitate MEK binding and 
phosphorylation (Gantke et al., 2012).  Phosphorylation at Ser 400 is also 
required for association of 14-3-3 with the Tpl-2 C terminus which increases the 
efficiency of MEK-1 phosphorylation, potentially by altering the inhibitory 
interaction between the Tpl-2 C terminus and kinase domain (Ben-Addi et al., 
2014).  
Although p105 maintains Tpl-2 in an inactive state in the cytoplasm of resting 
cells, p105 does not directly regulate Tpl-2 kinase activity (Figure 1.11). p105 
inhibits Tpl-2 dependent MEK phosphorylation by preventing Tpl-2/MEK 
interaction and as Tpl-2 catalytic activity is not inhibited by p105,  it is thought 
that Tpl-2 may have other substrates other than MEK . In support of this, recent 
work  has implicated Tpl-2 in the phosphorylation of histone H3 and was shown 
to be recruited to the  c-fos promoter directly activating AP-1 transcription 
(Choi et al., 2008). Steady state levels of Tpl-2 are regulated by interaction with 
p105, however following  stimulus- induced liberation from p105, Tpl-2 is rapidly 
degraded (Waterfield et al., 2003). Very little is known about the mechanisms 
governing this degradation or negative regulators of Tpl-2 following activation.  
In this chapter we further investigated the regulation of TLR signalling by Bcl-
3, specifically exploring the role of Bcl-3 in the MAPK pathway. Using 
macrophages derived from Bcl3-/- mice we analysed LPS-induced MAPK 
activation and MAPK dependent gene expression. ERK1/2 was found to be 
phosphorylated to a much greater extent in Bcl3 deficient cells, correlating with 
increased expression of ERK dependent gens Fos and Egr1. To delineate the 
function of Bcl-3 in ERK activation we examined the MAPK ERK cascade and 
identified Tpl-2 as a new interacting partner of Bcl-3.  This chapter illustrates 
a novel role for Bcl-3 in TLR signalling and as a potential negative regulator of 
the MAPK pathway. 
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5.3 RESULTS 
5.3.1 Bcl-3 Negatively Regulates ERK1/2 Signalling 
To search for novel functions of Bcl-3, the effect of Bcl3 deficiency on the 
activation of MAPK signalling pathways was investigated. The MAPK signalling 
cascade is one of the key downstream targets following LPS activation in 
macrophage. Bone marrow derived macrophages (BMDM) prepared from either 
wild-type or Bcl3-/- mice were stimulated with LPS and analysed by immunoblot 
and qPCR. Bcl-3 deficiency resulted in increased ERK1/2 phosphorylation (Figure 
5.1 A and B) and ERK-dependent gene expression following LPS stimulation 
(Figure 5.2). In addition to NF-κB dependent genes, Tnf and Il6, early growth 
response 1 (Egr1), a zinc finger transcription factor  (Guha et al., 2001, 
Waterfield et al., 2003, Robinson  et al., 2007) and  Fos, a proto-oncogene that 
forms part of the activator protein 1 (AP-1) transcription factor complex 
(Okazaki and Sagata, 1995, Zhao et al., 2012, Kaiser et al., 2009),  are 
downstream targets of the Tpl-2-MEK-ERK pathway and were significantly 
increased in Bcl3-/- macrophages relative to wild type following LPS stimulation.  
ERK activation following LPS stimulation is dependent on IKK activity and 
proteasomal degradation of p105 (Beinke et al., 2004, Waterfield et al., 2004). 
Consistent with previous reports (Beinke et al., 2004, Waterfield et al., 2004) 
pharmacological inhibition of IKK activation with BAY-11-7082 (Figure 5.3 A) and 
the proteasome with MG132 (Figure 5.3 B) inhibited LPS induced ERK 
phosphorylation. Although significantly more phosphorylated ERK1/2 was 
present in Bcl3-/- macrophage following stimulation, it was also sensitive to 
inhibition by these compounds. This suggested that the hyper-phosphorylation 
of ERK1/2 in Bcl3-/- macrophage was due to activation of the same signalling 
pathway as wild type macrophage. Taken together these data suggest a novel 
role for Bcl-3 as negative regulator of MAPK signalling and ERK-dependent gene 
expression. 
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Figure 5.1 Increased ERK MAPK signalling in Bcl-3-/-  macrophage.  
(A)  Macrophages derived from wild–type (WT) and Bcl3-/-  bone marrow combined from 
three mice were stimulated for 15 minutes with 1ng/ml, 10ng/ml and 100ng/ml LPS. 
Whole cell extracts were analysed by WB for phosphorylated and total ERK1/2. (B) 
Macrophage derived from wild–type (WT) and Bcl3-/-  bone marrow combined from three 
mice were stimulated with 100ng/ml LPS for the indicated times. Whole cell extracts 
were analysed by WB for phosphorylated and total ERK1/2. 
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Figure 5.2 Increased ERK-dependent gene expression in Bcl3-/- macrophage. 
(A)  Macrophages derived from wild–type (WT) (white circles) and Bcl3-/- (black circles) 
bone marrow combined from two mice were stimulated with 10ng/ml LPS for the 
indicated time. Gene expression levels were determined by real-time PCR. Data shown 
are means ± SEM of replicate samples and are representative of three independent 
experiments. 
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Figure 5.3 Proteasome and IKK activity is required for LPS activation of ERK1/2 in 
Bcl3-/-  macrophage .  
Macrophages derived from wild–type (WT) and Bcl3-/-  bone marrow combined from three 
mice were left untreated or pre-treated for one hour with (A)  20μM BAY-11-7082 or (B) 
20μM MG132  before stimulation with 100ng/ml LPS for the indicated times. Whole cell 
extracts were analysed by WB for phosphorylated and total ERK1/2. 
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5.3.2 Tpl-2 interacts with Bcl-3 independent of p105 
As the specific target for Bcl-3 mediated inhibition of ERK1/2 signalling was 
unknown, individual tiers of the MAPK cascade were next investigated. LPS 
induced ERK activation in primary macrophage is dependent on Tpl-2. Tpl-2 
interacts with p105, another IκB family member, thus it’s potential as a new 
binding partner of Bcl-3 was explored. The interaction of Tpl-2 with Bcl-3 was 
assessed by co-transfection in 293T cells (Figure 5.4 A). Tpl-2  is expressed in 
cells as a 58 and 52 kDa isoforms due to initiation of translation at alternative 
methionines, M1 and M30 respectively. Following immunoprecipitation with 
anti-FLAG, Tpl-2 was only detectable in immunoprecipitates co-transfected 
with Bcl-3-FLAG. This interaction was also dependent on the kinase activity of 
Tpl-2 (Figure 5.4 B). Tpl-2D270A contains a mutation in the kinase domain 
activation loop of Tpl-2 rendering it catalytically inactive (Beinke et al., 2003). 
Tpl-2D270A interacted with Bcl-3 at much reduced levels compared to wild type 
Tpl-2 and was only detectable after long exposure. 
A critical step in the activation of the Tpl-2-ERK1/2 pathway is the IKK induced 
proteolysis of p105. Phosphorylation of p105 at S927 and S932 is essential for  
release of Tpl-2 from p105 and activation of the MAPK cascade (Beinke et al., 
2004). Importantly, Bcl-3 did not block IKKβ induced phosphorylation of p105 
(Figure 5.5 A) suggesting Bcl-3 regulates MAPK signalling independently of p105. 
To explore the contribution of p105 in Tpl-2-Bcl-3 interaction, Nfkb1-/- MEFs 
which do not contain either p105 or p50 were also co-transfected with Bcl-3 and 
Tpl-2 (Figure 5.5 B). As Tpl-2 is inherently unstable in the absence of p105 
(Beinke et al., 2004, Waterfield et al., 2004), cells were treated with MG132 
prior to immunoprecipitation. Tpl-2 was again detectable in 
immunoprecipitates of Bcl-3-FLAG suggesting that Bcl-3 does not require p105 
for interaction with Tpl-2.  
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Figure 5.4 Bcl-3 interacts with Tpl-2.   
(A) HEK293T cells were transfected with pRK5-Bcl-3-FLAG and pcDNA3-Tpl-2-MYC 
expression vectors as indicated. Whole cell lysates were immunoprecipitated (IP) with 
anti-FLAG and analysed by WB with anti-Tpl-2 for Tpl-2 and anti-FLAG for Bcl-3. (B) 
HEK293T cells were transfected with pRK5-Bcl-3-FLAG and pcDNA3-Tpl-2-MYC or or a 
kinase dead Tpl-2D270A mutant. Whole cell lysates were immunoprecipitated  and 
analysed as in A. 
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Figure 5.5 p105 independent Bcl-3-Tpl-2 interaction.  
(A) Whole cell lysates were immunoprecipitated HEK293T cells were transfected with 
expression vectors for pEF4-105-Xpress, pRK5-Bcl-3-FLAG and pRK5-IKKβ-FLAG as 
indicated. Cells were treated with 20μM MG132 for 2 hours prior to harvest. Whole cell 
lysates were analysed by WB for phosphorylated  p105 with anti-phospho-p105 (S927). 
(B) Nfkb1-/- MEFs were transfected with pRK5-Bcl-3-FLAG and pcDNA3.Tpl-2-MYC 
expression vectors as indicated. Cells were treated with 20μM MG132 for 2 hours prior 
to harvest. Whole cell lysates were immunoprecipitated (IP) with anti-FLAG and 
analysed by WB with the indicated antibodies. 
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5.3.3 Bcl-3 negatively regulates Tpl-2 
5.3.3.1 Bcl-3 inhibits Tpl-2-MEK kinase activity 
As Bcl-3 interacts with Tpl-2, the possibility that Tpl-2 kinase activity is 
regulated by association with Bcl-3 was next investigated. MYC tagged Tpl2 was 
immunoprecipitated from 293T cells transfected with or without Bcl-3. Tpl-2 
kinase activity assay was assessed in vitro with inactive GST-MEK1 as a 
substrate. Immunoprecipitated Tpl-2 was incubated with inactive MEK1 in the 
presence of ATP and MEK phosphorylation was determined by Western blot with 
anti-phospho MEK1/2 antibody. Co-expression with Bcl-3 dramatically reduced 
in vitro Tpl-2 kinase activity (Figure 5.6 A). As only a fraction of overexpressed 
Tpl-2 is bound to p105 (Beinke et al., 2003), overexpression of Tpl-2 activates 
the MAPK pathway culminating in phosphorylation of ERK1/2. 293T cells were 
transfected with Tpl-2 on its own or with Bcl-3 and the phosphorylation of 
endogenous ERK1/2 was determined by Western blotting of cell lysates. Tpl-2 
induced phosphorylation of ERK1/2 which was significantly inhibited by co-
expression with Bcl-3 (Figure 5.6 B). 
 
5.3.3.2 Bcl-3 inhibits Tpl-2 dependent AP1 reporter activity 
AP-1 is a heterodimeric transcription factor composed of members of the Fos 
and Jun family that regulates a number of cellular processing including 
proliferation and cell survival (Angel and Karin, 1991). AP-1 activity is 
modulated by a variety of stimuli (extensively reviewed in (Shaulian and Karin, 
2002))  that activate MAPK signalling (Karin, 1995). ERK1/2 activation can 
modulate AP-1 activity via c-Fos induction and thus increased synthesis of c-Fos 
(Karin et al., 1997, Herrera et al., 1990, Monje et al., 2003). To further 
investigate the role of Bcl-3 as a negative regulator of MAPK dependent 
transcription, a luciferase reporter assay incorporating the multiple copies of 
the AP1 enhancer AP1 gene promoter was employed. RAW 264.7 macrophage 
cells were transfected with p-AP1-Luc reporter plasmid and  Renilla luciferase 
vectors and increasing amounts of Tpl-2. The total plasmid concentration was 
kept constant across all samples with an empty vector. Consistent with AP-1 
activation in other cell lines (Li et al., 2010) Tpl-2 dose dependently induced 
AP-1 reporter activity in RAW 264.7 macrophage cells (Figure 5.7 A) which was 
significantly reduced by co-expression with Bcl-3 (Figure 5.7 B). 
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Figure 5.6 Bcl-3 inhibits Tpl-2 MEK-kinase activity. 
(A) HEK293T cells were transfected with pRK5-Bcl-3-FLAG and pcDNA3.Tpl-2-MYC 
expression vectors as indicated. Tpl-2 was immunoprecipitated (IP) from whole cell 
lysates with anti-MYC and in vitro  MEK kinase assays (KA) were performed with  unactive 
GST-MEK1 as a substrate. MEK phosphorylation was determined by WB of kinase assay 
reaction with anti-phospho MEK1/2 antibody. Immunoprecipitates were analysed for 
equal loading with anti-Tpl-2.  (B) 293T cells were transfected with pRK5-Bcl-3-FLAG 
and pcDNA3. Tpl-3-MYC as indicated. Cytoplasmic extracts  were analysed  for 
endogenous ERK1/2 phosphorylation  by WB with anti- phospho ERK1/2. 
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Figure 5.7 Bcl-3 inhibits Tpl-2 induced AP-1 activation.  
(A) RAW 264.7 cells were transiently transfected with 100ng pAP1-Luc luciferase and 
10ng pRL-TK Renella luciferase expression vectors and increasing amounts 
(100,200,300,400 and 500ng) of Tpl-2-MYC (Tpl-2). The total amount of plasmid was 
kept constant across all samples by adjusting the amount of empty vector used. AP-1 
reporter activity is represented as fold increase over cells transfected with empty vector 
(Mock). The Renella luciferase expression vector pRL-TK was used as an internal control 
to normalise the transfection efficiency across all samples. AP1 reporter activity is 
represented as fold increase over untreated cells transfected with pAP1-Luc plasmid 
and empty vector expression (mock). Statistical significance was determined by 
Student’s t test; P<0.05 (*), P<0.01 (**), P<0.001(***). Data presented as +SEM of 
triplicate samples. (B)  RAW 264.7 cells were transiently transfected with 100ng pAP1-
Luc luciferase and 10ng pRL-TK Renella luciferase expression vectors and 300ng pcDNA3-
Tpl-2-MYC (Tpl-2) with or without 150ng pRK5-Bcl-3-FLAG (Bcl-3).  AP1 reporter activity 
was determined as A. 
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5.3.4 Accumulation of nuclear Tpl-2 with Bcl-3 co-
expression 
Tpl-2 is reported to be predominantly cytoplasmic in resting cells, however upon 
stimulation a number of other components of the ERK pathway can translocate 
to the nucleus. In order to determine the effect of Bcl-3 on subcellular 
localisation of Tpl-2, nuclear and cytoplasmic extracts were prepared from 293T 
transfected with Tpl-2 in the presence or absence of co-transfected Bcl-3 and 
analysed by western blot. In the absence of Bcl-3 the majority of Tpl-2 was 
contained in the cytoplasmic fraction, however when co-expressed with Bcl-3 
the level of nuclear Tpl-2 increased dramatically (Figure 5.8 A). As Bcl-3 
stabilises p50 protein levels through inhibition of p50 homodimer ubiquitination, 
we next investigated the ubiquitination status of Tpl-2 in the presence of Bcl-3. 
A ubiquitination assay in 293T cells transfected with HA-tagged ubiquitin and 
Tpl-2 with or without Bcl-3 was performed. Following denaturing lysis, Tpl-2 
was immunoprecipitated with anti-MYC and immunoblotted with anti-HA 
antibody to detect ubiquitinated Tpl-2 species. Tpl-2 underwent ubiquitination 
however it was not sensitive to inhibition by Bcl-3 (Figure 5.8 B).  
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Figure 5.8 Bcl-3 overexpression increases nuclear Tpl-2. 
(A) HEK293T cells were transfected with pRK5-Bcl-3-FLAG and pcDNA3.Tpl-2-MYC 
expression vectors as indicated. Nuclear and cytoplasmic extracts were analysed by WB 
with anti-FLAG and anti-Tpl-2 antibodies. Loading was assessed with antibodies for 
HDAC1 and tubulin. (B) HEK293T cells were transfected with pRK5-Bcl-3-FLAG and 
pcDNA3.Tpl-3-MYC  and UB-HA vectors as indicated. Tpl-2 was immunoprecipitated from 
whole cell lysates with anti-MYC and immunoblotted with anti-HA to detect 
ubiquitinated Tpl-2. 
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5.4  DISCUSSION 
TLR engagement leads to the production of pro-inflammatory cytokines and type 
I IFNs which are essential in mounting host defences during infection (Kondo et 
al., 2012). Although inflammation is a critical response required to eliminate 
specific pathogens and cellular debris, aberrant TLR activation may underlie the 
pathophysiology of a number of infectious and autoimmune diseases (Liew et 
al., 2005). Immune homeostasis is maintained by multiple negative regulatory 
mechanisms, which terminate TLR signalling to prevent harmful inflammatory 
responses. Bcl-3 was recently reported to act as an essential negative regulator 
of TLR signalling. Bcl-3 deficient mice and cells are hyper-responsive to TLR 
activation and hyper sensitive to septic shock (Carmody et al., 2007b). TLR 
stimulation initiates a number of signalling cascades which culminate in the 
activation of NF-κB and various MAPK cascades. Investigation of Bcl-3’s role in 
TLR signalling thus far has been restricted to the NF-κB pathway, however data 
presented here suggest that Bcl-3 also regulates the MAPK pathway. 
Following LPS stimulation, macrophages derived from Bcl3-/- bone marrow 
exhibit increased phosphorylation of ERK1/2. Consequently, due to increased 
ERK1/2 activation, ERK dependent gene transcription is also upregulated. LPS 
induction of Egr-1 and c-Fos, two early response genes dependent on ERK 
activation (Waterfield et al., 2003), was significantly increased in Bcl3-/- 
macrophages. ERK activation following LPS stimulation in macrophage is 
initiated by the MAP3K, Tpl-2.  In the present study, we shown that Bcl-3 
interacts with and dramatically inhibits Tpl-2. This presents a novel function of 
Bcl-3 as a negative regulator of MAPK signalling distinct from its previously 
identified role as an inhibitor of NF-κB mediated transcription. 
Although interaction with p50 is essential for Bcl-3 mediated inhibition of NF-
κB dependent gene expression, Bcl-3’s role in regulating ERK appears to be 
independent of p50. p105 maintains Tpl-2 stability and is thus an critical 
component of the ERK cascade, however the p50 subunit is not required for  ERK 
regulation (Yang et al., 2011). Reconstitution of Nfk1b-/- macrophages with a 
version of p105 lacking the N-terminus i.e. p50, is sufficient to restore defective 
ERK activation in these cells (Zhao et al., 2012). Furthermore, Bcl-3 can interact 
with Tpl-2 in Nfk1b-/- MEFs deficient in both p50 and p105. Nevertheless it would 
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be interesting to determine if the Tpl-2-Bcl-3 complex exists alone or as part of 
a larger complex containing p105. 
ERK1/2 is activated following a number sequential phosphorylation steps, 
however Bcl-3 interaction with Tpl-2 suggests that Bcl-3 directly inhibits Tpl-2, 
upstream of both MEK1 and ERK1/2. Consistent with this theory, co-expression 
with Bcl-3 prevents Tpl-2 MEK kinase activity in vitro. Furthermore, Bcl-3 
overexpression also inhibits Tpl-2 induced ERK1/2 phosphorylation and AP-1 
transcriptional activity. It is also possible that Bcl-3 inhibits activation of Tpl-2, 
however basal ERK1/2 phosphorylation in Bcl3-/- macrophages is unchanged and 
therefore it is more likely that Bcl-3 regulates Tpl-2 kinase activity following 
activation. Bcl-3 interacts with kinase domain mutant of Tpl-2 to a much lesser 
extent that wild type Tpl-2, suggesting that this domain may be important in 
facilitating this interaction. It is also possible that Bcl-3 preferentially interacts 
with an active form of Tpl-2, further supporting the idea that Bcl-3 regulates 
Tpl-2 activity following stimulation. p105 binds to and inhibits Tpl-2 in resting 
cells, however upon stimulation, p105 is degraded thus liberating Tpl-2. Bcl-3’s 
role may be to inhibit this active form of Tpl-2, thereby attenuating ERK 
signaling following stimulation. 
Signal strength and duration are critical factors in determining the specificity 
and outcome of the ERK cascade. ERK activation can elicit distinct biological 
responses and based on studies with PC12 cells. It was proposed that the 
duration of this activation controlled cell fate decisions [42]. Treatment of PC12 
cells with nerve growth factor (NGF) which results in sustained ERK activation 
precedes cellular differentiation whereas transient activation with epidermal 
growth factor (EGF) promotes proliferation. This correlation between the 
duration of ERK signalling and distinct cell behaviours has also been documented 
in fibroblasts, T lymphocytes and myeloid cells (Murphy and Blenis, 2006). The 
expression kinetics of immediate early genes (IEGs) in response to specific 
stimuli are thought to regulate cell fate decisions (Sharrocks, 2006, Murphy and 
Blenis, 2006). Transient ERK activation triggers the expression of IEGs such as c-
fos. c-Fos protein however is very unstable and is quickly degraded. C-terminal 
phosphorylation of c-Fos protects it from degradation and occurs only under 
sustained ERK activation. As c-Fos is an important factor of the AP-1 complex, 
this increased stability results in a second wave of transcription of late response 
genes (Sharrocks, 2006, Murphy and Blenis, 2006). LPS stimulation in wild type 
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macrophage results in transient ERK1/2 phosphorylation, with peak intensity at 
15minutes. In Bcl3-/- macrophages however, a significant amount of 
phosphorylated ERK1/2 is still present at later time points. The current analysis 
is limited by a relatively short time course, further study of the activation 
dynamics Bcl3-/- macrophages is needed to determine if ERK activation is 
sustained in the absence of Bcl-3. 
The exact mechanism by which Bcl-3 inhibits Tpl-2 activity is yet to be 
elucidated. p105 inhibits Tpl-2 MEK kinase activity by physically preventing Tpl-
2 access to MEK (Beinke et al., 2003), it is possible that Bcl-3 may also inhibit 
Tpl-2 activity by this method and is worth investigation. Previous reports suggest 
Tpl-2 is a cytoplasmic protein, however this raises the question as to how it 
interacts with Bcl-3, a predominantly nuclear protein, in vivo.  It is important 
to note that the most available subcellular localization studies of Tpl-2 were 
conducted in resting cells (Belich et al., 1999).  MEK1 and ERK1/2 which are also 
prominently localised to the cytoplasm in resting cells can translocate to the 
nucleus upon stimulation. ERK1/2 or MEK do not contain a classical nuclear 
localisation signal (NLS). Recent reports  however, suggest a novel nuclear 
translocation signal (NTS) may be responsible for stimulus dependent nuclear 
import of these proteins via the nuclear translocating protein, importin 7 
(Chuderland et al., 2008). MEK1 is  exported from the nucleus by CRM1 
dependent active transport facilitated by a classical NES located at its amino 
terminus,  whereas nuclear export of ERK1/2 is thought to be mediated directly 
by MEK (Fukuda et al., 1996). 
As substrates downstream of Tpl-2 can shuttle between the nucleus and the 
cytoplasm, the Tpl-2 sequence was analysed using NetNES prediction software 
(la Cour et al., 2004) to determine if Tpl-2 contained a putative NES (Figure 5.9 
A) (full results Appendix 7.9). This analysis identified putative NES in the C-
terminus of Tpl-2. The classical export pathway is dependent on CRM1, a 
member of the importin b superfamily of transport receptors and leucine-rich 
NESs (Lange et al., 2007). The consensus NES recognised by CRM1 is 
characterised as a short amino acid sequence of regularly spaced hydrophobic 
residues: Φ X2-3 Φ X 2-3 Φ x Φ where Φ=Leucine, isoleucine, valine, phenylalanine 
or methionine  and X is any amino acid (Lange et al., 2007). Preliminary 
experiments using LMB, an inhibitor of CRM1-mediated nuclear export suggest 
that Tpl-2 may indeed shuttle to the nucleus (Figure 5.9 B). In untreated cells, 
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Tpl-2 was found to be predominantly cytoplasmic in localisation as assessed by 
immunofluorescence, however following treatment with LMB for 2 hours, Tpl-2 
was also detected in the nucleus. Surprisingly, similar results were also obtained 
when cells were treated with MG132 alone, suggesting that nuclear Tpl-2 may 
be labile. These data suggest that, like other MAPK signalling proteins, Tpl-2 
may also be capable of nucleocytoplasmic shuttling however, it does not rule 
out the possibility that Tpl-2 interacts with Bcl-3 in the cytoplasm. Further 
investigation into the localisation of Tpl-2:Bcl-3 complexes is necessary but the 
possibility that Bcl-3 acts as a novel negative regulator of Tpl-2 in the nucleus 
is exciting and merits further investigation.  
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Figure 5.9 Potential nuclear export sequence in Tpl-2.   
(A) NetNes nuclear export prediction tool was used to identify residues potentially 
involved in nuclear export (underlined). Human Tpl-2 sequence is shown and grey 
shading indicates non conserved rat and mouse Tpl-2 residues. (B) NIH 3T3s were 
transfected with pcDNA3-Tpl-2-MYC for 48 hours and were left untreated (UNT), treated 
with 20nM LMB for 2 hours (LMB), treated with  20μM MG132 for 30 minutes (MG132) or 
a combination of 20nM LMB for 2 hours with 20 μM MG132 for the final 30 minutes. Cells 
were fixed cells and stained with anti-MYC and anti-Mouse-AF488. DMSO and ethanol 
were used as vehicle controls for MG132 and LMB respectively. 
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Chapter Six 
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6 General Discussion 
 
While TLR  activation is an essential part of innate immunity and is also required 
to mount an effective adaptive immune response, tight regulation of TLR 
signalling is crucial. Aberrant TLR signalling can result in excessive production 
of potentially damaging pro-inflammatory cytokines which can have deleterious 
consequences for the host. Several members of the TLR family have been 
implicated in the pathogenesis of autoimmune, chronic inflammatory and 
infectious diseases (Liew et al., 2005). Uncontrolled or chronic TLR4 signalling 
in response to LPS, for example, can result in one of the most severe TLR-related 
diseases, sepsis,  causing extreme inflammatory injuries to host tissues resulting 
in multiple organ dysfunction, shock, and eventual death (Van Amersfoort et 
al., 2003) . The necessity for the strict control of TLR signalling is evident and 
a multiple negative regulators have evolved to prevent harmful inflammatory 
responses (Liew et al., 2005, Kondo et al., 2012). 
The IκB protein Bcl-3, regulates NF-κB-dependent gene expression through 
interaction with homodimers of p50 and p52. p52 however, does not play a role 
in the classical NF-κB pathway and  p50 homodimers are thought to be the major 
target of Bcl-3 action in TLR signalling (Carmody et al., 2007b). Previous reports 
have shown that through the inhibition of p50 homodimer ubiquitination and 
subsequent degradation, Bcl-3 stabilises p50 homodimers, thus limiting NF-κB 
mediated transcription of pro-inflammatory cytokines (Carmody et al., 2007b). 
Bcl3-/- cells and mice and hyper-responsive to TLR signalling and are also 
defective in LPS tolerance. In addition to NF-κB subunits, Bcl-3 has also been 
reported to interact with a number other regulators of transcription (Na et al., 
1999, Jamaluddin et al., 2005, Yang et al., 2009, Viatour et al., 2004, Na et al., 
1998, Weyrich et al., 1998, Zhao et al., 2005, Kabuta et al., 2010, Southern et 
al., 2012). Therefore, the possibility that Bcl-3 may also function through p50-
independent mechanisms to regulate inflammatory gene transcription cannot 
be discounted in studies employing Bcl3-/- mice and cells. Previous to this study, 
it was unclear whether interaction with p50 was essential for the inhibition of 
NF-κB dependent cytokine expression or if other binding partners Bcl-3 are 
important. To further investigate this, we aimed to generate a p50 mutant 
incapable of binding to Bcl-3. We hypothesised that Bcl-3’s inhibitory activity 
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was dependent on interaction with p50 and thus cells expressing a version of 
p50 that was unable to interact with Bcl-3 would be hyper responsive to 
stimulation, recapitulating the Bcl3-/- phenotype. 
Peptide arrays were employed to identify critical residues of both p50 and Bcl-
3 required for this interaction. This method utilises a series of immobilised 
overlapping peptides encompassing the entire protein sequence being 
investigated.  This approach presents a rapid method to identify specific regions 
of interest and is advantageous over traditional deletional mutagengic 
approaches, which for NF-κB subunits can have severe consequences on DNA 
binding and dimerisation.  Recombinant Bcl-3 bound with high affinity to a 
number p50 peptides representing regions in both DNA binding and dimerisation 
regions of the p50 RHD. Using alanine substitution peptide arrays, specific 
residues within these peptides that contributed to Bcl-3 binding were identified. 
While peptide array data is extremely informative, p50 is a large 400 amino acid 
protein and binds Bcl-3 as part of a homodimer complex. Evaluation of the role 
of these residues in Bcl-3 interaction in full-length p50 was therefore essential. 
Based on the peptide array data, we generated a number of p50 mutants but 
found that only one mutant,  p50RKR,  was completely defective in  Bcl-3 binding.  
Suprisingly however, all mutations tested affected the ubiquitination status of 
p50 (Figure 6.1). 
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Figure 6.1 Summary of p50 mutants generated. 
(A) p50 homodimer crystal structure with specific regions mutated in this study 
highlighted in blue. (B) Table summarising the p50 mutants generated in this study with 
the associated ubiquitination status of each indicated. 
 
Region Mutant Mutation Ubiquitination 
Status 
R1 p50KRM  Lys249, Arg252, Met253 to 
alanine 
Increased 
R2 p50DFSPT Asp297, Phe298, Ser299, 
Pro300, Thr301 to alanine 
Increased 
R3 p50K315A,K317A 
p50Y316A 
p50Y316F 
p50K315A,Y316A,K317A 
Lys315, Lys317 to alanine 
Tyr316 to alanine 
Tyr316 to phenylalanine 
Tyr31,Tyr316,Lys317 to alanine 
Decreased 
Increased 
Increased 
Increased 
 
R4 p50RKR Arg359, Lys360 and Arg361 to 
alanine 
Increased 
 
- p50K128R Lys128 to arginine Decreased 
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The p50KRM and p50DFSPT mutants had a very similar phenotype and it is likely that 
Lys249, Arg252, M253 and Asp297, Phe298, Ser299, Pro300 and Thr301 
contribute to a shared protein interaction interface. Mutation of these residues 
resulted in a dramatic increase in p50 ubiquitination. While Bcl-3 interaction 
was reduced, Bcl-3 was able to bind to these mutants and also inhibit the 
ubiquitination, although not to the level seen with wild-type p50. It is possible 
that these residues contribute to interaction with Bcl-3, however, analysis of 
the crystal structure of the IκBα:NF-κB heterodimer complex revealed that 
Lys249, Arg252 and M253 of p50 also contact IκBα as part of a p65 heterodimer. 
Ser238, Phe239, Ser240, Gln341, and Ala342 of p65 which correspond to p50 
residues 297-301 identified by the peptide array, also contact IκBα in this 
complex. In addition, in silico modelling predicted that some of these residues 
may also bind other IκB proteins such as IκBNS as part of a p50 homodimer 
complex. Collectively, these data suggest that p50 residues 249,252-253 and 
297-301 may form as a general interface for interaction with IκB proteins.  IκB 
proteins are highly conserved and it is not surprising that overlap with p50 
interacting residues would occur. It would therefore be interesting to further 
test the p50KRM and p50DFSPT mutant’s ability to interact with other IκB family 
members apart from Bcl-3.  NF-κB monomers are inherently unstable and 
require dimerisation to avoid degradation, it is also thought that IκB interaction 
with NF-κB contributes to the stability of these dimer complexes.   Based on the 
available crystal structure and predicted IκB:p50 complexes it is highly likely 
that these mutants will be defective in binding to multiple IκB proteins, which 
may explain the instability of these mutants. We have also generated a Nfkb1-/-   
MEF cell line reconstituted version of p105 containing the KRM mutation. While 
p105 and p105RKR are equivalently expressed, p50KRM is almost undetectable.  
Studies using Nfkb1-/- cells investigating the role of p50 deficiency are limited, 
as in addition to p50,  these cells are also deficient in p105 an important 
inhibitor of NF-κB.  The p105KRM cell line therefore may also be a useful tool in 
investigating p50 specific functions. 
Binding to DNA triggers p50 ubiquitination, however the mechanisms preceding 
this event are unknown. The ubiquitination and degradation of p65 is regulated 
by a number of post translational modifications, such as acetylation, 
isomerisation and phosphorylation (Geng et al., 2009, Ryo et al., 2003, Li et al., 
2012, Saccani et al., 2004). TNF-induced phosphorylation on p65 Ser468 for 
example, regulates COMMD1-dependent ubiquitination of p65 (Geng et al., 
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2009). Similar to p65, p50 ubiquitination is induced following TLR and TNFR 
stimulation and it is likely that these signalling events also trigger post 
translational modification of p50  (Geng et al., 2009, Colleran et al., 2013, 
Carmody et al., 2007b). The KYK motif (p50 315-317) identified by the peptide 
array may contain a novel p50 phosphorylation site and merits further 
investigation (Appendix 7.10). Mutation of Tyr316 to alanine dramatically 
increased p50 ubiquitination which is not rescued by mutation to phenylalanine, 
a structurally more similar amino acid. This suggests modification of this 
tyrosine, possibly phosphorylation, is required to negatively regulate p50 
ubiquitination.  
It is apparent from these mutational studies that p50 ubiquitination must be a 
tightly regulated process. Mutation of even a single amino acid can alter the 
ubiquitination status of p50 and have dramatic effects on p50-regulated NF-κB 
inhibitory ability. Ubiquitination represents a critical regulatory step of NF-κB-
mediated transcription following TLR activation and we hypothesise that 
ubiquitination of p50 is required to remove inhibitory complexes from the 
promoters of NF-κB target genes. Identification of Lys128 as a target for p50 
ubiquitination will be valuable in investigating the role of p50 ubiquitination in 
regulating TLR-induced inflammatory gene expression and in innate immunity. 
NF-κB turnover on active chromatin is a rapid process occurring in less than 30 
seconds (Bosisio et al., 2006). We propose that a ubiquitination resistant version 
p50 would be highly stable therefore acting as super repressor of NF-κB 
mediated transcription. Currently however, it is not clear weather this lysine 
residue is specific to p50 homodimers or of this residue is also targeted in 
p50:p65 complexes. We have generated a Nfkb1-/- cell line stably expressing this 
ubiquitination defective version of p50 which will beneficial in investigating 
this.  
Previous studies have shown that Bcl-3 stabilises p50 homodimers through the 
inhibition of p50 ubiquitination however, the precise mechanism of this 
regulation was unknown. Our data demonstrates that Bcl-3-mediated repression 
of NF-κB –dependent gene expression requires interaction with p50. p50 that 
cannot interact with Bcl-3 (p50RKR) undergoes increased ubiquitination and 
degradation, even in the presence of over expressed Bcl-3. While Bcl-3 interacts 
with multiple regulators of transcription, our data suggests that p50 is the main 
target in the regulation of NF-κB-dependent inflammatory gene expression by 
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Bcl-3. How Bcl-3 interaction with p50 inhibits its ubiquitination however is still 
unclear. Bcl-3 may physically prevent binding of components of the 
ubiquitination machinery, for example an ubiquitin ligase or perhaps blocks a 
post-translational modification such as phosphorylation that may trigger 
degradation. Identification of the p50 ubiquitin ligase and signalling events 
preceding ubiquitination will be essential in elucidating the exact mechanism 
of Bcl-3-mediated inhibition of p50 ubiquitination. 
As elevated NF-κB activity contributes to the pathology of several human 
diseases, there has been significant interest in developing methods to limit NF-
κB signalling (Gilmore and Herscovitch, 0000). Many NF-κB inhibitors have 
entered clinical trials for the treatment of inflammatory diseases and as part of 
anti-cancer strategies (Gilmore and Garbati, 2011). The majority of inhibitors 
thus far act upstream of NF-κB activation, blocking NF-κB activity through the 
inhibition of receptors such as the TNF-R, and inhibition of IKK activity and IκB 
degradation (Song et al., 2002, Swinney et al., 2002, May et al., 2000). Due to 
the large number of NF-κB target genes, many involved in normal cell and tissue 
development, global inhibition of NF-κB activation is problematic. Focus is 
instead turning to the development of gene selective inhibitors of NF-κB. This 
is also proving a challenging task as many of the components involved in NF-κB 
activation overlap with other signal transduction pathways. Modulation or 
inhibition of individual NF-κB subunits therefore is an attractive approach and 
may provide a method to selectively block gene-specific events.  
Based our finding that interaction with p50 is necessary to limit NF-κB-mediated 
transcription, we explored the possibility of Bcl-3 mimetics as modulators as 
inhibitors of NF-κB activity. Again a peptide array approach was employed to 
identify the minimal regions of Bcl-3 capable mediating its function and binding 
p50. Based on the peptide array data and IκB multiple sequence alignment we 
identified a short, Bcl-3 specific peptide sequence that bound with high affinity 
to p50. The peptide sequence represented both α-helices of ANK1 and the first 
beta sheet of ANK2 and importantly was not well conserved among other IκB 
proteins. By the addition of the HIV–TAT peptide to our sequence, we were able 
to generate a cell permeable Bcl-3 derived peptide. These peptides were able 
to mimic Bcl-3 function and effectively inhibit NF-κB activity in vitro. While p50 
ubiquitination is required for establishment of innate immunity, tight control of 
this regulatory step is essential. As illustrated in this study and in previous 
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studies using Bcl3-/- cells (Carmody et al., 2007b), hyper ubiquitination of p50 
reduces p50 half-life resulting in increased NF-κB dependent cytokine 
expression. Stabilising p50 homodimers and thus inhibiting NF-κB-mediated 
transcription through Bcl-3 derived peptides represents a novel therapeutic 
approach to regulate the inflammatory response in a gene specific manner. The 
sBDP developed during this study is currently being tested  in vivo in a model of 
carrageenan-induced inflammation in collaboration with Dr. Gianluca Grassia 
and Prof. Armando Lalenti (University of Naples Federico II, Napoli, Italy) 
(Appendix 7.11). Preliminary data generated from this trial is very promising 
and indicates that Bcl-3 peptides are effective in vivo. These peptides not only 
provide proof of principle of Bcl-3 mimetics as inhibitors of NF-κB activity but 
also provide a basis for developing novel Bcl-3 based strategies for the 
treatment of inflammatory diseases.  
Identification of Tpl-2 as a novel binding partner of Bcl-3 in this study reinforces 
the need to develop specific inhibitors of NF-κB in order to be therapeutically 
beneficial. Surprisingly we found that in addition to NF-κB, Bcl-3 also critically 
regulates TLR-induced MAPK signalling. Bcl3 deficiency results in increased 
ERK1/2 activation and consequently increased ERK1/2-dependent gene 
expression. The dynamics of growth factor-induced ERK1/2 signalling through  
Raf have been extensively studied however ERK1/2 activation following TLR 
signalling is relatively unexplored. We have identified Bcl-3 as a novel negative 
regulator of this pathway, although the mechanism of this inhibition is as of yet 
unclear. LPS induced ERK1/2 activation is very transient, however in the 
absence of Bcl-3, the duration of ERK1/2 activity appears to be increased. 
Strong activation of ERK1/2 however generally leads to long term activity and 
so further investigation into the dynamics of ERK1/2 activation in the Bcl3-/- 
cells is needed to discriminate between these effects (Ebisuya et al., 2005).  A 
number of strength-controlling and temporal regulators of ERK1/2 activity exist 
which determine the duration and magnitude of the ERK1/2 response (Ebisuya 
et al., 2005). In many cell types ERK activation is not an all-or-none response 
and as shown by us and by others for EGF- and PMA- induced ERK signalling, the 
amplitude of ERK1/2 activation is proportional to the concentration of external 
stimulus (Whitehurst et al., 2004). Bcl3 deficient macrophages are hyper-
sensitive to TLR stimulation and produce a more robust ERK response at lower 
concentrations of LPS compared to wild type. Bcl3 deficiency reduces the 
threshold for ERK activation but it is unclear from our current analysis whether 
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this is due to increased numbers of cells responding to activation or if the 
amplitude of activation in a fraction of the cells is increased. Further 
investigation using phosho-flow and single cell immunofluorescence based 
techniques will be necessary to clarify the role of Bcl-3 in regulating the 
amplitude of the ERK response.  
Tpl-2 is the sole MAP3K responsible for activation of the ERK1/2 MAPK pathway 
following LPS stimulation in macrophages and we reason that Bcl-3 acts to 
regulate the ERK pathway at the level of Tpl-2. Based on our current data there 
are several possible mechanisms of Bcl-3 mediated ERK1/2 regulation which 
require further investigation (Figure 6.2). As other components of the ERK 
pathway MEK1/2 and ERK1/2 both translocate to the nucleus following 
activation, nucleocytoplasmic shuttling of active Tpl-2 is not unlikely. Nuclear 
localization of Tpl-2 in 293T cells has been reported following UVB radiation 
(Choi et al., 2008) and we have demonstrated accumulation of Tpl-2 in the 
nucleus following LMB treatment. As Bcl-3 is predominantly a nuclear protein, 
we postulate that Bcl-3 regulates nuclear Tpl-2, however, it is possible that Bcl-
3 may also act in the cytoplasm. Free Tpl-2 is extremely unstable and following 
LPS stimulation, Tpl-2 is rapidly degraded (Waterfield et al., 2003). We found 
that in addition to treatment with LMB, blocking the proteasome also resulted 
in a build-up of nuclear Tpl-2. This suggests that the nuclear pool of Tpl-2 is 
extremely labile which may explain the very low steady state levels of Tpl-2 in 
Nfkb1-/- cells. Without a cytoplasmic anchor, Tpl-2 may be free to constantly 
shuttle to the nucleus. Why nuclear Tpl-2 is unstable is yet to be determined 
but it is possible that Tpl-2 is modified in the nucleus in such a way that triggers 
its degradation and thus limits the ERK response. 
There are several known spatial regulators of  ERK activity and it is possible Tpl-
2 is also regulated in a similar manner by Bcl-3. The golgi-localised scaffold  
protein Sef for example, binds to activated MEK and prevents ERK dissociation 
thereby targeting ERK activity to the cytoplasm (Torii et al., 2004). ERK 
activation can result in diverse cellular responses, which are influenced by the 
subcellular localisation of activated ERK and the subsequent phosphorylation of 
cytoplasmic and nuclear effectors. Nuclear localisation of active ERK, increases 
Elk-1 activity and induces the expression of a number of immediate early target 
genes such as Fos, Jun and Egr1, increasing proliferation in fibroblasts and 
epithelial cells. In contrast cytoplasmic retention of activated ERK can suppress 
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Fos expression and proliferation (Ebisuya et al., 2005). It is possible that 
interaction with Bcl-3 may prevent nuclear export of Tpl-2 simply by masking a 
NES or perhaps preventing interaction with other binding partners of Tpl-2. MEKs 
can interact with ERKs in the nucleus and actively export them back to the 
cytoplasm, nuclear export by MEK however is not restricted to ERKs and the 
nuclear receptor PPARγ is also regulated in this manner following mitogen 
stimulation (Adachi et al., 2000, Burgermeister et al., 2007).  It would be 
interesting to determine if Tpl-2:MEK complexes are restricted to the cytoplasm 
or if active Tpl-2 also interacts with MEK in the nucleus.  
As mentioned the duration of the ERK response can determine the fate of certain 
cellular responses such as differentiation and proliferation. Subtle differences 
in the time course of activation can change the biological outcome of ERK 
activation. Sustained ERK activation in PC12 cells induced by NGF precedes 
cellular differentiation whereas EGF induced transient activation results in 
proliferation (Qiu and Green, 1992). These distinct biological outcomes are also 
dependent on the cell type however and sustained ERK activation by PDGF is 
required for quiescent fibroblasts to begin to proliferate. Macrophages have an 
essential role during the immune response and act as regulators of homeostasis, 
effector cells in inflammation and promoters of wound healing  (Murray and 
Wynn, 2011). Macrophages are highly heterogeneous and in response to local 
environment can rapidly change function (Valledor et al., 2000). Tissue 
macrophages can either proliferate, further differentiate to more specialised 
resident macrophages such as Kupffer cells and osteoclasts or become activated 
(Murray and Wynn, 2011). Correct  control of macrophage proliferation, 
differentiation and survival is paramount in regulating the duration and 
magnitude of the immune response (Xaus et al., 2001). The kinetics of ERK 
activation in macrophages have also been implicated in directing macrophage 
response to stimuli (Valledor et al., 2000). The MEK/ERK cascade is essential for 
macrophage proliferation in response to M-CSF, the major growth factor for 
these cells (Valledor et al., 2000, Stanley et al., 1997, Comalada et al., 2003). 
In contrast, macrophages cease proliferating in response to LPS and acquire 
effector functions such as the production of pro-inflammatory cytokines (Xaus 
et al., 2001). LPS activation of macrophages is also dependent on ERK activation 
but follows a delayed time course compared to that of M-CSF, which peaks at 5 
minutes post stimulation and is directed through a Raf-1 dependent pathway 
(Comalada et al., 2003).  
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While activation of macrophages is critical for rapid elimination of invading 
microorganisms during the initial stages of inflammation, aberrant and chronic 
activation is associated with the pathogenesis of diseases including  
atherosclerosis, obesity-induced insulin resistance and LPS induced septic shock 
(Tabas, 2010, Valledor et al., 2010, Odegaard and Chawla, 2008). Thus 
maintaining the correct balance between macrophage activation and 
deactivation is crucial in the resolution of inflammation and preventing 
inappropriate inflammation-associated pathology. The mechanisms involved in 
regulation of the ERK cascade following LPS are poorly understood but the MAPK 
phosphatase, MKP-1 has been shown to be essential in macrophage deactivation 
through down regulation of MAPKs, p38 and JNK. Mkp1−/− macrophages exhibit 
prolonged p38 and JNK activation following LPS and Mkp1 deficiency renders 
mice hyper-responsive to LPS challenge and consequently more susceptible 
septic shock (Zhao et al., 2006, Hammer et al., 2006). This raises question as to 
the physiological role of Bcl-3 and if negative regulation of ERK activation by 
Bcl-3 controls cell fate to limit the inflammatory response. In a model of 
inflammatory lung injury, Bcl-3 was found to have an important role in 
regulating both the differentiation and proliferation of myeloid progenitors in 
emergency granulopoiesis and prevention of acute lung injury (Kreisel et al., 
2011). Bcl3 deficiency has also been recently shown to exacerbate insulitis and 
intraislet infiltration by inflammatory cells in models of Type 1 diabetes (Ruan 
et al., 2010). Moreover, Bcl-3 was found to play a significant role in regulating 
proliferation of intestinal epithelial cells following dextran-sodium sulphate 
(DSS)-induced colitis (O'Carroll et al., 2013). The mechanisms associated with 
Bcl-3 function in these studies is unknown and it is possible that Bcl-3-mediated 
regulation of ERK activation may not be limited to macrophages, suggesting a 
greater role for Bcl-3 in the resolution of the immune response.  
Collectively the findings of this thesis demonstrate that Bcl-3 is a multifaceted 
regulator of TLR-induced inflammatory responses. In addition to identification 
of a novel binding partner of Bcl-3 we have shown an essential role for Bcl-3 in 
limiting both NF-κB and MAPK activity. Bcl-3 can no longer be simply thought of 
as an IκB protein and the role of dysregulated ERK activation must now be 
carefully considered in interpretation of any studies using Bcl3-/- cells and mice. 
Furthermore, the success in establishing functional Bcl-3 derived peptides 
provides an excellent basis for a gene-specific approach in the treatment of 
inflammatory diseases. 
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Figure 6.2 Schematic model of Bcl-3 mediated MAPK regulation 
In resting cells, Tpl-2 is associated with an inhibitory cytoplasmic complex of p105 and 
ABIN2. Following LPS stimulation and IKK activation, p105 is phosphorylated and 
subsequently degraded. Liberated Tpl-2 initiates the ERK MAPK pathway by 
phosphorylation of MEK1/2, which in turn phosphorylates ERK1/2. Activated ERK 
dissociates from cytoplasmic anchors such as MEK and MAP kinase phosphatase (MKP) 
and phosphorylates a number of cytoplasmic targets such as RSK2. Activated ERK can 
also translocate to the nucleus phosphorylating several nuclear substrates such as Elk-1 
resulting in distinct cellular responses. Cytoplasmic ERK substrates once activated can 
also translocate to the nucleus where they phosphorylate and activate transcription 
regulators such as E26 transformation-specific (Ets) and CREB to induce immediate early 
gens.  
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7 Appendix 
7.1 p50 Peptide Array Sequences 
Peptide 
Number 
Amino Acid 
start # 
Amino acid Sequence Amino Acid 
end # 
1 1 MADDDPYGTGQMFHLNTA 18 
2 4 DDPYGTGQMFHLNTALTH 21 
3 7 YGTGQMFHLNTALTHSIF 24 
4 10 GQMFHLNTALTHSIFNAE 27 
5 13 FHLNTALTHSIFNAELYS 30 
6 16 NTALTHSIFNAELYSPEI 33 
7 19 LTHSIFNAELYSPEIPLS 36 
8 22 SIFNAELYSPEIPLSTDG 39 
9 25 NAELYSPEIPLSTDGPYL 42 
10 28 LYSPEIPLSTDGPYLQIL 45 
11 31 PEIPLSTDGPYLQILEQP 48 
12 34 PLSTDGPYLQILEQPKQR 51 
13 37 TDGPYLQILEQPKQRGFR 54 
14 40 PYLQILEQPKQRGFRFRY 57 
15 43 QILEQPKQRGFRFRYVCE 60 
16 46 EQPKQRGFRFRYVCEGPS 63 
17 49 KQRGFRFRYVCEGPSHGG 66 
18 52 GFRFRYVCEGPSHGGLPG 69 
19 55 FRYVCEGPSHGGLPGASS 72 
20 58 VCEGPSHGGLPGASSEKN 75 
21 61 GPSHGGLPGASSEKNKKS 78 
22 64 HGGLPGASSEKNKKSYPQ 81 
23 67 LPGASSEKNKKSYPQVKI 84 
24 70 ASSEKNKKSYPQVKICNY 87 
25 73 EKNKKSYPQVKICNYVGP 90 
26 76 KKSYPQVKICNYVGPAKV 93 
27 79 YPQVKICNYVGPAKVIVQ 96 
28 82 VKICNYVGPAKVIVQLVT 99 
29 85 CNYVGPAKVIVQLVTNGK 102 
30 88 VGPAKVIVQLVTNGKNIH 105 
31 91 AKVIVQLVTNGKNIHLHA 108 
32 94 IVQLVTNGKNIHLHAHSL 111 
33 97 LVTNGKNIHLHAHSLVGK 114 
34 100 NGKNIHLHAHSLVGKHCE 117 
35 103 NIHLHAHSLVGKHCEDGV 120 
36 106 LHAHSLVGKHCEDGVCTV 123 
37 109 HSLVGKHCEDGVCTVTAG 126 
38 112 VGKHCEDGVCTVTAGPKD 129 
39 115 HCEDGVCTVTAGPKDMVV 132 
40 118 DGVCTVTAGPKDMVVGFA 135 
41 121 CTVTAGPKDMVVGFANLG 138 
42 124 TAGPKDMVVGFANLGILH 141 
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43 127 PKDMVVGFANLGILHVTK 144 
44 130 MVVGFANLGILHVTKKKV 147 
45 133 GFANLGILHVTKKKVFET 150 
46 136 NLGILHVTKKKVFETLEA 153 
47 139 ILHVTKKKVFETLEARMT 156 
48 142 VTKKKVFETLEARMTEAC 159 
49 145 KKVFETLEARMTEACIRG 162 
50 148 FETLEARMTEACIRGYNP 165 
51 151 LEARMTEACIRGYNPGLL 168 
52 154 RMTEACIRGYNPGLLVHS 171 
53 157 EACIRGYNPGLLVHSDLA 174 
54 160 IRGYNPGLLVHSDLAYLQ 177 
55 163 YNPGLLVHSDLAYLQAEG 180 
56 166 GLLVHSDLAYLQAEGGGD 183 
57 169 VHSDLAYLQAEGGGDRQL 186 
58 172 DLAYLQAEGGGDRQLTDR 189 
59 175 YLQAEGGGDRQLTDREKE 192 
60 178 AEGGGDRQLTDREKEIIR 195 
61 181 GGDRQLTDREKEIIRQAA 198 
62 184 RQLTDREKEIIRQAAVQQ 201 
63 187 TDREKEIIRQAAVQQTKE 204 
64 190 EKEIIRQAAVQQTKEMDL 207 
65 193 IIRQAAVQQTKEMDLSVV 210 
66 196 QAAVQQTKEMDLSVVRLM 213 
67 199 VQQTKEMDLSVVRLMFTA 216 
68 202 TKEMDLSVVRLMFTAFLP 219 
69 205 MDLSVVRLMFTAFLPDST 222 
70 208 SVVRLMFTAFLPDSTGSF 225 
71 211 RLMFTAFLPDSTGSFTRR 228 
72 214 FTAFLPDSTGSFTRRLEP 231 
73 217 FLPDSTGSFTRRLEPVVS 234 
74 220 DSTGSFTRRLEPVVSDAI 237 
75 223 GSFTRRLEPVVSDAIYDS 240 
76 226 TRRLEPVVSDAIYDSKAP 243 
77 229 LEPVVSDAIYDSKAPNAS 246 
78 232 VVSDAIYDSKAPNASNLK 249 
79 235 DAIYDSKAPNASNLKIVR 252 
80 238 YDSKAPNASNLKIVRMDR 255 
81 241 KAPNASNLKIVRMDRTAG 258 
82 244 NASNLKIVRMDRTAGCVT 261 
83 247 NLKIVRMDRTAGCVTGGE 264 
84 250 IVRMDRTAGCVTGGEEIY 267 
85 253 MDRTAGCVTGGEEIYLLC 270 
86 256 TAGCVTGGEEIYLLCDKV 273 
87 259 CVTGGEEIYLLCDKVQKD 276 
88 262 GGEEIYLLCDKVQKDDIQ 279 
89 265 EIYLLCDKVQKDDIQIRF 282 
90 268 LLCDKVQKDDIQIRFYEE 285 
91 271 DKVQKDDIQIRFYEEEEN 288 
92 274 QKDDIQIRFYEEEENGGV 291 
 187 
 
 
  
93 277 DIQIRFYEEEENGGVWEG 294 
94 280 IRFYEEEENGGVWEGFGD 297 
95 283 YEEEENGGVWEGFGDFSP 300 
96 286 EENGGVWEGFGDFSPTDV 303 
97 289 GGVWEGFGDFSPTDVHRQ 306 
98 292 WEGFGDFSPTDVHRQFAI 309 
99 295 FGDFSPTDVHRQFAIVFK 312 
100 298 FSPTDVHRQFAIVFKTPK 315 
101 301 TDVHRQFAIVFKTPKYKD 318 
102 304 HRQFAIVFKTPKYKDVNI 321 
103 307 FAIVFKTPKYKDVNITKP 324 
104 310 VFKTPKYKDVNITKPASV 327 
105 313 TPKYKDVNITKPASVFVQ 330 
106 316 YKDVNITKPASVFVQLRR 333 
107 319 VNITKPASVFVQLRRKSD 336 
108 322 TKPASVFVQLRRKSDLET 339 
109 325 ASVFVQLRRKSDLETSEP 342 
110 328 FVQLRRKSDLETSEPKPF 345 
111 331 LRRKSDLETSEPKPFLYY 348 
112 334 KSDLETSEPKPFLYYPEI 351 
113 337 LETSEPKPFLYYPEIKDK 354 
114 340 SEPKPFLYYPEIKDKEEV 357 
115 343 KPFLYYPEIKDKEEVQRK 360 
116 346 LYYPEIKDKEEVQRKRQK 363 
117 349 PEIKDKEEVQRKRQKLMP 366 
118 352 KDKEEVQRKRQKLMPNFS 369 
119 355 EEVQRKRQKLMPNFSDSF 372 
120 358 QRKRQKLMPNFSDSFGGG 375 
121 361 RQKLMPNFSDSFGGGSGA 378 
122 364 LMPNFSDSFGGGSGAGAG 381 
123 367 NFSDSFGGGSGAGAGGGG 384 
124 370 DSFGGGSGAGAGGGGMFG 387 
125 373 GGGSGAGAGGGGMFGSGG 390 
126 376 SGAGAGGGGMFGSGGGGG 393 
127 379 GAGGGGMFGSGGGGGSTG 396 
128 382 GGGMFGSGGGGGSTGSPG 399 
129 385 GMFGSGGGGGSTGSPGPG 402 
 188 
 
7.2 p50 Alanine Substitution Array Sequences 
Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
20 A1 V-C-E-G-P-S-H-G-G-L-P-G-A-S-S-E-K-N 
 A2 A-C-E-G-P-S-H-G-G-L-P-G-A-S-S-E-K-N 
 A3 V-A-E-G-P-S-H-G-G-L-P-G-A-S-S-E-K-N 
 A4 V-C-A-G-P-S-H-G-G-L-P-G-A-S-S-E-K-N 
 A5 V-C-E-A-P-S-H-G-G-L-P-G-A-S-S-E-K-N 
 A6 V-C-E-G-A-S-H-G-G-L-P-G-A-S-S-E-K-N 
 A7 V-C-E-G-P-A-H-G-G-L-P-G-A-S-S-E-K-N 
 A8 V-C-E-G-P-S-A-G-G-L-P-G-A-S-S-E-K-N 
 A9 V-C-E-G-P-S-H-A-G-L-P-G-A-S-S-E-K-N 
 A10 V-C-E-G-P-S-H-G-A-L-P-G-A-S-S-E-K-N 
 A11 V-C-E-G-P-S-H-G-G-A-P-G-A-S-S-E-K-N 
 A12 V-C-E-G-P-S-H-G-G-L-A-G-A-S-S-E-K-N 
 A13 V-C-E-G-P-S-H-G-G-L-P-A-A-S-S-E-K-N 
 A14 V-C-E-G-P-S-H-G-G-L-P-G-A-S-S-E-K-N 
 A15 V-C-E-G-P-S-H-G-G-L-P-G-A-A-S-E-K-N 
 A16 V-C-E-G-P-S-H-G-G-L-P-G-A-S-A-E-K-N 
 A17 V-C-E-G-P-S-H-G-G-L-P-G-A-S-S-A-K-N 
 A18 V-C-E-G-P-S-H-G-G-L-P-G-A-S-S-E-A-N 
 A19 V-C-E-G-P-S-H-G-G-L-P-G-A-S-S-E-K-A 
 
 
 
Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
22 A21 H-G-G-L-P-G-A-S-S-E-K-N-K-K-S-Y-P-Q 
 A22 A-G-G-L-P-G-A-S-S-E-K-N-K-K-S-Y-P-Q 
 A23 H-A-G-L-P-G-A-S-S-E-K-N-K-K-S-Y-P-Q 
 A24 H-G-A-L-P-G-A-S-S-E-K-N-K-K-S-Y-P-Q 
 A25 H-G-G-A-P-G-A-S-S-E-K-N-K-K-S-Y-P-Q 
 A26 H-G-G-L-A-G-A-S-S-E-K-N-K-K-S-Y-P-Q 
 A27 H-G-G-L-P-A-A-S-S-E-K-N-K-K-S-Y-P-Q 
 A28 H-G-G-L-P-G-A-S-S-E-K-N-K-K-S-Y-P-Q 
 A29 H-G-G-L-P-G-A-A-S-E-K-N-K-K-S-Y-P-Q 
 A30 H-G-G-L-P-G-A-S-A-E-K-N-K-K-S-Y-P-Q 
 B1 H-G-G-L-P-G-A-S-S-A-K-N-K-K-S-Y-P-Q 
 B2 H-G-G-L-P-G-A-S-S-E-A-N-K-K-S-Y-P-Q 
 B3 H-G-G-L-P-G-A-S-S-E-K-A-K-K-S-Y-P-Q 
 B4 H-G-G-L-P-G-A-S-S-E-K-N-A-K-S-Y-P-Q 
 B5 H-G-G-L-P-G-A-S-S-E-K-N-K-A-S-Y-P-Q 
 B6 H-G-G-L-P-G-A-S-S-E-K-N-K-K-A-Y-P-Q 
 B7 H-G-G-L-P-G-A-S-S-E-K-N-K-K-S-A-P-Q 
 B8 H-G-G-L-P-G-A-S-S-E-K-N-K-K-S-Y-A-Q 
 B9 H-G-G-L-P-G-A-S-S-E-K-N-K-K-S-Y-P-A 
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24 B11 A-S-S-E-K-N-K-K-S-Y-P-Q-V-K-I-C-N-Y 
 B12 A-S-S-E-K-N-K-K-S-Y-P-Q-V-K-I-C-N-Y 
 B13 A-A-S-E-K-N-K-K-S-Y-P-Q-V-K-I-C-N-Y 
 B14 A-S-A-E-K-N-K-K-S-Y-P-Q-V-K-I-C-N-Y 
 B15 A-S-S-A-K-N-K-K-S-Y-P-Q-V-K-I-C-N-Y 
 B16 A-S-S-E-A-N-K-K-S-Y-P-Q-V-K-I-C-N-Y 
 B17 A-S-S-E-K-A-K-K-S-Y-P-Q-V-K-I-C-N-Y 
 B18 A-S-S-E-K-N-A-K-S-Y-P-Q-V-K-I-C-N-Y 
 B19 A-S-S-E-K-N-K-A-S-Y-P-Q-V-K-I-C-N-Y 
 B20 A-S-S-E-K-N-K-K-A-Y-P-Q-V-K-I-C-N-Y 
 B21 A-S-S-E-K-N-K-K-S-A-P-Q-V-K-I-C-N-Y 
 B22 A-S-S-E-K-N-K-K-S-Y-A-Q-V-K-I-C-N-Y 
 B23 A-S-S-E-K-N-K-K-S-Y-P-A-V-K-I-C-N-Y 
 B24 A-S-S-E-K-N-K-K-S-Y-P-Q-A-K-I-C-N-Y 
 B25 A-S-S-E-K-N-K-K-S-Y-P-Q-V-A-I-C-N-Y 
 B26 A-S-S-E-K-N-K-K-S-Y-P-Q-V-K-A-C-N-Y 
 B27 A-S-S-E-K-N-K-K-S-Y-P-Q-V-K-I-A-N-Y 
 B28 A-S-S-E-K-N-K-K-S-Y-P-Q-V-K-I-C-A-Y 
 B29 A-S-S-E-K-N-K-K-S-Y-P-Q-V-K-I-C-N-A 
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26 C1 K-K-S-Y-P-Q-V-K-I-C-N-Y-V-G-P-A-K-V 
 C2 A-K-S-Y-P-Q-V-K-I-C-N-Y-V-G-P-A-K-V 
 C3 K-A-S-Y-P-Q-V-K-I-C-N-Y-V-G-P-A-K-V 
 C4 K-K-A-Y-P-Q-V-K-I-C-N-Y-V-G-P-A-K-V 
 C5 K-K-S-A-P-Q-V-K-I-C-N-Y-V-G-P-A-K-V 
 C6 K-K-S-Y-A-Q-V-K-I-C-N-Y-V-G-P-A-K-V 
 C7 K-K-S-Y-P-A-V-K-I-C-N-Y-V-G-P-A-K-V 
 C8 K-K-S-Y-P-Q-A-K-I-C-N-Y-V-G-P-A-K-V 
 C9 K-K-S-Y-P-Q-V-A-I-C-N-Y-V-G-P-A-K-V 
 C10 K-K-S-Y-P-Q-V-K-A-C-N-Y-V-G-P-A-K-V 
 C11 K-K-S-Y-P-Q-V-K-I-A-N-Y-V-G-P-A-K-V 
 C12 K-K-S-Y-P-Q-V-K-I-C-A-Y-V-G-P-A-K-V 
 C13 K-K-S-Y-P-Q-V-K-I-C-N-A-V-G-P-A-K-V 
 C14 K-K-S-Y-P-Q-V-K-I-C-N-Y-A-G-P-A-K-V 
 C15 K-K-S-Y-P-Q-V-K-I-C-N-Y-V-A-P-A-K-V 
 C16 K-K-S-Y-P-Q-V-K-I-C-N-Y-V-G-A-A-K-V 
 C17 K-K-S-Y-P-Q-V-K-I-C-N-Y-V-G-P-A-K-V 
 C18 K-K-S-Y-P-Q-V-K-I-C-N-Y-V-G-P-A-A-V 
 C19 K-K-S-Y-P-Q-V-K-I-C-N-Y-V-G-P-A-K-A 
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28 C21 V-K-I-C-N-Y-V-G-P-A-K-V-I-V-Q-L-V-T 
 C22 A-K-I-C-N-Y-V-G-P-A-K-V-I-V-Q-L-V-T 
 C23 V-A-I-C-N-Y-V-G-P-A-K-V-I-V-Q-L-V-T 
 C24 V-K-A-C-N-Y-V-G-P-A-K-V-I-V-Q-L-V-T 
 C25 V-K-I-A-N-Y-V-G-P-A-K-V-I-V-Q-L-V-T 
 C26 V-K-I-C-A-Y-V-G-P-A-K-V-I-V-Q-L-V-T 
 C27 V-K-I-C-N-A-V-G-P-A-K-V-I-V-Q-L-V-T 
 C28 V-K-I-C-N-Y-A-G-P-A-K-V-I-V-Q-L-V-T 
 C29 V-K-I-C-N-Y-V-A-P-A-K-V-I-V-Q-L-V-T 
 C30 V-K-I-C-N-Y-V-G-A-A-K-V-I-V-Q-L-V-T 
 D1 V-K-I-C-N-Y-V-G-P-A-K-V-I-V-Q-L-V-T 
 D2 V-K-I-C-N-Y-V-G-P-A-A-V-I-V-Q-L-V-T 
 D3 V-K-I-C-N-Y-V-G-P-A-K-A-I-V-Q-L-V-T 
 D4 V-K-I-C-N-Y-V-G-P-A-K-V-A-V-Q-L-V-T 
 D5 V-K-I-C-N-Y-V-G-P-A-K-V-I-A-Q-L-V-T 
 D6 V-K-I-C-N-Y-V-G-P-A-K-V-I-V-A-L-V-T 
 D7 V-K-I-C-N-Y-V-G-P-A-K-V-I-V-Q-A-V-T 
 D8 V-K-I-C-N-Y-V-G-P-A-K-V-I-V-Q-L-A-T 
 D9 V-K-I-C-N-Y-V-G-P-A-K-V-I-V-Q-L-V-A 
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30 D11 V-G-P-A-K-V-I-V-Q-L-V-T-N-G-K-N-I-H 
 D12 A-G-P-A-K-V-I-V-Q-L-V-T-N-G-K-N-I-H 
 D13 V-A-P-A-K-V-I-V-Q-L-V-T-N-G-K-N-I-H 
 D14 V-G-A-A-K-V-I-V-Q-L-V-T-N-G-K-N-I-H 
 D15 V-G-P-A-K-V-I-V-Q-L-V-T-N-G-K-N-I-H 
 D16 V-G-P-A-A-V-I-V-Q-L-V-T-N-G-K-N-I-H 
 D17 V-G-P-A-K-A-I-V-Q-L-V-T-N-G-K-N-I-H 
 D18 V-G-P-A-K-V-A-V-Q-L-V-T-N-G-K-N-I-H 
 D19 V-G-P-A-K-V-I-A-Q-L-V-T-N-G-K-N-I-H 
 D20 V-G-P-A-K-V-I-V-A-L-V-T-N-G-K-N-I-H 
 D21 V-G-P-A-K-V-I-V-Q-A-V-T-N-G-K-N-I-H 
 D22 V-G-P-A-K-V-I-V-Q-L-A-T-N-G-K-N-I-H 
 D23 V-G-P-A-K-V-I-V-Q-L-V-A-N-G-K-N-I-H 
 D24 V-G-P-A-K-V-I-V-Q-L-V-T-A-G-K-N-I-H 
 D25 V-G-P-A-K-V-I-V-Q-L-V-T-N-A-K-N-I-H 
 D26 V-G-P-A-K-V-I-V-Q-L-V-T-N-G-A-N-I-H 
 D27 V-G-P-A-K-V-I-V-Q-L-V-T-N-G-K-A-I-H 
 D28 V-G-P-A-K-V-I-V-Q-L-V-T-N-G-K-N-A-H 
 D29 V-G-P-A-K-V-I-V-Q-L-V-T-N-G-K-N-I-A 
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46 E1 N-L-G-I-L-H-V-T-K-K-K-V-F-E-T-L-E-A 
 E2 A-L-G-I-L-H-V-T-K-K-K-V-F-E-T-L-E-A 
 E3 N-A-G-I-L-H-V-T-K-K-K-V-F-E-T-L-E-A 
 E4 N-L-A-I-L-H-V-T-K-K-K-V-F-E-T-L-E-A 
 E5 N-L-G-A-L-H-V-T-K-K-K-V-F-E-T-L-E-A 
 E6 N-L-G-I-A-H-V-T-K-K-K-V-F-E-T-L-E-A 
 E7 N-L-G-I-L-A-V-T-K-K-K-V-F-E-T-L-E-A 
 E8 N-L-G-I-L-H-A-T-K-K-K-V-F-E-T-L-E-A 
 E9 N-L-G-I-L-H-V-A-K-K-K-V-F-E-T-L-E-A 
 E10 N-L-G-I-L-H-V-T-A-K-K-V-F-E-T-L-E-A 
 E11 N-L-G-I-L-H-V-T-K-A-K-V-F-E-T-L-E-A 
 E12 N-L-G-I-L-H-V-T-K-K-A-V-F-E-T-L-E-A 
 E13 N-L-G-I-L-H-V-T-K-K-K-A-F-E-T-L-E-A 
 E14 N-L-G-I-L-H-V-T-K-K-K-V-A-E-T-L-E-A 
 E15 N-L-G-I-L-H-V-T-K-K-K-V-F-A-T-L-E-A 
 E16 N-L-G-I-L-H-V-T-K-K-K-V-F-E-A-L-E-A 
 E17 N-L-G-I-L-H-V-T-K-K-K-V-F-E-T-A-E-A 
 E18 N-L-G-I-L-H-V-T-K-K-K-V-F-E-T-L-A-A 
 E19 N-L-G-I-L-H-V-T-K-K-K-V-F-E-T-L-E-A 
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60 E21 A-E-G-G-G-D-R-Q-L-T-D-R-E-K-E-I-I-R 
 E22 A-E-G-G-G-D-R-Q-L-T-D-R-E-K-E-I-I-R 
 E23 A-A-G-G-G-D-R-Q-L-T-D-R-E-K-E-I-I-R 
 E24 A-E-A-G-G-D-R-Q-L-T-D-R-E-K-E-I-I-R 
 E25 A-E-G-A-G-D-R-Q-L-T-D-R-E-K-E-I-I-R 
 E26 A-E-G-G-A-D-R-Q-L-T-D-R-E-K-E-I-I-R 
 E27 A-E-G-G-G-A-R-Q-L-T-D-R-E-K-E-I-I-R 
 E28 A-E-G-G-G-D-A-Q-L-T-D-R-E-K-E-I-I-R 
 E29 A-E-G-G-G-D-R-A-L-T-D-R-E-K-E-I-I-R 
 E30 A-E-G-G-G-D-R-Q-A-T-D-R-E-K-E-I-I-R 
 F1 A-E-G-G-G-D-R-Q-L-A-D-R-E-K-E-I-I-R 
 F2 A-E-G-G-G-D-R-Q-L-T-A-R-E-K-E-I-I-R 
 F3 A-E-G-G-G-D-R-Q-L-T-D-A-E-K-E-I-I-R 
 F4 A-E-G-G-G-D-R-Q-L-T-D-R-A-K-E-I-I-R 
 F5 A-E-G-G-G-D-R-Q-L-T-D-R-E-A-E-I-I-R 
 F6 A-E-G-G-G-D-R-Q-L-T-D-R-E-K-A-I-I-R 
 F7 A-E-G-G-G-D-R-Q-L-T-D-R-E-K-E-A-I-R 
 F8 A-E-G-G-G-D-R-Q-L-T-D-R-E-K-E-I-A-R 
 F9 A-E-G-G-G-D-R-Q-L-T-D-R-E-K-E-I-I-A 
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78 F11 V-V-S-D-A-I-Y-D-S-K-A-P-N-A-S-N-L-K 
 F12 A-V-S-D-A-I-Y-D-S-K-A-P-N-A-S-N-L-K 
 F13 V-A-S-D-A-I-Y-D-S-K-A-P-N-A-S-N-L-K 
 F14 V-V-A-D-A-I-Y-D-S-K-A-P-N-A-S-N-L-K 
 F15 V-V-S-A-A-I-Y-D-S-K-A-P-N-A-S-N-L-K 
 F16 V-V-S-D-A-I-Y-D-S-K-A-P-N-A-S-N-L-K 
 F17 V-V-S-D-A-A-Y-D-S-K-A-P-N-A-S-N-L-K 
 F18 V-V-S-D-A-I-A-D-S-K-A-P-N-A-S-N-L-K 
 F19 V-V-S-D-A-I-Y-A-S-K-A-P-N-A-S-N-L-K 
 F20 V-V-S-D-A-I-Y-D-A-K-A-P-N-A-S-N-L-K 
 F21 V-V-S-D-A-I-Y-D-S-A-A-P-N-A-S-N-L-K 
 F22 V-V-S-D-A-I-Y-D-S-K-A-P-N-A-S-N-L-K 
 F23 V-V-S-D-A-I-Y-D-S-K-A-A-N-A-S-N-L-K 
 F24 V-V-S-D-A-I-Y-D-S-K-A-P-A-A-S-N-L-K 
 F25 V-V-S-D-A-I-Y-D-S-K-A-P-N-A-S-N-L-K 
 F26 V-V-S-D-A-I-Y-D-S-K-A-P-N-A-A-N-L-K 
 F27 V-V-S-D-A-I-Y-D-S-K-A-P-N-A-S-A-L-K 
 F28 V-V-S-D-A-I-Y-D-S-K-A-P-N-A-S-N-A-K 
 F29 V-V-S-D-A-I-Y-D-S-K-A-P-N-A-S-N-L-A 
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80 G1 Y-D-S-K-A-P-N-A-S-N-L-K-I-V-R-M-D-R 
 G2 A-D-S-K-A-P-N-A-S-N-L-K-I-V-R-M-D-R 
 G3 Y-A-S-K-A-P-N-A-S-N-L-K-I-V-R-M-D-R 
 G4 Y-D-A-K-A-P-N-A-S-N-L-K-I-V-R-M-D-R 
 G5 Y-D-S-A-A-P-N-A-S-N-L-K-I-V-R-M-D-R 
 G6 Y-D-S-K-A-P-N-A-S-N-L-K-I-V-R-M-D-R 
 G7 Y-D-S-K-A-A-N-A-S-N-L-K-I-V-R-M-D-R 
 G8 Y-D-S-K-A-P-A-A-S-N-L-K-I-V-R-M-D-R 
 G9 Y-D-S-K-A-P-N-A-S-N-L-K-I-V-R-M-D-R 
 G10 Y-D-S-K-A-P-N-A-A-N-L-K-I-V-R-M-D-R 
 G11 Y-D-S-K-A-P-N-A-S-A-L-K-I-V-R-M-D-R 
 G12 Y-D-S-K-A-P-N-A-S-N-A-K-I-V-R-M-D-R 
 G13 Y-D-S-K-A-P-N-A-S-N-L-A-I-V-R-M-D-R 
 G14 Y-D-S-K-A-P-N-A-S-N-L-K-A-V-R-M-D-R 
 G15 Y-D-S-K-A-P-N-A-S-N-L-K-I-A-R-M-D-R 
 G16 Y-D-S-K-A-P-N-A-S-N-L-K-I-V-A-M-D-R 
 G17 Y-D-S-K-A-P-N-A-S-N-L-K-I-V-R-A-D-R 
 G18 Y-D-S-K-A-P-N-A-S-N-L-K-I-V-R-M-A-R 
 G19 Y-D-S-K-A-P-N-A-S-N-L-K-I-V-R-M-D-A 
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82 G21 N-A-S-N-L-K-I-V-R-M-D-R-T-A-G-C-V-T 
 G22 A-A-S-N-L-K-I-V-R-M-D-R-T-A-G-C-V-T 
 G23 N-A-S-N-L-K-I-V-R-M-D-R-T-A-G-C-V-T 
 G24 N-A-A-N-L-K-I-V-R-M-D-R-T-A-G-C-V-T 
 G25 N-A-S-A-L-K-I-V-R-M-D-R-T-A-G-C-V-T 
 G26 N-A-S-N-A-K-I-V-R-M-D-R-T-A-G-C-V-T 
 G27 N-A-S-N-L-A-I-V-R-M-D-R-T-A-G-C-V-T 
 G28 N-A-S-N-L-K-A-V-R-M-D-R-T-A-G-C-V-T 
 G29 N-A-S-N-L-K-I-A-R-M-D-R-T-A-G-C-V-T 
 G30 N-A-S-N-L-K-I-V-A-M-D-R-T-A-G-C-V-T 
 H1 N-A-S-N-L-K-I-V-R-A-D-R-T-A-G-C-V-T 
 H2 N-A-S-N-L-K-I-V-R-M-A-R-T-A-G-C-V-T 
 H3 N-A-S-N-L-K-I-V-R-M-D-A-T-A-G-C-V-T 
 H4 N-A-S-N-L-K-I-V-R-M-D-R-A-A-G-C-V-T 
 H5 N-A-S-N-L-K-I-V-R-M-D-R-T-A-G-C-V-T 
 H6 N-A-S-N-L-K-I-V-R-M-D-R-T-A-A-C-V-T 
 H7 N-A-S-N-L-K-I-V-R-M-D-R-T-A-G-A-V-T 
 H8 N-A-S-N-L-K-I-V-R-M-D-R-T-A-G-C-A-T 
 H9 N-A-S-N-L-K-I-V-R-M-D-R-T-A-G-C-V-A 
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91 H11 D-K-V-Q-K-D-D-I-Q-I-R-F-Y-E-E-E-E-N 
 H12 A-K-V-Q-K-D-D-I-Q-I-R-F-Y-E-E-E-E-N 
 H13 D-A-V-Q-K-D-D-I-Q-I-R-F-Y-E-E-E-E-N 
 H14 D-K-A-Q-K-D-D-I-Q-I-R-F-Y-E-E-E-E-N 
 H15 D-K-V-A-K-D-D-I-Q-I-R-F-Y-E-E-E-E-N 
 H16 D-K-V-Q-A-D-D-I-Q-I-R-F-Y-E-E-E-E-N 
 H17 D-K-V-Q-K-A-D-I-Q-I-R-F-Y-E-E-E-E-N 
 H18 D-K-V-Q-K-D-A-I-Q-I-R-F-Y-E-E-E-E-N 
 H19 D-K-V-Q-K-D-D-A-Q-I-R-F-Y-E-E-E-E-N 
 H20 D-K-V-Q-K-D-D-I-A-I-R-F-Y-E-E-E-E-N 
 H21 D-K-V-Q-K-D-D-I-Q-A-R-F-Y-E-E-E-E-N 
 H22 D-K-V-Q-K-D-D-I-Q-I-A-F-Y-E-E-E-E-N 
 H23 D-K-V-Q-K-D-D-I-Q-I-R-A-Y-E-E-E-E-N 
 H24 D-K-V-Q-K-D-D-I-Q-I-R-F-A-E-E-E-E-N 
 H25 D-K-V-Q-K-D-D-I-Q-I-R-F-Y-A-E-E-E-N 
 H26 D-K-V-Q-K-D-D-I-Q-I-R-F-Y-E-A-E-E-N 
 H27 D-K-V-Q-K-D-D-I-Q-I-R-F-Y-E-E-A-E-N 
 H28 D-K-V-Q-K-D-D-I-Q-I-R-F-Y-E-E-E-A-N 
 H29 D-K-V-Q-K-D-D-I-Q-I-R-F-Y-E-E-E-E-A 
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93 I1 D-I-Q-I-R-F-Y-E-E-E-E-N-G-G-V-W-E-G 
 I2 A-I-Q-I-R-F-Y-E-E-E-E-N-G-G-V-W-E-G 
 I3 D-A-Q-I-R-F-Y-E-E-E-E-N-G-G-V-W-E-G 
 I4 D-I-A-I-R-F-Y-E-E-E-E-N-G-G-V-W-E-G 
 I5 D-I-Q-A-R-F-Y-E-E-E-E-N-G-G-V-W-E-G 
 I6 D-I-Q-I-A-F-Y-E-E-E-E-N-G-G-V-W-E-G 
 I7 D-I-Q-I-R-A-Y-E-E-E-E-N-G-G-V-W-E-G 
 I8 D-I-Q-I-R-F-A-E-E-E-E-N-G-G-V-W-E-G 
 I9 D-I-Q-I-R-F-Y-A-E-E-E-N-G-G-V-W-E-G 
 I10 D-I-Q-I-R-F-Y-E-A-E-E-N-G-G-V-W-E-G 
 I11 D-I-Q-I-R-F-Y-E-E-A-E-N-G-G-V-W-E-G 
 I12 D-I-Q-I-R-F-Y-E-E-E-A-N-G-G-V-W-E-G 
 I13 D-I-Q-I-R-F-Y-E-E-E-E-A-G-G-V-W-E-G 
 I14 D-I-Q-I-R-F-Y-E-E-E-E-N-A-G-V-W-E-G 
 I15 D-I-Q-I-R-F-Y-E-E-E-E-N-G-A-V-W-E-G 
 I16 D-I-Q-I-R-F-Y-E-E-E-E-N-G-G-A-W-E-G 
 I17 D-I-Q-I-R-F-Y-E-E-E-E-N-G-G-V-A-E-G 
 I18 D-I-Q-I-R-F-Y-E-E-E-E-N-G-G-V-W-A-G 
 I19 D-I-Q-I-R-F-Y-E-E-E-E-N-G-G-V-W-E-A 
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Peptide 
Number 
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95 I21 Y-E-E-E-E-N-G-G-V-W-E-G-F-G-D-F-S-P 
 I22 A-E-E-E-E-N-G-G-V-W-E-G-F-G-D-F-S-P 
 I23 Y-A-E-E-E-N-G-G-V-W-E-G-F-G-D-F-S-P 
 I24 Y-E-A-E-E-N-G-G-V-W-E-G-F-G-D-F-S-P 
 I25 Y-E-E-A-E-N-G-G-V-W-E-G-F-G-D-F-S-P 
 I26 Y-E-E-E-A-N-G-G-V-W-E-G-F-G-D-F-S-P 
 I27 Y-E-E-E-E-A-G-G-V-W-E-G-F-G-D-F-S-P 
 I28 Y-E-E-E-E-N-A-G-V-W-E-G-F-G-D-F-S-P 
 I29 Y-E-E-E-E-N-G-A-V-W-E-G-F-G-D-F-S-P 
 I30 Y-E-E-E-E-N-G-G-A-W-E-G-F-G-D-F-S-P 
 J1 Y-E-E-E-E-N-G-G-V-A-E-G-F-G-D-F-S-P 
 J2 Y-E-E-E-E-N-G-G-V-W-A-G-F-G-D-F-S-P 
 J3 Y-E-E-E-E-N-G-G-V-W-E-A-F-G-D-F-S-P 
 J4 Y-E-E-E-E-N-G-G-V-W-E-G-A-G-D-F-S-P 
 J5 Y-E-E-E-E-N-G-G-V-W-E-G-F-A-D-F-S-P 
 J6 Y-E-E-E-E-N-G-G-V-W-E-G-F-G-A-F-S-P 
 J7 Y-E-E-E-E-N-G-G-V-W-E-G-F-G-D-A-S-P 
 J8 Y-E-E-E-E-N-G-G-V-W-E-G-F-G-D-F-A-P 
 J9 Y-E-E-E-E-N-G-G-V-W-E-G-F-G-D-F-S-A 
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97 J11 G-G-V-W-E-G-F-G-D-F-S-P-T-D-V-H-R-Q 
 J12 A-G-V-W-E-G-F-G-D-F-S-P-T-D-V-H-R-Q 
 J13 G-A-V-W-E-G-F-G-D-F-S-P-T-D-V-H-R-Q 
 J14 G-G-A-W-E-G-F-G-D-F-S-P-T-D-V-H-R-Q 
 J15 G-G-V-A-E-G-F-G-D-F-S-P-T-D-V-H-R-Q 
 J16 G-G-V-W-A-G-F-G-D-F-S-P-T-D-V-H-R-Q 
 J17 G-G-V-W-E-A-F-G-D-F-S-P-T-D-V-H-R-Q 
 J18 G-G-V-W-E-G-A-G-D-F-S-P-T-D-V-H-R-Q 
 J19 G-G-V-W-E-G-F-A-D-F-S-P-T-D-V-H-R-Q 
 J20 G-G-V-W-E-G-F-G-A-F-S-P-T-D-V-H-R-Q 
 J21 G-G-V-W-E-G-F-G-D-A-S-P-T-D-V-H-R-Q 
 J22 G-G-V-W-E-G-F-G-D-F-A-P-T-D-V-H-R-Q 
 J23 G-G-V-W-E-G-F-G-D-F-S-A-T-D-V-H-R-Q 
 J24 G-G-V-W-E-G-F-G-D-F-S-P-A-D-V-H-R-Q 
 J25 G-G-V-W-E-G-F-G-D-F-S-P-T-A-V-H-R-Q 
 J26 G-G-V-W-E-G-F-G-D-F-S-P-T-D-A-H-R-Q 
 J27 G-G-V-W-E-G-F-G-D-F-S-P-T-D-V-A-R-Q 
 J28 G-G-V-W-E-G-F-G-D-F-S-P-T-D-V-H-A-Q 
 J29 G-G-V-W-E-G-F-G-D-F-S-P-T-D-V-H-R-A 
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99 K1 F-G-D-F-S-P-T-D-V-H-R-Q-F-A-I-V-F-K 
 K2 A-G-D-F-S-P-T-D-V-H-R-Q-F-A-I-V-F-K 
 K3 F-A-D-F-S-P-T-D-V-H-R-Q-F-A-I-V-F-K 
 K4 F-G-A-F-S-P-T-D-V-H-R-Q-F-A-I-V-F-K 
 K5 F-G-D-A-S-P-T-D-V-H-R-Q-F-A-I-V-F-K 
 K6 F-G-D-F-A-P-T-D-V-H-R-Q-F-A-I-V-F-K 
 K7 F-G-D-F-S-A-T-D-V-H-R-Q-F-A-I-V-F-K 
 K8 F-G-D-F-S-P-A-D-V-H-R-Q-F-A-I-V-F-K 
 K9 F-G-D-F-S-P-T-A-V-H-R-Q-F-A-I-V-F-K 
 K10 F-G-D-F-S-P-T-D-A-H-R-Q-F-A-I-V-F-K 
 K11 F-G-D-F-S-P-T-D-V-A-R-Q-F-A-I-V-F-K 
 K12 F-G-D-F-S-P-T-D-V-H-A-Q-F-A-I-V-F-K 
 K13 F-G-D-F-S-P-T-D-V-H-R-A-F-A-I-V-F-K 
 K14 F-G-D-F-S-P-T-D-V-H-R-Q-A-A-I-V-F-K 
 K15 F-G-D-F-S-P-T-D-V-H-R-Q-F-A-I-V-F-K 
 K16 F-G-D-F-S-P-T-D-V-H-R-Q-F-A-A-V-F-K 
 K17 F-G-D-F-S-P-T-D-V-H-R-Q-F-A-I-A-F-K 
 K18 F-G-D-F-S-P-T-D-V-H-R-Q-F-A-I-V-A-K 
 K19 F-G-D-F-S-P-T-D-V-H-R-Q-F-A-I-V-F-A 
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103 K21 F-A-I-V-F-K-T-P-K-Y-K-D-V-N-I-T-K-P 
 K22 A-A-I-V-F-K-T-P-K-Y-K-D-V-N-I-T-K-P 
 K23 F-A-I-V-F-K-T-P-K-Y-K-D-V-N-I-T-K-P 
 K24 F-A-A-V-F-K-T-P-K-Y-K-D-V-N-I-T-K-P 
 K25 F-A-I-A-F-K-T-P-K-Y-K-D-V-N-I-T-K-P 
 K26 F-A-I-V-A-K-T-P-K-Y-K-D-V-N-I-T-K-P 
 K27 F-A-I-V-F-A-T-P-K-Y-K-D-V-N-I-T-K-P 
 K28 F-A-I-V-F-K-A-P-K-Y-K-D-V-N-I-T-K-P 
 K29 F-A-I-V-F-K-T-A-K-Y-K-D-V-N-I-T-K-P 
 K30 F-A-I-V-F-K-T-P-A-Y-K-D-V-N-I-T-K-P 
 L1 F-A-I-V-F-K-T-P-K-A-K-D-V-N-I-T-K-P 
 L2 F-A-I-V-F-K-T-P-K-Y-A-D-V-N-I-T-K-P 
 L3 F-A-I-V-F-K-T-P-K-Y-K-A-V-N-I-T-K-P 
 L4 F-A-I-V-F-K-T-P-K-Y-K-D-A-N-I-T-K-P 
 L5 F-A-I-V-F-K-T-P-K-Y-K-D-V-A-I-T-K-P 
 L6 F-A-I-V-F-K-T-P-K-Y-K-D-V-N-A-T-K-P 
 L7 F-A-I-V-F-K-T-P-K-Y-K-D-V-N-I-A-K-P 
 L8 F-A-I-V-F-K-T-P-K-Y-K-D-V-N-I-T-A-P 
 L9 F-A-I-V-F-K-T-P-K-Y-K-D-V-N-I-T-K-A 
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105 L11 T-P-K-Y-K-D-V-N-I-T-K-P-A-S-V-F-V-Q 
 L12 A-P-K-Y-K-D-V-N-I-T-K-P-A-S-V-F-V-Q 
 L13 T-A-K-Y-K-D-V-N-I-T-K-P-A-S-V-F-V-Q 
 L14 T-P-A-Y-K-D-V-N-I-T-K-P-A-S-V-F-V-Q 
 L15 T-P-K-A-K-D-V-N-I-T-K-P-A-S-V-F-V-Q 
 L16 T-P-K-Y-A-D-V-N-I-T-K-P-A-S-V-F-V-Q 
 L17 T-P-K-Y-K-A-V-N-I-T-K-P-A-S-V-F-V-Q 
 L18 T-P-K-Y-K-D-A-N-I-T-K-P-A-S-V-F-V-Q 
 L19 T-P-K-Y-K-D-V-A-I-T-K-P-A-S-V-F-V-Q 
 L20 T-P-K-Y-K-D-V-N-A-T-K-P-A-S-V-F-V-Q 
 L21 T-P-K-Y-K-D-V-N-I-A-K-P-A-S-V-F-V-Q 
 L22 T-P-K-Y-K-D-V-N-I-T-A-P-A-S-V-F-V-Q 
 L23 T-P-K-Y-K-D-V-N-I-T-K-A-A-S-V-F-V-Q 
 L24 T-P-K-Y-K-D-V-N-I-T-K-P-A-S-V-F-V-Q 
 L25 T-P-K-Y-K-D-V-N-I-T-K-P-A-A-V-F-V-Q 
 L26 T-P-K-Y-K-D-V-N-I-T-K-P-A-S-A-F-V-Q 
 L27 T-P-K-Y-K-D-V-N-I-T-K-P-A-S-V-A-V-Q 
 L28 T-P-K-Y-K-D-V-N-I-T-K-P-A-S-V-F-A-Q 
 L29 T-P-K-Y-K-D-V-N-I-T-K-P-A-S-V-F-V-A 
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107 M1 V-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M2 A-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M3 V-A-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M4 V-N-A-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M5 V-N-I-A-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M6 V-N-I-T-A-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M7 V-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M8 V-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M9 V-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M10 V-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M11 V-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M12 V-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M13 V-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M14 V-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M15 V-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M16 V-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M17 V-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M18 V-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
 M19 V-N-I-T-K-P-A-S-V-F-V-Q-L-R-R-K-S-D 
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115 M21 K-P-F-L-Y-Y-P-E-I-K-D-K-E-E-V-Q-R-K 
 M22 A-P-F-L-Y-Y-P-E-I-K-D-K-E-E-V-Q-R-K 
 M23 K-A-F-L-Y-Y-P-E-I-K-D-K-E-E-V-Q-R-K 
 M24 K-P-A-L-Y-Y-P-E-I-K-D-K-E-E-V-Q-R-K 
 M25 K-P-F-A-Y-Y-P-E-I-K-D-K-E-E-V-Q-R-K 
 M26 K-P-F-L-A-Y-P-E-I-K-D-K-E-E-V-Q-R-K 
 M27 K-P-F-L-Y-A-P-E-I-K-D-K-E-E-V-Q-R-K 
 M28 K-P-F-L-Y-Y-A-E-I-K-D-K-E-E-V-Q-R-K 
 M29 K-P-F-L-Y-Y-P-A-I-K-D-K-E-E-V-Q-R-K 
 M30 K-P-F-L-Y-Y-P-E-A-K-D-K-E-E-V-Q-R-K 
 N1 K-P-F-L-Y-Y-P-E-I-A-D-K-E-E-V-Q-R-K 
 N2 K-P-F-L-Y-Y-P-E-I-K-A-K-E-E-V-Q-R-K 
 N3 K-P-F-L-Y-Y-P-E-I-K-D-A-E-E-V-Q-R-K 
 N4 K-P-F-L-Y-Y-P-E-I-K-D-K-A-E-V-Q-R-K 
 N5 K-P-F-L-Y-Y-P-E-I-K-D-K-E-A-V-Q-R-K 
 N6 K-P-F-L-Y-Y-P-E-I-K-D-K-E-E-A-Q-R-K 
 N7 K-P-F-L-Y-Y-P-E-I-K-D-K-E-E-V-A-R-K 
 N8 K-P-F-L-Y-Y-P-E-I-K-D-K-E-E-V-Q-A-K 
 N9 K-P-F-L-Y-Y-P-E-I-K-D-K-E-E-V-Q-R-A 
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117 N11 P-E-I-K-D-K-E-E-V-Q-R-K-R-Q-K-L-M-P 
 N12 A-E-I-K-D-K-E-E-V-Q-R-K-R-Q-K-L-M-P 
 N13 P-A-I-K-D-K-E-E-V-Q-R-K-R-Q-K-L-M-P 
 N14 P-E-A-K-D-K-E-E-V-Q-R-K-R-Q-K-L-M-P 
 N15 P-E-I-A-D-K-E-E-V-Q-R-K-R-Q-K-L-M-P 
 N16 P-E-I-K-A-K-E-E-V-Q-R-K-R-Q-K-L-M-P 
 N17 P-E-I-K-D-A-E-E-V-Q-R-K-R-Q-K-L-M-P 
 N18 P-E-I-K-D-K-A-E-V-Q-R-K-R-Q-K-L-M-P 
 N19 P-E-I-K-D-K-E-A-V-Q-R-K-R-Q-K-L-M-P 
 N20 P-E-I-K-D-K-E-E-A-Q-R-K-R-Q-K-L-M-P 
 N21 P-E-I-K-D-K-E-E-V-A-R-K-R-Q-K-L-M-P 
 N22 P-E-I-K-D-K-E-E-V-Q-A-K-R-Q-K-L-M-P 
 N23 P-E-I-K-D-K-E-E-V-Q-R-A-R-Q-K-L-M-P 
 N24 P-E-I-K-D-K-E-E-V-Q-R-K-A-Q-K-L-M-P 
 N25 P-E-I-K-D-K-E-E-V-Q-R-K-R-A-K-L-M-P 
 N26 P-E-I-K-D-K-E-E-V-Q-R-K-R-Q-A-L-M-P 
 N27 P-E-I-K-D-K-E-E-V-Q-R-K-R-Q-K-A-M-P 
 N28 P-E-I-K-D-K-E-E-V-Q-R-K-R-Q-K-L-A-P 
 N29 P-E-I-K-D-K-E-E-V-Q-R-K-R-Q-K-L-M-A 
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119 O1 E-E-V-Q-R-K-R-Q-K-L-M-P-N-F-S-D-S-F 
 O2 A-E-V-Q-R-K-R-Q-K-L-M-P-N-F-S-D-S-F 
 O3 E-A-V-Q-R-K-R-Q-K-L-M-P-N-F-S-D-S-F 
 O4 E-E-A-Q-R-K-R-Q-K-L-M-P-N-F-S-D-S-F 
 O5 E-E-V-A-R-K-R-Q-K-L-M-P-N-F-S-D-S-F 
 O6 E-E-V-Q-A-K-R-Q-K-L-M-P-N-F-S-D-S-F 
 O7 E-E-V-Q-R-A-R-Q-K-L-M-P-N-F-S-D-S-F 
 O8 E-E-V-Q-R-K-A-Q-K-L-M-P-N-F-S-D-S-F 
 O9 E-E-V-Q-R-K-R-A-K-L-M-P-N-F-S-D-S-F 
 O10 E-E-V-Q-R-K-R-Q-A-L-M-P-N-F-S-D-S-F 
 O11 E-E-V-Q-R-K-R-Q-K-A-M-P-N-F-S-D-S-F 
 O12 E-E-V-Q-R-K-R-Q-K-L-A-P-N-F-S-D-S-F 
 O13 E-E-V-Q-R-K-R-Q-K-L-M-A-N-F-S-D-S-F 
 O14 E-E-V-Q-R-K-R-Q-K-L-M-P-A-F-S-D-S-F 
 O15 E-E-V-Q-R-K-R-Q-K-L-M-P-N-A-S-D-S-F 
 O16 E-E-V-Q-R-K-R-Q-K-L-M-P-N-F-A-D-S-F 
 O17 E-E-V-Q-R-K-R-Q-K-L-M-P-N-F-S-A-S-F 
 O18 E-E-V-Q-R-K-R-Q-K-L-M-P-N-F-S-D-A-F 
 O19 E-E-V-Q-R-K-R-Q-K-L-M-P-N-F-S-D-S-A 
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121 O21 R-Q-K-L-M-P-N-F-S-D-S-F-G-G-G-S-G-A 
 O22 A-Q-K-L-M-P-N-F-S-D-S-F-G-G-G-S-G-A 
 O23 R-A-K-L-M-P-N-F-S-D-S-F-G-G-G-S-G-A 
 O24 R-Q-A-L-M-P-N-F-S-D-S-F-G-G-G-S-G-A 
 O25 R-Q-K-A-M-P-N-F-S-D-S-F-G-G-G-S-G-A 
 O26 R-Q-K-L-A-P-N-F-S-D-S-F-G-G-G-S-G-A 
 O27 R-Q-K-L-M-A-N-F-S-D-S-F-G-G-G-S-G-A 
 O28 R-Q-K-L-M-P-A-F-S-D-S-F-G-G-G-S-G-A 
 O29 R-Q-K-L-M-P-N-A-S-D-S-F-G-G-G-S-G-A 
 O30 R-Q-K-L-M-P-N-F-A-D-S-F-G-G-G-S-G-A 
 P1 R-Q-K-L-M-P-N-F-S-A-S-F-G-G-G-S-G-A 
 P2 R-Q-K-L-M-P-N-F-S-D-A-F-G-G-G-S-G-A 
 P3 R-Q-K-L-M-P-N-F-S-D-S-A-G-G-G-S-G-A 
 P4 R-Q-K-L-M-P-N-F-S-D-S-F-A-G-G-S-G-A 
  P5 R-Q-K-L-M-P-N-F-S-D-S-F-G-A-G-S-G-A 
 P6 R-Q-K-L-M-P-N-F-S-D-S-F-G-G-A-S-G-A 
 P7 R-Q-K-L-M-P-N-F-S-D-S-F-G-G-G-A-G-A 
 P8 R-Q-K-L-M-P-N-F-S-D-S-F-G-G-G-S-A-A 
 P9 R-Q-K-L-M-P-N-F-S-D-S-F-G-G-G-S-G-A 
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7.3 p50 Alanine Substitution Peptide Array Data 
 
Figure 7.1 Full p50 alanine substitution peptide array. 
The 18 amino acids of the p50-derivied peptides 20, 22, 24, 26, 28, 30, 46, 60, 78, 80,82, 
91, 93, 95, 97, 99, 103,105, 107, 115, 117, 119 and 121  were sequentially substituted 
with alanine. See Appendix 7.2 for peptide locations on array. Arrays were probed with 
GST-Bcl-3 and detected by immunoblotting with anti-GST antibody. GST-Bcl-3 binding 
was quantified by densitometry and represented as a percentage binding of the control 
control parent peptide peptides (see below). 
 
 
  
 
 
  
   
   
     
 
   
 
Peptide 20 
Intensity 
Percent 
Binding 
A.A 
Sub 
9.3 100.0 _ 
7.1 75.7 V 
2.7 29.1 C 
12.5 134.1 E 
10.0 107.2 G 
9.6 102.4 P 
10.1 107.8 S 
10.5 112.3 H 
10.3 110.6 G 
10.9 117.1 G 
17.1 183.2 L 
12.8 137.0 P 
13.5 145.0 G 
19.4 208.0 A 
11.3 120.9 S 
16.0 170.9 S 
38.0 407.2 E 
7.5 80.4 K 
10.1 108.2 N 
Peptide 22 
Intensity 
Percent 
Binding 
A.A 
Sub 
70.1 100.0 _ 
52.2 74.5 H 
56.6 80.8 G 
54.1 77.2 G 
48.9 69.8 L 
48.7 69.5 P 
38.1 54.4 G 
42.1 60.1 A 
40.8 58.2 S 
34.9 49.8 S 
31.9 45.6 E 
43.0 61.4 K 
25.3 36.1 N 
32.3 46.2 K 
34.4 49.1 K 
48.7 69.5 S 
49.3 70.3 Y 
45.8 65.3 P 
62.8 89.6 Q 
G
S
T
-B
c
l-3
 
 201 
 
  
 
 
  
   
   
     
 
 
Peptide 24 
Intensity 
Percent 
Binding 
A.A 
Sub 
55.8 100.0 _ 
52.8 94.5 A 
56.5 101.2 S 
50.9 91.1 S 
51.6 92.4 E 
59.9 107.3 K 
43.3 77.6 N 
42.4 75.9 K 
46.3 83.0 K 
64.5 115.5 S 
58.6 105.0 Y 
54.4 97.4 P 
55.5 99.4 Q 
50.8 91.0 V 
49.2 88.2 K 
66.7 119.5 I 
35.1 62.9 C 
41.5 74.4 N 
47.2 84.5 Y 
Peptide 26 
Intensity 
Percent 
Binding 
A.A 
Sub 
43.4 100.0 _ 
34.8 80.2 K 
51.9 119.5 K 
46.7 107.6 S 
53.3 122.7 Y 
64.0 147.5 P 
67.0 154.2 Q 
72.8 167.6 V 
88.4 203.7 K 
91.5 210.8 I 
85.2 196.2 C 
65.3 150.4 N 
74.3 171.2 Y 
59.0 135.9 V 
85.4 196.8 G 
79.6 183.3 P 
56.0 129.0 A 
60.3 138.9 K 
67.9 156.4 V 
Peptide 28 
Intensity 
Percent 
Binding 
A.A 
Sub 
42.5 100.0 _ 
40.6 95.5 V 
18.3 43.1 K 
39.3 92.5 I 
31.0 73.0 C 
30.6 72.0 N 
34.9 82.3 Y 
28.8 67.8 V 
28.1 66.0 G 
29.6 69.8 P 
19.9 46.8 A 
10.2 24.1 K 
37.3 87.8 V 
27.6 65.0 I 
35.4 83.4 V 
29.8 70.1 Q 
45.8 107.8 L 
34.4 81.1 V 
42.3 99.7 T 
Peptide 30 
Intensity 
Percent 
Binding 
A.A 
Sub 
54.7 100.0 _ 
45.0 82.2 V 
55.7 101.8 G 
45.3 82.7 P 
50.0 91.3 A 
60.4 110.3 K 
56.7 103.6 V 
51.5 94.0 I 
57.7 105.4 V 
47.6 87.0 Q 
58.2 106.3 L 
48.5 88.5 V 
60.7 110.9 T 
38.8 70.9 N 
53.0 96.9 G 
22.0 40.2 K 
39.5 72.1 N 
40.0 73.0 I 
42.9 78.4 H 
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Peptide 46 
Intensity 
Percent 
Binding 
A.A 
Sub 
9.1 100.0 _ 
8.0 87.8 N 
11.2 122.6 L 
16.1 176.5 G 
15.1 165.4 I 
13.3 145.9 L 
35.8 392.8 H 
22.7 249.3 V 
29.9 327.7 T 
10.4 114.4 K 
9.1 100.2 K 
7.2 79.1 K 
28.4 310.7 V 
18.7 205.0 F 
49.7 544.9 E 
28.1 308.4 T 
26.5 290.6 L 
68.3 748.0 E 
29.0 317.4 A 
Peptide 60 
Intensity 
Percent 
Binding 
A.A 
Sub 
7.9 100.0 _ 
6.1 77.3 A 
8.5 108.3 E 
5.8 74.2 G 
6.6 84.3 G 
5.9 74.3 G 
4.7 59.4 D 
8.7 110.4 R 
7.2 91.9 Q 
3.8 48.3 L 
12.5 158.5 T 
17.4 221.4 D 
3.0 37.8 R 
39.6 503.3 E 
3.4 43.2 K 
68.4 868.3 E 
3.4 43.6 I 
13.7 174.5 I 
3.2 40.2 R 
Peptide 78 
Intensity 
Percent 
Binding 
A.A 
Sub 
92.1 100.0  
73.1 79.4 V 
116.1 126.1 V 
93.4 101.4 S 
79.8 86.6 D 
101.8 110.5 A 
52.0 56.4 I 
86.1 93.5 Y 
82.7 89.8 D 
66.3 72.0 S 
57.1 62.0 K 
90.3 98.1 A 
72.1 78.2 P 
92.4 100.3 N 
82.1 89.1 A 
79.1 85.9 S 
83.2 90.3 N 
59.7 64.8 L 
3.6 3.9 K 
Peptide 80 
Intensity 
Percent 
Binding 
A.A 
Sub 
40.5 100.0 Y 
35.5 87.6 D 
46.7 115.4 S 
43.5 107.4 K 
51.3 126.7 A 
56.2 138.8 P 
41.5 102.5 N 
52.2 128.9 A 
55.7 137.7 S 
67.7 167.3 N 
51.9 128.1 L 
59.3 146.4 K 
37.4 92.3 I 
71.3 176.1 V 
79.5 196.4 R 
44.9 110.9 M 
52.1 128.7 D 
63.6 157.1 R 
51.1 126.3 Y 
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Peptide 82 
Intensity 
Percent 
Binding 
A.A 
Sub 
28.6 100.0 _ 
38.7 135.4 N 
28.7 100.5 A 
31.4 109.6 S 
38.3 134.0 N 
33.8 118.2 L 
9.5 33.1 K 
18.3 63.8 I 
24.1 84.1 V 
6.0 21.0 R 
14.0 49.0 M 
34.3 120.0 D 
7.9 27.6 R 
22.3 77.8 T 
28.8 100.7 A 
31.0 108.5 G 
43.7 152.9 C 
34.3 119.7 V 
32.5 113.6 T 
Peptide 91 
Intensity 
Percent 
Binding 
A.A 
Sub 
21.0 100.0 _ 
18.0 85.8 D 
15.6 74.5 K 
15.6 74.4 V 
26.7 127.6 Q 
17.3 82.4 K 
10.3 49.2 D 
36.8 175.7 D 
18.1 86.4 I 
38.4 183.2 Q 
31.0 148.0 I 
41.7 199.0 R 
4.8 23.0 F 
3.3 15.7 Y 
17.3 82.4 E 
14.0 66.8 E 
9.4 44.8 E 
13.0 62.2 E 
23.7 113.3 N 
Peptide 95 
Intensity 
Percent 
Binding 
A.A 
Sub 
30.2 100.0 _ 
16.0 53.0 Y 
29.8 98.7 E 
27.8 92.0 E 
28.6 94.6 E 
30.4 100.7 E 
25.3 83.7 N 
28.0 92.7 G 
19.9 65.9 G 
15.7 52.0 V 
6.0 19.7 W 
13.1 43.4 E 
21.4 70.7 G 
16.0 53.0 F 
20.2 66.9 G 
14.8 49.0 D 
23.6 78.2 F 
21.5 71.3 S 
31.7 104.8 P 
Peptide 93 
Intensity 
Percent 
Binding 
A.A 
Sub 
12.3 100.0 _ 
12.8 104.4 D 
20.8 169.4 I 
16.1 131.4 Q 
31.5 256.5 I 
22.0 179.7 R 
11.2 91.6 F 
9.3 75.6 Y 
12.5 101.7 E 
14.4 117.8 E 
13.5 109.7 E 
17.8 145.1 E 
31.8 259.6 N 
31.6 257.8 G 
32.5 265.0 G 
26.4 215.3 V 
36.1 294.2 W 
16.7 136.3 E 
30.2 246.5 G 
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Peptide 97 
Intensity 
Percent 
Binding 
A.A 
Sub 
24.0 100.0 _ 
17.8 74.4 G 
17.5 73.0 G 
16.2 67.4 V 
3.5 14.8 W 
10.1 42.2 E 
10.0 41.9 G 
5.6 23.3 F 
9.9 41.5 G 
9.6 39.9 D 
8.0 33.3 F 
12.2 50.8 S 
15.4 64.3 P 
13.5 56.4 T 
19.4 81.0 D 
14.3 59.6 V 
8.9 36.9 H 
10.1 42.1 R 
9.4 39.1 Q 
Peptide 99 
Intensity 
Percent 
Binding 
A.A 
Sub 
32.3 100.0 _ 
26.8 82.8 F 
30.2 93.5 G 
44.5 137.6 D 
33.9 104.7 F 
39.3 121.4 S 
35.1 108.7 P 
45.0 139.2 T 
35.6 110.2 D 
39.4 122.0 V 
46.0 142.2 H 
12.6 38.9 R 
34.2 105.8 Q 
51.5 159.2 F 
25.7 79.5 A 
95.3 295.0 I 
43.0 133.2 V 
79.2 245.0 F 
6.6 20.5 K 
Peptide 103 
Intensity 
 
Percent 
Binding 
 
A.A 
Sub 
 
53.9 100.0 _ 
55.6 103.1 F 
65.3 121.1 A 
77.2 143.2 I 
67.3 124.8 V 
78.2 144.9 F 
48.0 88.9 K 
45.4 84.2 T 
51.9 96.3 P 
38.7 71.8 K 
27.9 51.8 Y 
29.8 55.2 K 
46.2 85.7 D 
51.8 96.1 V 
39.8 73.7 N 
69.9 129.7 I 
55.8 103.5 T 
44.5 82.5 K 
54.2 100.5 P 
Peptide 105 
Intensity 
 
Percent 
Binding 
 
A.A 
Sub 
 
42.6 100.0 _ 
36.3 85.2 T 
47.8 112.0 P 
9.2 21.5 K 
45.2 106.0 Y 
14.6 34.4 K 
42.2 99.0 D 
48.8 114.4 V 
31.4 73.8 N 
58.5 137.3 I 
46.3 108.6 T 
10.5 24.7 K 
49.7 116.5 P 
42.4 99.5 A 
46.0 108.0 S 
62.4 146.3 V 
46.6 109.4 F 
53.1 124.5 V 
43.1 101.2 Q 
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Peptide 107 
Intensity 
Percent 
Binding 
A.A 
Sub 
34.0 100.0 _ 
32.1 94.5 V 
44.0 129.5 N 
49.3 145.2 I 
40.2 118.3 T 
46.9 138.0 K 
48.1 141.7 P 
40.2 118.4 A 
43.3 127.3 S 
55.2 162.6 V 
36.3 106.9 F 
43.9 129.2 V 
42.0 123.5 Q 
38.1 112.1 L 
40.2 118.2 R 
37.0 108.9 R 
11.9 35.0 K 
33.5 98.7 S 
55.1 162.2 D 
Peptide 115 
Intensity 
Percent 
Binding 
A.A 
Sub 
58.9 100.0 _ 
27.4 46.5 K 
71.8 122.0 P 
63.0 107.0 F 
65.4 111.2 L 
77.4 131.5 Y 
50.9 86.5 Y 
50.6 85.9 P 
70.1 119.1 E 
55.7 94.7 I 
18.5 31.4 K 
51.4 87.3 D 
18.1 30.7 K 
47.4 80.5 E 
83.5 141.8 E 
86.0 146.1 V 
31.9 54.1 Q 
32.5 55.2 R 
5.4 9.2 K 
Peptide 117 
Intensity 
Percent 
Binding 
A.A 
Sub 
62.8 100.0 _ 
65.6 104.5 P 
65.9 105.0 E 
60.5 96.4 I 
62.3 99.2 K 
67.7 107.9 D 
76.8 122.3 K 
64.4 102.6 E 
53.9 85.8 E 
71.5 113.9 V 
61.6 98.2 Q 
67.1 106.9 R 
83.6 133.3 K 
58.9 93.9 R 
63.4 101.1 Q 
83.9 133.7 K 
69.8 111.3 L 
62.5 99.6 M 
42.8 68.3 P 
Peptide 119 
Intensity 
Percent 
Binding 
A.A 
Sub 
22.0 100.0 _ 
43.1 195.8 E 
57.1 259.2 E 
27.2 123.8 V 
18.4 83.4 Q 
10.5 47.7 R 
7.8 35.5 K 
6.4 29.0 R 
17.6 79.8 Q 
10.1 45.8 K 
18.7 85.1 L 
12.8 58.3 M 
12.2 55.6 P 
12.1 55.1 N 
19.6 89.1 F 
19.7 89.5 S 
56.6 257.0 D 
22.0 99.9 S 
20.1 91.3 F 
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Peptide 121 
Intensity 
Percent 
Binding 
A.A 
Sub 
6.8 100.0 _ 
3.3 48.3 R 
7.0 102.6 Q 
3.7 54.4 K 
7.3 107.0 L 
5.3 78.4 M 
7.4 108.1 P 
5.0 73.1 N 
4.2 62.0 F 
6.0 88.6 S 
29.4 431.8 D 
19.4 285.0 S 
13.6 199.9 F 
13.5 197.9 G 
10.7 156.6 G 
14.2 207.9 G 
11.1 162.5 S 
11.9 175.3 G 
8.5 124.4 A 
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7.4 Additional p50 Ubiquitination Data 
 
 
 
 
 
Figure 7.2. p50 is ubiquitinated via K48 linked ubiquitination  
Work carried out by Dr. Ruaidhrí.J.Carmody 
HEK293T cells were transfected with XPRESS (XP) tagged p50 and ubiquitin wild-type and 
ubiquitin mutants constructs as indicated. p50 ubiquitination was determined by IP from 
whole cell lysates with anti-XPRESS and WB with anti-HA for HA-ubiquitin.  
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7.5 Bcl-3 Peptide Array Sequences 
Peptide 
Number 
Amino  
Acid start # 
Amino acid Sequence Amino  
Acid end # 
1 1 MPRCPAGAMDEGPVDLRT 18 
2 5 PAGAMDEGPVDLRTRPKG 22 
3 9 MDEGPVDLRTRPKGTPGA 26 
4 13 PVDLRTRPKGTPGAALPL 30 
5 17 RTRPKGTPGAALPLRKRP 34 
6 21 KGTPGAALPLRKRPLRPA 38 
7 25 GAALPLRKRPLRPASPEP 42 
8 29 PLRKRPLRPASPEPATTR 46 
9 33 RPLRPASPEPATTRSPAG 50 
10 37 PASPEPATTRSPAGPLDA 54 
11 41 EPATTRSPAGPLDALRSG 58 
12 45 TRSPAGPLDALRSGCDVP 62 
13 49 AGPLDALRSGCDVPVVPG 66 
14 53 DALRSGCDVPVVPGPPHC 70 
15 57 SGCDVPVVPGPPHCVARP 74 
16 61 VPVVPGPPHCVARPEALY 78 
17 65 PGPPHCVARPEALYYQGP 82 
18 69 HCVARPEALYYQGPLMPI 86 
19 73 RPEALYYQGPLMPIYSTP 90 
20 77 LYYQGPLMPIYSTPTMAP 94 
21 81 GPLMPIYSTPTMAPHFPL 98 
22 85 PIYSTPTMAPHFPLLNLP 102 
23 89 TPTMAPHFPLLNLPTHPY 106 
24 93 APHFPLLNLPTHPYSMIC 110 
25 97 PLLNLPTHPYSMICPMEH 114 
26 101 LPTHPYSMICPMEHPLSA 118 
27 105 PYSMICPMEHPLSADIAM 122 
28 109 ICPMEHPLSADIAMATRV 126 
29 113 EHPLSADIAMATRVDEDG 130 
30 117 SADIAMATRVDEDGDTPL 134 
31 121 AMATRVDEDGDTPLHIAV 138 
32 125 RVDEDGDTPLHIAVVQNN 142 
33 129 DGDTPLHIAVVQNNIAAV 146 
34 133 PLHIAVVQNNIAAVYRIL 150 
35 137 AVVQNNIAAVYRILSLFK 154 
36 141 NNIAAVYRILSLFKLGSR 158 
37 145 AVYRILSLFKLGSREVDV 162 
38 149 ILSLFKLGSREVDVHNNL 166 
39 153 FKLGSREVDVHNNLRQTP 170 
40 157 SREVDVHNNLRQTPLHLA 174 
41 161 DVHNNLRQTPLHLAVITT 178 
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42 165 NLRQTPLHLAVITTLPDM 182 
43 169 TPLHLAVITTLPDMVRLL 186 
44 173 LAVITTLPDMVRLLVTAG 190 
45 177 TTLPDMVRLLVTAGASPM 194 
46 181 DMVRLLVTAGASPMALDR 198 
47 185 LLVTAGASPMALDRHGQT 202 
48 189 AGASPMALDRHGQTAIHL 206 
49 193 PMALDRHGQTAIHLACEH 210 
50 197 DRHGQTAIHLACEHRSPS 214 
51 201 QTAIHLACEHRSPSCLQA 218 
52 205 HLACEHRSPSCLQALLDS 222 
53 209 EHRSPSCLQALLDSATSG 226 
54 213 PSCLQALLDSATSGSVDL 230 
55 217 QALLDSATSGSVDLEVRN 234 
56 221 DSATSGSVDLEVRNYEGL 238 
57 225 SGSVDLEVRNYEGLTALH 242 
58 229 DLEVRNYEGLTALHVAVN 246 
59 233 RNYEGLTALHVAVNTGCQ 250 
60 237 GLTALHVAVNTGCQEAVL 254 
61 241 LHVAVNTGCQEAVLLLLE 258 
62 245 VNTGCQEAVLLLLERGAD 262 
63 249 CQEAVLLLLERGADIDAV 266 
64 253 VLLLLERGADIDAVDIKS 270 
65 257 LERGADIDAVDIKSGRSP 274 
66 261 ADIDAVDIKSGRSPLIHA 278 
67 265 AVDIKSGRSPLIHAVENN 282 
68 269 KSGRSPLIHAVENNSLNM 286 
69 273 SPLIHAVENNSLNMVQLL 290 
70 277 HAVENNSLNMVQLLLLHG 294 
71 281 NNSLNMVQLLLLHGANVN 298 
72 285 NMVQLLLLHGANVNAQMY 302 
73 289 LLLLHGANVNAQMYSGSS 306 
74 293 HGANVNAQMYSGSSALHS 310 
75 297 VNAQMYSGSSALHSASGR 314 
76 301 MYSGSSALHSASGRGLLP 318 
77 305 SSALHSASGRGLLPLVRT 322 
78 309 HSASGRGLLPLVRTLVRS 326 
79 313 GRGLLPLVRTLVRSGADS 330 
80 317 LPLVRTLVRSGADSGLKN 334 
81 321 RTLVRSGADSGLKNCHND 338 
82 325 RSGADSGLKNCHNDTPLM 342 
83 329 DSGLKNCHNDTPLMVARS 346 
84 333 KNCHNDTPLMVARSRRVI 350 
85 337 NDTPLMVARSRRVIDILR 354 
86 341 LMVARSRRVIDILRGKAS 358 
87 345 RSRRVIDILRGKASRAAS 362 
88 349 VIDILRGKASRAASGSQT 366 
89 353 LRGKASRAASGSQPEPSP 370 
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90 357 ASRAASGSQPEPSPDQSA 374 
91 361 ASGSQPEPSPDQSATNSP 378 
92 365 QPEPSPDQSATNSPESSS 382 
93 369 SPDQSATNSPESSSRLSS 386 
94 373 SATNSPESSSRLSSNGLQ 390 
95 377 SPESSSRLSSNGLQSSPS 394 
96 381 SSRLSSNGLQSSPSSSPS 398 
97 385 SSNGLQSSPSSSPSLSPP 402 
98 389 LQSSPSSSPSLSPPKDAP 406 
99 393 PSSSPSLSPPKDAPGFPA 410 
100 397 PSLSPPKDAPGFPATPQN 414 
101 401 PPKDAPGFPATPQNFFLP 418 
102 405 APGFPATPQNFFLPTTST 422 
103 409 PATPQNFFLPTTSTPAFL 426 
104 413 QNFFLPTTSTPAFLPFPG 430 
105 417 LPTTSTPAFLPFPGVLRG 434 
106 421 STPAFLPFPGVLRGPGRP 438 
107 425 FLPFPGVLRGPGRPVPPS 442 
108 429 PGVLRGPGRPVPPSPAPG 446 
109 431 VLRGPGRPVPPSPAPGSS 448 
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7.6 Bcl-3 Alanine Substitution Peptide Array Sequences 
Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
2 A1 PAGAMDEGPVDLRTRPKG 
 A2 AAGAMDEGPVDLRTRPKG 
 A3 PDGAMDEGPVDLRTRPKG 
 A4 PAAAMDEGPVDLRTRPKG 
 A5 PAGDMDEGPVDLRTRPKG 
 A6 PAGAADEGPVDLRTRPKG 
 A7 PAGAMAEGPVDLRTRPKG 
 A8 PAGAMDAGPVDLRTRPKG 
 A9 PAGAMDEAPVDLRTRPKG 
 A10 PAGAMDEGAVDLRTRPKG 
 A11 PAGAMDEGPADLRTRPKG 
 A12 PAGAMDEGPVALRTRPKG 
 A13 PAGAMDEGPVDARTRPKG 
 A14 PAGAMDEGPVDLATRPKG 
 A15 PAGAMDEGPVDLRARPKG 
 A16 PAGAMDEGPVDLRTAPKG 
 A17 PAGAMDEGPVDLRTRAKG 
 A18 PAGAMDEGPVDLRTRPAG 
 A19 PAGAMDEGPVDLRTRPKA 
 
 
 
Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
5 A21 RTRPKGTPGAALPLRKRP 
 A22 ATRPKGTPGAALPLRKRP 
 A23 RARPKGTPGAALPLRKRP 
 A24 RTAPKGTPGAALPLRKRP 
 A25 RTRAKGTPGAALPLRKRP 
 A26 RTRPAGTPGAALPLRKRP 
 A27 RTRPKATPGAALPLRKRP 
 A28 RTRPKGAPGAALPLRKRP 
 A29 RTRPKGTAGAALPLRKRP 
 A30 RTRPKGTPAAALPLRKRP 
 B1 RTRPKGTPGDALPLRKRP 
 B2 RTRPKGTPGADLPLRKRP 
 B3 RTRPKGTPGAAAPLRKRP 
 B4 RTRPKGTPGAALALRKRP 
 B5 RTRPKGTPGAALPARKRP 
 B6 RTRPKGTPGAALPLAKRP 
 B7 RTRPKGTPGAALPLRARP 
 B8 RTRPKGTPGAALPLRKAP 
 B9 RTRPKGTPGAALPLRKRA 
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Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
6 B11 KGTPGAALPLRKRPLRPA 
 B12 AGTPGAALPLRKRPLRPA 
 B13 KATPGAALPLRKRPLRPA 
 B14 KGAPGAALPLRKRPLRPA 
 B15 KGTAGAALPLRKRPLRPA 
 B16 KGTPAAALPLRKRPLRPA 
 B17 KGTPGDALPLRKRPLRPA 
 B18 KGTPGADLPLRKRPLRPA 
 B19 KGTPGAAAPLRKRPLRPA 
 B20 KGTPGAALALRKRPLRPA 
 B21 KGTPGAALPARKRPLRPA 
 B22 KGTPGAALPLAKRPLRPA 
 B23 KGTPGAALPLRARPLRPA 
 B24 KGTPGAALPLRKAPLRPA 
 B25 KGTPGAALPLRKRALRPA 
 B26 KGTPGAALPLRKRPARPA 
 B27 KGTPGAALPLRKRPLAPA 
 B28 KGTPGAALPLRKRPLRAA 
 B29 KGTPGAALPLRKRPLRPD 
 
 
 
Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
8 C1 PLRKRPLRPASPEPATTR 
 C2 ALRKRPLRPASPEPATTR 
 C3 PARKRPLRPASPEPATTR 
 C4 PLAKRPLRPASPEPATTR 
 C5 PLRARPLRPASPEPATTR 
 C6 PLRKAPLRPASPEPATTR 
 C7 PLRKRALRPASPEPATTR 
 C8 PLRKRPARPASPEPATTR 
 C9 PLRKRPLAPASPEPATTR 
 C10 PLRKRPLRAASPEPATTR 
 C11 PLRKRPLRPDSPEPATTR 
 C12 PLRKRPLRPAAPEPATTR 
 C13 PLRKRPLRPASAEPATTR 
 C14 PLRKRPLRPASPAPATTR 
 C15 PLRKRPLRPASPEAATTR 
 C16 PLRKRPLRPASPEPDTTR 
 C17 PLRKRPLRPASPEPAATR 
 C18 PLRKRPLRPASPEPATAR 
 C19 PLRKRPLRPASPEPATTA 
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Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
35 C21 AVVQNNIAAVYRILSLFK 
 C22 DVVQNNIAAVYRILSLFK 
 C23 AAVQNNIAAVYRILSLFK 
 C24 AVAQNNIAAVYRILSLFK 
 C25 AVVANNIAAVYRILSLFK 
 C26 AVVQANIAAVYRILSLFK 
 C27 AVVQNAIAAVYRILSLFK 
 C28 AVVQNNAAAVYRILSLFK 
 C29 AVVQNNIDAVYRILSLFK 
 C30 AVVQNNIADVYRILSLFK 
 D1 AVVQNNIAAAYRILSLFK 
 D2 AVVQNNIAAVDRILSLFK 
 D3 AVVQNNIAAVYAILSLFK 
 D4 AVVQNNIAAVYRALSLFK 
 D5 AVVQNNIAAVYRIASLFK 
 D6 AVVQNNIAAVYRILALFK 
 D7 AVVQNNIAAVYRILSAFK 
 D8 AVVQNNIAAVYRILSLAK 
 D9 AVVQNNIAAVYRILSLFA 
 
 
 
 
Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
36 D11 NNIAAVYRILSLFKLGSR 
 D12 ANIAAVYRILSLFKLGSR 
 D13 NAIAAVYRILSLFKLGSR 
 D14 NNAAAVYRILSLFKLGSR 
 D15 NNIDAVYRILSLFKLGSR 
 D16 NNIAAVYRILSLFKLGSR 
 D17 NNIAAAYRILSLFKLGSR 
 D18 NNIAAVARILSLFKLGSR 
 D19 NNIAAVYAILSLFKLGSR 
 D20 NNIAAVYRALSLFKLGSR 
 D21 NNIAAVYRIASLFKLGSR 
 D22 NNIAAVYRILALFKLGSR 
 D23 NNIAAVYRILSAFKLGSR 
 D24 NNIAAVYRILSLAKLGSR 
 D25 NNIAAVYRILSLFALGSR 
 D26 NNIAAVYRILSLFKAGSR 
 D27 NNIAAVYRILSLFKLASR 
 D28 NNIAAVYRILSLFKLGAR 
 D29 NNIAAVYRILSLFKLGSA 
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Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
46 E1 DMVRLLVTAGASPMALDR 
 E2 AMVRLLVTAGASPMALDR 
 E3 DAVRLLVTAGASPMALDR 
 E4 DMARLLVTAGASPMALDR 
 E5 DMVALLVTAGASPMALDR 
 E6 DMVRALVTAGASPMALDR 
 E7 DMVRLAVTAGASPMALDR 
 E8 DMVRLLATAGASPMALDR 
 E9 DMVRLLVAAGASPMALDR 
 E10 DMVRLLVTDGASPMALDR 
 E11 DMVRLLVTAAASPMALDR 
 E12 DMVRLLVTAGDSPMALDR 
 E13 DMVRLLVTAGAAPMALDR 
 E14 DMVRLLVTAGASAMALDR 
 E15 DMVRLLVTAGASPADLDR 
 E16 DMVRLLVTAGASPMALDR 
 E17 DMVRLLVTAGASPMAADR 
 E18 DMVRLLVTAGASPMALAR 
 E19 DMVRLLVTAGASPMALDA 
 
 
 
 
Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
75 E21 VNAQMYSGSSALHSASGR 
 E22 ANAQMYSGSSALHSASGR 
 E23 VAAQMYSGSSALHSASGR 
 E24 VNDQMYSGSSALHSASGR 
 E25 VNAAMYSGSSALHSASGR 
 E26 VNAQAYSGSSALHSASGR 
 E27 VNAQMASGSSALHSASGR 
 E28 VNAQMYAGSSALHSASGR 
 E29 VNAQMYSASSALHSASGR 
 E30 VNAQMYSGASALHSASGR 
 F1 VNAQMYSGSAALHSASGR 
 F2 VNAQMYSGSSDLHSASGR 
 F3 VNAQMYSGSSAAHSASGR 
 F4 VNAQMYSGSSALASASGR 
 F5 VNAQMYSGSSALHAASGR 
 F6 VNAQMYSGSSALHSDSGR 
 F7 VNAQMYSGSSALHSAAGR 
 F8 VNAQMYSGSSALHSASAR 
 F9 VNAQMYSGSSALHSASGA 
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Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
78 F11 HSASGRGLLPLVRTLVRS 
 F12 ASASGRGLLPLVRTLVRS 
 F13 HAASGRGLLPLVRTLVRS 
 F14 HSDSGRGLLPLVRTLVRS 
 F15 HSAAGRGLLPLVRTLVRS 
 F16 HSASARGLLPLVRTLVRS 
 F17 HSASGAGLLPLVRTLVRS 
 F18 HSASGRALLPLVRTLVRS 
 F19 HSASGRGALPLVRTLVRS 
 F20 HSASGRGLAPLVRTLVRS 
 F21 HSASGRGLLALVRTLVRS 
 F22 HSASGRGLLPAVRTLVRS 
 F23 HSASGRGLLPLARTLVRS 
 F24 HSASGRGLLPLVATLVRS 
 F25 HSASGRGLLPLVRALVRS 
 F26 HSASGRGLLPLVRTAVRS 
 F27 HSASGRGLLPLVRTLARS 
 F28 HSASGRGLLPLVRTLVAS 
 F29 HSASGRGLLPLVRTLVAA 
 
 
 
 
Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
80 G1 LPLVRTLVRSGADSGLKN 
 G2 APLVRTLVRSGADSGLKN 
 G3 LALVRTLVRSGADSGLKN 
 G4 LPAVRTLVRSGADSGLKN 
 G5 LPLARTLVRSGADSGLKN 
 G6 LPLVATLVRSGADSGLKN 
 G7 LPLVRALVRSGADSGLKN 
 G8 LPLVRTAVRSGADSGLKN 
 G9 LPLVRTLARSGADSGLKN 
 G10 LPLVRTLVASGADSGLKN 
 G11 LPLVRTLVRAGADSGLKN 
 G12 LPLVRTLVRSAADSGLKN 
 G13 LPLVRTLVRSGDDSGLKN 
 G14 LPLVRTLVRSGAASGLKN 
 G15 LPLVRTLVRSGADAGLKN 
 G16 LPLVRTLVRSGADSALKN 
 G17 LPLVRTLVRSGADSGAKN 
 G18 LPLVRTLVRSGADSGLAN 
 G19 LPLVRTLVRSGADSGLKA 
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Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
85 G21 NDTPLMVARSRRVIDILR 
 G22 ADTPLMVARSRRVIDILR 
 G23 NATPLMVARSRRVIDILR 
 G24 NDAPLMVARSRRVIDILR 
 G25 NDTALMVARSRRVIDILR 
 G26 NDTPAMVARSRRVIDILR 
 G27 NDTPLAVARSRRVIDILR 
 G28 NDTPLMAARSRRVIDILR 
 G29 NDTPLMVDRSRRVIDILR 
 G30 NDTPLMVAASRRVIDILR 
 H1 NDTPLMVARARRVIDILR 
 H2 NDTPLMVARSARVIDILR 
 H3 NDTPLMVARSRAVIDILR 
 H4 NDTPLMVARSRRAIDILR 
 H5 NDTPLMVARSRRVADILR 
 H6 NDTPLMVARSRRVIAILR 
 H7 NDTPLMVARSRRVIDALR 
 H8 NDTPLMVARSRRVIDIAR 
 H9 NDTPLMVARSRRVIDILA 
 
 
 
 
Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
87 H11 RSRRVIDILRGKASRAAS 
 H12 ASRRVIDILRGKASRAAS 
 H13 RARRVIDILRGKASRAAS 
 H14 RSARVIDILRGKASRAAS 
 H15 RSRAVIDILRGKASRAAS 
 H16 RSRRAIDILRGKASRAAS 
 H17 RSRRVADILRGKASRAAS 
 H18 RSRRVIAILRGKASRAAS 
 H19 RSRRVIDALRGKASRAAS 
 H20 RSRRVIDIARGKASRAAS 
 H21 RSRRVIDILAGKASRAAS 
 H22 RSRRVIDILRAKASRAAS 
 H23 RSRRVIDILRGAASRAAS 
 H24 RSRRVIDILRGKDSRAAS 
 H25 RSRRVIDILRGKAARAAS 
 H26 RSRRVIDILRGKASAAAS 
 H27 RSRRVIDILRGKASRDAS 
 H28 RSRRVIDILRGKASRADS 
 H29 RSRRVIDILRGKASRAAA 
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Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
 I1 LRGKASRAASGSQPEPSP 
89 I2 ARGKASRAASGSQPEPSP 
 I3 LAGKASRAASGSQPEPSP 
 I4 LRAKASRAASGSQPEPSP 
 I5 LRGAASRAASGSQPEPSP 
 I6 LRGKDSRAASGSQPEPSP 
 I7 LRGKAARAASGSQPEPSP 
 I8 LRGKASAAASGSQPEPSP 
 I9 LRGKASRDASGSQPEPSP 
 I10 LRGKASRADSGSQPEPSP 
 I11 LRGKASRAAAGSQPEPSP 
 I12 LRGKASRAASASQPEPSP 
 I13 LRGKASRAASGAQPEPSP 
 I14 LRGKASRAASGSAPEPSP 
 I15 LRGKASRAASGSQAEPSP 
 I16 LRGKASRAASGSQPAPSP 
 I17 LRGKASRAASGSQPEASP 
 I18 LRGKASRAASGSQPEPAP 
 I19 LRGKASRAASGSQPEPSA 
 
 
 
 
Original 
Peptide 
Peptide 
Number 
Amino acid Sequence 
109 I21 VLRGPGRPVPPSPAPGSS 
 I22 ALRGPGRPVPPSPAPGSS 
 I23 VARGPGRPVPPSPAPGSS 
 I24 VLAGPGRPVPPSPAPGSS 
 I25 VLRAPGRPVPPSPAPGSS 
 I26 VLRGAGRPVPPSPAPGSS 
 I27 VLRGPARPVPPSPAPGSS 
 I28 VLRGPGAPVPPSPAPGSS 
 I29 VLRGPGRAVPPSPAPGSS 
 I30 VLRGPGRPAPPSPAPGSS 
 J1 VLRGPGRPVAPSPAPGSS 
 J2 VLRGPGRPVPASPAPGSS 
 J3 VLRGPGRPVPPAPAPGSS 
 J4 VLRGPGRPVPPSAAPGSS 
 J5 VLRGPGRPVPPSPDPGSS 
 J6 VLRGPGRPVPPSPAAGSS 
 J7 VLRGPGRPVPPSPAPASS 
 J8 VLRGPGRPVPPSPAPGAS 
 J9 VLRGPGRPVPPSPAPGSA 
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7.7 Bcl-3 Alanine Substitution Peptide Array Data 
 
 
 
 
 
 
Figure 7.3 Full Bcl-3 alanine substitution peptide array. 
The 18 amino acids of the Bcl-3 derivied peptides 2, 5, 6, 8, 35, 36, 46, 75, 78, 80, 85, 87, 
89 and 109  were sequentially substituted with alanine. See Appendix 7.6 for peptide 
locations on array. Arrays were probed with GST-p50 and detected by immunoblotting with 
anti-GST antibody. GST-p50 binding was quantified by densitometry and represented as a 
percentage binding of the control parent peptide peptides (see below).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide 2 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.268 100 _ 
0.228 85.07463 P 
0.328 122.3881 A 
0.308 114.9254 G 
0.438 163.4328 A 
0.428 159.7015 M 
0.438 163.4328 D 
0.408 152.2388 E 
0.528 197.0149 G 
0.498 185.8209 P 
0.638 238.0597 V 
1.038 387.3134 D 
0.618 230.597 L 
0.158 58.95522 R 
0.448 167.1642 T 
0.148 55.22388 R 
0.578 215.6716 P 
0.058 21.64179 K 
0.458 170.8955 G 
Peptide 5 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.648 100 _ 
0.638 98.45679 R 
0.768 118.5185 T 
0.738 113.8889 R 
0.628 96.91358 P 
0.548 84.5679 K 
0.648 100 G 
0.488 75.30864 T 
0.608 93.82716 P 
0.548 84.5679 G 
0.258 39.81481 A 
0.298 45.98765 A 
0.358 55.24691 L 
0.558 86.11111 P 
0.488 75.30864 L 
0.438 67.59259 R 
0.498 76.85185 K 
0.438 67.59259 R 
1.348 208.0247 P 
G
S
T
-p
5
0
 
A 
B 
C 
D 
E 
F 
G 
H 
I 
J 
1 10
0 
20
0 
30
0 
 219 
 
 
 
 
 
 
   
 
  
Peptide 6 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.948 100 _ 
1.028 108.4388 K 
0.918 96.83544 G 
0.778 82.06751 T 
0.648 68.35443 P 
0.678 71.51899 G 
0.668 70.46414 A 
0.538 56.75105 A 
0.828 87.34177 L 
0.878 92.61603 P 
0.488 51.47679 L 
0.548 57.80591 R 
0.678 71.51899 K 
0.538 56.75105 R 
0.778 82.06751 P 
0.458 48.31224 L 
0.448 47.25738 R 
0.598 63.08017 P 
0.408 43.03797 A 
Peptide 8 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.188 100 _ 
0.218 115.9574 P 
0.258 137.234 L 
0.288 153.1915 R 
0.318 169.1489 K 
0.238 126.5957 R 
0.498 264.8936 P 
0.388 206.383 L 
0.328 174.4681 R 
0.528 280.8511 P 
0.798 424.4681 A 
0.888 472.3404 S 
0.748 397.8723 P 
0.788 419.1489 E 
0.488 259.5745 P 
0.398 211.7021 A 
0.568 302.1277 T 
0.618 328.7234 T 
0.198 105.3191 D 
Peptide 35 
Intensity 
Percent 
Binding 
A.A 
Sub 
1.858 100 _ 
1.308 70.39828 A 
1.908 102.6911 V 
1.498 80.62433 V 
1.428 76.85684 Q 
1.828 98.38536 N 
1.598 86.00646 N 
1.418 76.31862 I 
1.038 55.86652 A 
1.118 60.17223 A 
0.778 41.87298 V 
0.668 35.95264 Y 
0.988 53.17546 R 
1.468 79.00969 I 
1.508 81.16254 L 
1.418 76.31862 S 
1.458 78.47147 L 
0.908 48.86975 F 
0.168 9.041981 K 
Peptide 36 
Intensity 
Percent 
Binding 
A.A 
Sub 
1.818 100 _ 
1.428 78.54785 N 
1.308 71.94719 N 
1.588 87.34873 I 
1.168 64.24642 A 
1.708 93.94939 A 
1.758 96.69967 V 
1.588 87.34873 Y 
1.788 98.34983 R 
1.898 104.4004 I 
1.738 95.59956 L 
1.478 81.29813 S 
1.218 66.9967 L 
1.378 75.79758 F 
0.798 43.89439 K 
1.578 86.79868 L 
1.378 75.79758 G 
1.188 65.34653 S 
0.518 28.49285 R 
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Peptide 46 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.048 100 _ 
0.038 79.16667 D 
0.068 141.6667 M 
0.068 141.6667 V 
0.068 141.6667 R 
0.038 79.16667 L 
0.038 79.16667 L 
0.078 162.5 V 
0.068 141.6667 T 
0.048 100 A 
0.048 100 G 
0.098 204.1667 A 
0.068 141.6667 S 
0.108 225 P 
0.068 141.6667 M 
0.098 204.1667 A 
0.108 225 L 
0.518 1079.167 D 
0.098 204.1667 R 
Peptide 75 
Intensity 
Percent 
Binding 
A.A 
Sub 
1.098 100 _ 
0.888 80.87432 V 
0.738 67.21311 N 
0.638 58.10565 A 
0.898 81.78506 Q 
0.888 80.87432 M 
0.628 57.1949 Y 
0.708 64.48087 S 
0.648 59.01639 G 
0.528 48.08743 S 
0.378 34.42623 S 
0.078 7.103825 A 
0.438 39.89071 L 
0.608 55.37341 H 
0.438 39.89071 S 
0.078 7.103825 A 
0.598 54.46266 S 
0.568 51.73042 G 
0.068 6.193078 R 
Peptide 78 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.778 100 _ 
0.838 107.7121 H 
0.818 105.1414 S 
0.698 89.71722 A 
0.728 93.57326 S 
0.958 123.1362 G 
0.768 98.71465 R 
0.678 87.14653 G 
1.188 152.6992 L 
1.118 143.7018 L 
0.798 102.5707 P 
1.178 151.4139 L 
1.148 147.5578 V 
0.258 33.16195 R 
0.818 105.1414 T 
0.918 117.9949 L 
0.868 111.5681 V 
0.218 28.02057 R 
0.648 83.29049 S 
Peptide 80 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.298 100 _ 
0.238 79.86577 L 
0.308 103.3557 P 
0.378 126.8456 L 
0.408 136.9128 V 
0.318 106.7114 R 
0.348 116.7785 T 
0.318 106.7114 L 
0.428 143.6242 V 
0.068 22.81879 R 
0.668 224.1611 S 
0.528 177.1812 G 
0.138 46.30872 A 
0.558 187.2483 D 
0.538 180.5369 S 
0.548 183.8926 G 
0.558 187.2483 L 
0.088 29.5302 K 
0.558 187.2483 N 
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Peptide 85 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.928 100 _ 
0.688 74.13793 N 
0.858 92.4569 D 
0.638 68.75 T 
0.618 66.59483 P 
0.718 77.37069 L 
0.568 61.2069 M 
0.568 61.2069 V 
0.578 62.28448 A 
0.508 54.74138 R 
0.398 42.88793 S 
0.298 32.11207 R 
0.298 32.11207 R 
0.648 69.82759 V 
0.538 57.97414 I 
0.958 103.2328 D 
0.628 67.67241 I 
0.628 67.67241 L 
0.198 21.33621 R 
Peptide 87 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.928 100 _ 
0.778 83.83621 R 
0.728 78.44828 S 
0.618 66.59483 R 
0.538 57.97414 R 
0.708 76.2931 V 
0.708 76.2931 I 
0.888 95.68966 D 
0.848 91.37931 I 
0.768 82.75862 L 
0.668 71.98276 R 
0.878 94.61207 G 
0.758 81.68103 K 
0.678 73.06034 A 
0.748 80.60345 S 
0.608 65.51724 R 
0.588 63.36207 A 
0.408 43.96552 A 
0.698 75.21552 S 
Peptide 89 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.078 100 _ 
0.098 125.641 L 
0.078 100 R 
0.138 176.9231 G 
0.088 112.8205 K 
0.078 100 A 
0.128 164.1026 S 
0.058 74.35897 R 
0.098 125.641 A 
0.118 151.2821 A 
0.248 317.9487 S 
0.218 279.4872 G 
0.208 266.6667 S 
0.118 151.2821 Q 
0.148 189.7436 P 
0.318 407.6923 E 
0.248 317.9487 P 
0.168 215.3846 S 
0.388 497.4359 P 
Peptide109 
Intensity 
Percent 
Binding 
A.A 
Sub 
0.048 100 _ 
0.048 100 V 
0.058 120.8333 L 
0.048 100 R 
0.068 141.6667 G 
0.078 162.5 P 
0.058 120.8333 G 
0.048 100 R 
0.038 79.16667 P 
0.028 58.33333 V 
0.028 58.33333 P 
0.028 58.33333 P 
0.028 58.33333 S 
0.068 141.6667 P 
0.058 120.8333 A 
0.048 100 P 
0.048 100 G 
0.058 120.8333 S 
0.058 120.8333 S 
 222 
 
7.8 Murine IκB Protein Alignment 
                  1                                               50 
    Bcl-3  (127) DEDGDTPLHIAVVQNNIAAVYRILSLFK--LGSREVDVHNNLRQTPLHLA 
     IκBα   (92) TEDGDSFLHLAIIHEEKPLTMEVIGQVK--GDLAFLNFQNNLQQTPLHLA 
     IKBβ   (55) TEDGDTALHLAVIHQHEPFLDFLLGFSA---GTEYLDLQNDLGQTALHLA 
     IκBε  (120) SEDGDTLLHLAVIHEAPSVLFCCLAFLP----QEVLDIQNNLYQTALHLA 
     IKBNS  (60) DEEGDTLLHLFAARGLRWAAYAAAEVLQ---MYRQLDIREHKGKTPLLVA 
     IκBζ  (451) DGDGDTFLHIAVAQGRRALSYVLARKMN---ALHMLDIKEHNGQSAFQVA 
     p100  (485) DENGDTPLHLAIIHGQTGVIEQIAHVIYHAQYLGVINLTNHLHQTPLHLA 
     p105  (536) DENGDSVLHLAIIHLHAQLVRDLLEVTSGLISDDIINMRNDLYQTPLHLA 
 
                 51                                             100 
    Bcl-3  (175) VITTLPDMVRLLVTAGASPMALDRHGQTAIHLACEHR--SPSCLQALLDS 
     IκBα  (140) VITNQPGIAEALLKAGCDPELRDFRGNTPLHLACEQG--CLASVAVLTQT 
     IκBβ  (102) AILGEASTVEKLYAAGAGVLVAERGGHTALHLACRVR--AHTCACVLLQP 
     IκBε  (166) VHLDQPDVVRALVLKGASRILQDQHGDTALHVACRRQ--NLACACCLLEE 
    IKBNS  (107) AAANQPLIVEDLLSLGAEPNATDHQGRSVLHVAATYG--LPGVLSAVFKS 
     IκBζ  (498) VAANQHLIVQDLVNLGAQVNTTDCWGRTPLHVCAEKG--HSQVLQAIQKG 
     p100  (535) VITGQTRVVSFLLQVGADPTLLDRHGDSALHLALRAGAAAPELLQALLRS 
     p105  (586) VITKQEDVVEDLLRVGADLSLLDRWGNSVLHLAAKEG--HDRILSILLKS 
 
                 101                                            150 
    Bcl-3  (223) AT-----------------SGS--------------------------VD 
     IκBα  (188) CT-----------------PQHLH------------------------SV 
     IκBβ  (150) RPSHPRDASDTYLTQSQDCTPDTSHAPAAVDSQPNPENEEEPRDEDWRLQ 
     IκBε  (214) QP-----------------EPGRQLSHP--------------------LD 
    IKBNS  (155) GI-----------------Q----------------------------VD 
     IκBζ  (546) AV-----------------RSNQF------------------------VD 
     p100  (585) GA-----------------HAVP-------------------------QI 
     p105  (634) RK-----------------AA---------------------------PL 
 
                 151                                            200 
    Bcl-3  (230) LEVRNYEGLTALHVAVNTGC---------------------------QEA 
     IκBα  (197) LQATNYNGHTCLHLASIHGY---------------------------LAI 
     IκBβ  (200) LEAENYDGHTPLHVAVIHKD---------------------------AEM 
     IκBε  (227) LQLKNWQGLACLHIATLQRN---------------------------QPL 
    IKBNS  (160) LEARDFEGLTPLHTAVLALNAAM-------LPASVCPRMQNSQARDRLTC 
     IκBζ  (555) LEATNYDGLTPLHCAVVAHNAVVHELQRNRQSHSPEVQDLLLRNKSLVDT 
     p100  (593) LHMPDFEGLYPVHLAVHARS---------------------------PEC 
     p105  (640) IDHPNGEGLNAIHIAVMSNS---------------------------LPC 
 
                 201                                            250 
    Bcl-3  (253) VLLLLERGADIDAVDIKSGRSPLIHAVENNSLNMVQ-LLLLHG-----AN 
     IκBα  (220) VEHLVTLGADVNAQEPCNGRTALHLAVDLQNPDLVS-LLLKCG-----AD 
     IκBβ  (223) VRLLRDAGADLNKPEPTCGRTPLHLAVEAQAASVLE-LLLKAG-----AD 
     IκBε  (250) IELLLQNGADIDVQEGTSGKTALHLAVETQERSLVQ-FLLQAG-----AR 
    IKBNS  (203) VQMLLQMGASHTSQEIKSNKTILHLAVQAANPTLVQ-LLLGLPRGDLRAF 
     IκBζ  (605) IKCLIQMGAAVEAKDRKSGRTALHLAAEEANLELIR-LFLELP--SCLSF 
     p100  (616) LDLLVDCGAEVEAPERQGGRTALHLATEMEELGLVTHLVTKLH-----AN 
     p105  (663) LLLLVAAGAEVNAQEQKSGRTALHLAVEYDNISLAGCLLLEGD-----AH 
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                 251                                            300 
    Bcl-3  (297) VNAQMYSGSSALHSASGRG----LLPLVRTLVRSGADSG--LKNCHND-- 
     IκBα  (264) VNRVTYQGYSPYQLTWGRP----STRIQQQLGQLTLENLQMLPESEDE-- 
     IκBβ  (267) PTARMYGGRTPLGSALLRP----NPILARLLRAHGAPEP--EDEDDKL-- 
     IκBε  (294) VDARMLNGCTPLHLAAGRG----LNSISSTLCEAGADSL--LLNVEDE-- 
    IKBNS  (252) VNMKAH-GNTALHMAAALPPGPPQEAIVRHLLAAGADPT--LRNLENE-- 
     IκBζ  (652) VNAKAYNGNTALHVAASLQYRVTQLDAVRLLMRKGADPS--TRNLENE-- 
     p100  (661) VNARTFAGNTPLHLAAGLG---SPTLTRLLLKAGADIHA--ENEEPLCPL 
     p105  (708) VDSTTYDGTTPLHIAAGRG---STRLAALLKAAGADPLV--ENFEPLYDL 
 
 
                 301                       328 
    Bcl-3  (339) -------------TPLMVARSRRVIDIL 
     IκBα  (308) -------------ESYDTESEFTEDE-- 
     IκBβ  (309) -------------SPCSSSGSDSDS---  
     IκBε  (336) -------------TPQDLAEDLLSYLPF  
    IKBNS  (297) -------------QPVHLLRPGPGPEGL 
     IκBζ  (698) -------------QPVHLVPDGPVGEQI 
     p100  (706) PSPSTSGSDSDSE--------------- 
     p105  (753) DDSWEKAGEDEGVVPGTTPLDMAANWQV 
 
 
 
Colour coding: 
 non similar amino acids black on white background 
 identical amino acids red on yellow background  
 conservative amino acids black on green background 
 block of similar amino acids black on blue background  
 weakly similar amino acids green on white background 
Only identical and similar amino acids used in consensus calculation. 
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7.9 NetNES Prediction Results 
Analyzed using NetNES 1.1 (la Cour et al., 2004) 
Tpl2(human): NCBI Reference Sequence: NP_001231063. 
 
 
Nes Prediction 
#Seq-Pos-Residue           ANN     HMM     NES   Predicted 
Sequence-406-L            0.180   0.790   0.552      Yes 
Sequence-407-E            0.092   0.790   0.550      Yes 
Sequence-408-R            0.121   0.790   0.560      Yes 
Sequence-409-K            0.098   0.804   0.577      Yes 
Sequence-410-R            0.431   0.804   1.047      Yes 
Sequence-411-L            0.224   0.825   0.654      Yes 
Sequence-412-L            0.160   0.850   0.675      Yes 
Sequence-413-S            0.144   0.850   0.686      Yes 
Sequence-414-R            0.286   0.850   0.719      Yes 
Sequence-415-K            0.092   0.850   0.717      Yes 
Sequence-416-E            0.120   0.850   0.655      Yes 
Sequence-417-L            0.211   0.852   0.654      Yes 
Sequence-418-E            0.079   0.851   0.638      Yes 
Sequence-419-L            0.398   0.851   0.688      Yes 
 
 
Artificial Neural Network (ANN)  
Hidden Markov models (HMM) 
Nuclear Export Sequence (NES) 
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7.10 NetPhos Prediction Results 
Analyzed using NetPhos 2.0 (Blom et al., 1999) 
p50 (mouse): NCBI Reference Sequence AAH50841.1 
 
  
 
 
 
Tyrosine predictions 
 
Name           Pos   Context    Score  Pred 
_________________________v_________________ 
Sequence         7   DDDPYGTGQ  0.941  *Y* 
Sequence        29   NAELYSPEI  0.089    . 
Sequence        41   TDGPYLQIL  0.687  *Y* 
Sequence        57   FRFRYVCEG  0.711  *Y* 
Sequence        79   NKKSYPQVK  0.709  *Y* 
Sequence        87   KICNYVGPA  0.126    . 
Sequence       163   CIRGYNPGL  0.009    . 
Sequence       175   SDLAYLQAE  0.774  *Y* 
Sequence       238   SDAIYDSKA  0.959  *Y* 
Sequence       267   GEEIYLLCD  0.761  *Y* 
Sequence       283   QIRFYEEEE  0.013    . 
Sequence       316   KTPKYKDVN  0.984  *Y* 
Sequence       347   KPFLYYPEI  0.010    . 
Sequence       348   PFLYYPEIK  0.131    . 
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7.11 Bcl-3 Derived Peptide in vivo trial 
 
 
 
Figure 7. 4 Bcl-3 derived peptide inhibits carrageenan-induced inflammation 
Work carried out in coleraboation with Dr. Gianluca Grassia and Prof. Armando Lalenti 
(University of Naples Federico II, Napoli, Italy). 
(A) Paw edema was induced by subplantar injection of 50 μl of sterile saline containing 2% 
λ-carrageenin (Sigma Aldrich, Italy) into the right hind paw. Paw volumes were measured 
by a plethysmometer (Ugo Basile, Milan, Italy) at varying time intervals. Edema was 
evaluated as difference between the paw volume measured at each time point and the basal 
paw volume measured immediately before carrageenin injection. 1hr before edema 
induction, mice were pretreated with PBS (Control), 1 mg/kg Dexamethsasone (DEX),  
10mg/kg sBDP or 10mg/kg mBDP. (B) 24 hour post edema induction time point from A. 
Statistical significance was determined by one way anova and Tukey’s multiple comparison  
test; P<0.05 (*), P<0.01 (**), P<0.001(***). 
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7.12 Supplementary Figures 
 
 
 
 
Figure 7.5 EMSA. 
HEK293T cells were transfected with empty vector (lane2), pRK5-p50-FLAG (lane3) or pRK5-
p50-FLAG in which Lys249, Arg252 and Met253 of p50 are mutated to alanine (p50KRM)) 
(lane4).  5ug of Nuclear extracts were prepared from the transfected cells and tested in an 
Electrophoretic Mobility Shift Assay (EMSA) using the consensus NF‐κB binding nucleotide. 
As a negative control, in addition to the KRM mutation, residues critical for DNA binding, 
Y57 and D60 were mutated to alanine and aspartic acid respectively (p50 KRM,DBM) to 
produce a DNA binding deficient mutant (lane5). Binding reactions were resolved on a 5% 
non-denaturing polyacrylamide gel at 300V at 4°C. The gel was visualised using LI-COR 
Odyssey, scanned on the 800nm channel. The EMSA reaction mixture minus nuclear extract 
was loaded in lane 1 and free probe is apparent at the bottom of the gel. 
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Figure 7.6 p50 and Bcl-3 co-immunoprecipitation. 
HEK293T cells were transfected with pRK5-p50-FLAG (p50) or pRK5-p50-FLAG in which 
Lys249, Arg252 and Met253 of p50 are mutated to alanine (p50KRM ) with or without 
pcDNA3.1‐Bcl‐3-MYC (Bcl-3). Whole cell lysates were immunoprecipitated (IP) with anti-
FLAG and analysed by Western blot (WB) with anti-FLAG and and MYC for p50 and Bcl-3 
respectively. Western Blots were visualised using LI-COR Odyssey scanned on the 800nm 
channel following incubation with DyLight 800 conjugated anti-mouse antibody. For A 
(input) and B (IP) the images shown represent the same membrane probed with different 
antibodies as indicated. The heavy chain from the immunoprecipitating antibody is also 
indicated. 
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Figure 7. 7 Tpl-2 and Bcl-3 co-immunoprecipitation. 
HEK293T cells were transfected with pRK5-Bcl-3-FLAG and pcDNA3-Tpl-2-MYC expression 
vectors as indicated. Whole cell lysates were immunoprecipitated (IP) with anti-FLAG and 
analysed by WB with anti-Tpl-2 for Tpl-2 and anti-FLAG for Bcl-3. Bound protein was 
detected with HRP-conjugated secondary antibodies and WesternBright ECL 
chemiluminescent HRP substrate. The images shown represent the same membrane probed 
with different antibodies as indicated. The heavy chain from the immunoprecipitating 
antibody is also indicated 
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Figure 7.8 p50 homodimer co-immunoprecipitation. 
HEK293T cells were transfected as indicated with  pRK5-p50-FLAG and pEF4a-p50-MYC (p50) 
or pRK5-p50-FLAG and pEF4a-p50-MYC in which Arg359, Lys360 and Arg361 of p50 were 
mutated to alanine (p50RKR). FLAG-p50 or FLAG-p50RKR  were immunoprecipitated (IP) from 
whole cell lysates with anti-FLAG(mouse) and analysed by western blot (WB) with anti-MYC 
(mouse) and DyLight 800 conjugated anti-mouse antibody for MYC–p50 and p50RKR.  FLAG- 
p50 and p50RKR were visualised with anti-FLAG (rabbit) and DyLight 680 conjugated anti-
rabbit antibody. Western Blots were visualised using LI-COR Odyssey scanned separately on 
the 800nm and 700nm channels for DyLight 800 and  DyLight 680 conjugated antibodies 
respectively. The heavy chain from the immunoprecipitating antibody is also indicated. 
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Figure 7. 9 p50 ubiquitination assay. 
HEK293T cells were transfected as indicated with  pRK5-p50-FLAG or pRK5-p50-FLAG in 
which Lys363 of p50 was mutated to alanine (p50K363A) with or without pcDNA3.1-Bcl-3-MYC 
(Bcl-3). All samples were also transfected with ubiquitin-HA, the total concentration of 
plasmid was maintained constant with the addition of empty expression vector . p50/ 
p50K363A ubiquitination was determined by immunoprecipitation (IP) from whole cell lysates 
with anti-FLAG and Western blot (WB) with anti-HA for HA-ubiquitin. For A (IP) and B(input) 
the images shown represent the same membrane probed with different antibodies as 
indicated. Bound protein was detected with HRP-conjugated secondary antibodies and 
WesternBright ECL chemiluminescent HRP substrate. The heavy chain from the 
immunoprecipitating antibody is also indicated. 
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Figure 7.10 GST Pull down assay. 
Purified bacterial recombinant GST or GST-Bcl-3 was incubated with a HEK293 whole cell 
lysate overexpressing FLAG-p50. GST recombinant proteins were affinity purified with GSH 
agarose.  Pull down complexes were resolved by SDS-PAGE and immunoblotted with anti-
FLAG(mouse) and DyLight 800 conjugated anti-mouse antibody for FLAG-p50 and anti-
GST(rabbit) and DyLight 680 conjugated anti-rabbit antibody for GST and GST-Bcl-3. 
Western Blots were visualised using LI-COR Odyssey scanned separately on the 800nm and 
700nm channels for DyLight 800 and  DyLight 680 conjugated antibodies respectively .The 
image shown is an overlay of both channels. 
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Figure 7.11 TNF induced Iκα phosphorylation in p105 stable cell lines. 
Nfkb1-/- MEF cells were stably transfected with expression vectors encoding p105WT or 
p105RKR. p105WT or p105RKR MEFs were stimulated with 20ng/ml TNF for the indicated times 
prior to lysis. Whole cell extracts were analysed by Western blotting for phosphorylated 
IκBα and total IκBα. The images shown represent the same membrane probed with different 
antibodies as indicated. 
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Figure 7.12 MEK-Kinase assay. 
HEK293T cells were transfected with pRK5-Bcl-3-FLAG(Bcl-3) and pcDNA3.Tpl-2-MYC(Tpl-2) 
expression vectors as follows lane 1 mock transfection, lane 2 Tpl-2 and lane 3 Tpl-2 and 
Bcl-3. Tpl-2 was immunoprecipitated (IP) from whole cell lysates with anti-MYC and used in 
an in vitro  MEK kinase assay with  unactive GST-MEK1 as a substrate. MEK phosphorylation 
was determined by WB of kinase assay reaction (A) with anti-phospho MEK1/2 antibody. 
Immunoprecipitates (B) and inputs (C) were also analysed by Western blot.   
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